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Abstract
?
? Synthetic oligonucleotides and peptides have found wide applications in 
industry and academic research labs. There are ~60 peptide drugs on the market and 
over 500 under development. The global annual sale of peptide drugs in 2010 was 
estimated to be $13 billion. There are three oligonucleotide-based drugs on market; 
among them, the FDA newly approved Kynamro was predicted to have a $100 
million annual sale. The annual sale of oligonucleotides to academic labs was 
estimated to be $700 million. Both bio-oligomers are mostly synthesized on 
automated synthesizers using solid phase synthesis technology, in which nucleoside 
or amino acid monomers are added sequentially until the desired full-length sequence 
is reached. The additions cannot be complete, which generates truncated undesired 
failure sequences. For almost all applications, these impurities must be removed. The 
most widely used method is HPLC. However, the method is slow, expensive, labor-
intensive, not amendable for automation, difficult to scale up, and unsuitable for high 
throughput purification. It needs large capital investment, and consumes large 
volumes of harmful solvents. The purification costs are estimated to be more than 
50% of total production costs. Other methods for bio-oligomer purification also have 
drawbacks, and are less favored than HPLC for most applications.  
To overcome the problems of known biopolymer purification technologies, 
we have developed two non-chromatographic purification methods. They are (1) 
catching failure sequences by polymerization, and (2) catching full-length sequences 
??
?
by polymerization. In the first method, a polymerizable group is attached to the 
failure sequences of the bio-oligomers during automated synthesis; purification is 
achieved by simply polymerizing the failure sequences into an insoluble gel and 
extracting full-length sequences. In the second method, a polymerizable group is 
attached to the full-length sequences, which are then incorporated into a polymer; 
impurities are removed by washing, and pure product is cleaved from polymer. These 
methods do not need chromatography, and all drawbacks of HPLC no longer exist. 
Using them, purification is achieved by simple manipulations such as shaking and 
extraction. Therefore, they are suitable for large scale purification of oligonucleotide 
and peptide drugs, and also ideal for high throughput purification, which currently has 
a high demand for research projects involving total gene synthesis.  
 The dissertation will present the details about the development of the 
techniques. Chapter 1 will make an introduction to oligodeoxynucleotides (ODNs), 
their synthesis and purification. Chapter 2 will describe the detailed studies of using 
the catching failure sequences by polymerization method to purify ODNs. Chapter 3 
will describe the further optimization of the catching failure sequences by 
polymerization ODN purification technology to the level of practical use. Chapter 4 
will present using the catching full-length sequence by polymerization method for 
ODN purification using acid-cleavable linker. Chapter 5 will make an introduction to 
peptides, their synthesis and purification. Chapter 6 will describe the studies using the 
catching full-length sequence by polymerization method for peptide purification.  
??
?
Chapter 1 
Introduction to Oligodeoxynucleotides Purification 
?
1.1 Oligodeoxynucleotides (ODNs) 
?
Oligodeoxynucleotides (ODNs) 1.1 are short single-stranded 
deoxyribonucleic acid or DNA. They are comprised of four nucleosides 
deoxyadenosine (dA), thymidine (dT), deoxycytidine (dC), and deoxyguanosine (dG). 
Each nucleoside is comprised of a 2?-deoxyribose sugar and nucleobase such as 
adenine, thymine, cytosine and guanine. The nucleosides with phosphate group are 
known as nucleotides. Multiple nucleosides linked together by phosphate diester 
linkages form ODN. Usually, ODN refers to deoxyribonucleic acids with lengths of  
15 to 200 nucleotide units. 
?
Figure 1.1. Structure of ODN 
??
?
1.2 Applications of ODN 
?
Synthetic ODNs encompass a wide range of applications in the area of 
genomics, medical diagnosis, forensic science and nanotechnology.[1] Recently, 
synthetic ODNs have been booming in therapeutics and antisense therapy.[2] The 
antisense therapy is based on specific binding of ODN sequences on specific gene 
sequence and is used to treat diseases caused by genetic disorders.[3] Currently, three 
oligonucleotide based drugs are on the market. Kynamro is the newly approved drug 
by FDA which was predicted to have a $100 million annual sale?[4]. In academic lab, 
the annual sale of oligonucleotide is $700 million?[5]. More than 60 drugs based on 
oligonucleotide are in various stages of preclinical and clinical testing for treating 
diseases such as cancer, viral infection and diabetes. In addition synthetic ODNs have 
been widely used as  primers for DNA sequencing and polymerase chain reaction 
(PCR).[6] 
1.3 Synthesis
?
The most widely used method for ODN synthesis is the phosphoramidite 
chemistry. Usually, the synthesis is carried out on a solid support. During synthesis 
the first nucleoside is pre-anchored to the support, and nucleoside phosphoramidite 
monomers are added sequentially one at a time. Each addition requires four steps,[7] 
which is called a synthetic cycle. The four steps are detritylation, coupling, capping 
and oxidation. At the end of synthesis, the ODNs are cleaved from the solid support 
??
?
and fully deprotected. The following paragraphs give detailed description of the four 
steps and the most widely used conditions for cleavage and deprotection.  
1.3.1 Detritylation 
This is the first step of ODN synthesis cycle. As shown in scheme 1.1, it 
converts 1.2 to 1.3. The 5?-OH group of nucleoside phosphoramidite is protected with 
the 4,4?-dimethoxytrityl (DMTr) group. Thus the growing chain of ODN contains 
DMTr group at the 5? end. This group needs to be removed in each cycle before the 
coupling step. This group is acid labile and is usually removed by 3% trichloroacetic 
acid in dichloromethane. Once the DMTr group is removed, 5?-OH group 1.3 is 
generated and the solid support is ready for the coupling step in the cycle.  
 
 
??
?
?
Scheme 1.1. Oligodeoxynucleotide synthesis cycle using phosphoramidite chemistry 
??
?
1.3.2 Coupling 
After detritylation, the next step is coupling in which 1.3 reacts with 
phosphoramidite monomer 1.4 to give 1.5 (Scheme 1.1). The nucleoside 
phosphoramidite 1.4 and activator 1H-tetrazole or 4,5-dicyanoimidazole are delivered 
to the synthesis column, which contains the solid support. The activator protonates 
the diisopropylamino group of nucleoside phosphoramidite making it a better leaving 
group. The free 5?-OH group readily displaces the leaving group and the phosphite 
triester 1.5 is generated.  
1.3.3 Capping 
After coupling, the next step is capping. The coupling step cannot be 100% 
complete. Some nucleosides with free 5?-OH group (1.6) will remain unreacted. If 
they are not blocked right after coupling, they will continue to elongate in the next 
synthetic cycles giving what is called deletion sequences. Deletion sequences are very 
difficult to remove during purification. As a result, these 5?-OH groups are capped 
with large excess of acetic anhydride to give the failure sequences 1.7. 
1.3.4 Oxidation 
After capping, an oxidation step is executed. The newly formed triester 
linkage in 1.5 in the coupling step is unstable under next detritylation conditions, 
which is acidic. It must be converted to the stable phosphate triester 1.8. The step is 
achieved by treating with iodine in water in the presence of pyridine. After oxidation, 
the cycle is completed, and this finishes addition of one nucleoside phosphoramidite 
??
?
monomer, and the ODN grows one nucleotide longer. The synthesizer repeats the 
cycles until the desire ODN length is reached. 
1.3.5 Cleavage 
In phosphoramidite chemistry, the succinyl linker connects 3? end of ODN to 
the solid support. This linker is stable to all the reagents used during solid phase 
synthesis. As the desired length of ODN is reached, the linker is usually cleaved with 
concentrated ammonium hydroxide solution at room temperature. The cleavage 
reaction can be carried out either on the synthesizer automatically or off the 
synthesizer manually.
1.3.6 Deprotection
The exocyclic amino groups on the heterocyclic bases (A, C, and G) are 
nucleophilic and should be protected thoughout the ODN synthesis. The most 
commonly used protecting groups for A and C are benzoyl and for G isobutyryl. 
These protecting groups can be removed with concentrated ammonium hydroxide 
solution at 55 ?C for 15 hours. In some cases, the Ultramild protecting groups are 
used and are attached to the monomers. The Ultramild protecting group for A, C and 
G are phenoxyacetyl, acetyl  and isopropyl phenoxyacetyl, respectively. These 
protecting groups can be readily removed by concentrated ammonium hydroxide 
solution at room temperature in 2 hours.
During synthesis, the phosphate groups are also protected. The mostly used 
group is the 2-cyanoethyl group. The protecting groups are usually easy to remove. 
??
?
They usually fall off during cleavage via a ?-elimination mechanism caused by a base 
such as ammonia.
1.4 Impurities
?
The ODNs cleaved from the synthesizer and full deprotected contain 
impurities. They must be removed before most applications. The impurities are 
classified into three different types. 
The first type is called truncated failure sequences. They are generated in each 
synthetic cycle due to incomplete coupling of nucleoside phosphoramidite monomer. 
The amount of failure sequences in crude ODN depends on the sequence, scale, and 
length of ODNs. For example, in a normal 20-mer ODN synthesis, failure sequences 
constitute 30-60% ODN content.[8] The failure sequences have similar physical 
properties as the full-length ODN which make them difficult to be separated.  
The second type of impurities is small organic molecules from the protecting 
groups. These molecules are neutral. They are easy to remove from the negatively 
charged full-length sequences. These small molecules are soluble in ethanol or n-
butanol while the full-length ODNs are insoluble. Simple precipitation can remove 
these small organic molecules. 
The third types of impurities are deletion sequences, addition sequences and 
sequences resulted from depurination. Deletion sequences are resulted from 
incomplete capping and incomplete de-tritylation. Addition sequences are resulted 
from premature de-tritylation. The deletion and addition sequences are very difficult 
??
?
to remove. They should be minimized by careful tuning synthesis conditions. Based 
on the above analysis, the major task of ODN purification is the removal of failure 
sequences. 
1.5 Current Purification Methods 
?
Currently there are several known methods to purify ODN. They include 
reversed-phase (RP) high performance liquid chromatography (HPLC), anion-
exchange HPLC, gel electrophoresis, fluorous affinity purification, RP cartridge 
chromatography and biotin-avidin based affinity purification. The following 
paragraphs describe the principle, advantages and disadvantages of these methods.
1.5.1 RP HPLC 
 The principle of this method is based on the hydrophobic interaction between 
ODN and stationary phase. The stationary phase contains long hydrophobic chain. 
More hydrophobic ODNs interact with the stationary phase more strongly and elute 
slowly while less hydrophobic impurities move faster. The ODNs with fluorescent 
dyes and DMTr groups are more hydrophobic which makes the purification easier.[6] 
This method is very efficient and is most widely used in industrial processes. It can 
separate ODNs of similar size on the basis of hydrophobicity.  However, the ODNs 
which form stable secondary structure is difficult to separate by RP HPLC because 
the ODN elutes as a broad peak or multiple peaks. In addition the method needs 
expensive instruments and columns. It also requires large volume of solvents and is 
??
?
highly labor-demanding.[9] As a result, RP HPLC is difficult to scale up, and is 
expensive for large-scale ODN purification. 
1.5.2 Anion-Exchange HPLC 
In anion-exchange HPLC, the stationary phase contains positively charged 
functional groups. The mobile phase is usually 25 mM Tris/Cl, 1 mM EDTA and 25 
mM Tris/Cl 1 mM EDTA, 1.0 M NaCl. ODN is negatively charged. It has rich 
interaction with the stationary phase. The interactions are different for different ODN 
sequences. As a result, they are eluted by the mobile phase with different rate. 
Although this method can purify short ODN with good resolution, it needs expensive 
instruments, column and large volume of solvents. It is also labor intensive. The 
purified ODN needs further desalting because the eluent contains non-vaporizable 
salts. 
1.5.2 Gel-Electrophoresis 
In gel-electrophoresis, an electrical field is applied across a gel. The ODN is 
loaded at one side of the gel. Because ODN is negatively charged, it travels from high 
potential end of the electrical field to the low potential end. Different ODNs have 
different mass to charge ratios, and they travel with different speeds. As a result, they 
are separated in the process. This method can produce ODN in high levels of purity 
but is only suitable for very small scale purification.[6] It cannot be scaled up for 
large scale purifications. 
???
?
1.5.3 Fluorous Affinity Purification 
During ODN synthesis, the full-length sequences are tagged with a molecule 
containing multiple fluorine atoms. The failure sequences are not tagged. During 
purification, the crude ODN solution is passed through a column containing 
fluorinated stationary phase. Due to the strong attraction forces between fluorinated 
molecules on the full-length sequences and the stationary phase, the full-length 
sequences have a much longer retention time than the failure ones.[8] As a result, the 
full-length sequences are easily separated from failure ones and other impurities. The 
method can purify ODN in high levels of purity but it has disadvantages. It is 
expensive to scale up and fluorous column is not reusable.  
1.5.4 RP Cartridge  
RP cartridge is a disposable column that contains C-18 alkyl group 
functionalized silica gel. The surface of the silica gel is hydrophobic. During ODN 
synthesis, the DMTr group on the full-length sequences is not removed. The failure 
sequences and other molecules do not contain DMTr group. During purification, the 
crude ODN solution is passed through the column. Due to strong hydrophobic 
attraction, the full-length sequences are eluted much slower than the failure ones, and 
the two are separated.[10] This method is cheap and convenient for short ODNs. 
However, this purification method is not suitable for longer ODNs. The 
hydrophobicity effect of the DMTr groups ultimately diminishes with increasing 
ODNs size. This results in a less efficient purification process overall. Another 
???
?
drawback of this method lies with the extremely susceptible characteristic of the 5?-
DMTr group which results in a general low yield.[8]  
1.5.5 Biotin-Avidin Based Affinity Purification 
The principle of this method is based on the interaction between biotin and 
avidin. A biotin molecule is tagged with full-length ODN during the synthesis. The 
full-length ODN with biotin binds with avidin while the failure sequences which lack 
biotin tag are washed away. The desired ODN is cleaved from avidin 
microspheres.[11-13] This method is convenient to purify small quantities of ODN. 
However, it has disadvantages. It requires harsh conditions to cleave ODN from 
avidin-biotin linkage and is expensive because of the high cost associated with avidin 
which is not reusable. 
1.6 Our Catching by Polymerization ODN Purification Methods 
?
To overcome the problems of known ODN purification technologies, we have 
developed two new methods. Both methods are based on a new concept which is 
catching by polymerization. The following paragraphs briefly describe the principle 
of the two methods and their advantages over known methods.  
1.6.1 First Method: Catching Failure Sequences by Polymerization 
?
The first method is called catching failure sequences by polymerization. 
During automated synthesis, the failure sequences are capped with a phosphoramidite 
that contain a polymerizable group. The full-length sequences are not capped with 
???
?
this phosphoramidite. As a result, the failure sequences contain a polymerizable 
group while the full-length sequences do not. During purification, the crude ODN is 
subjected into a polymerization condition. The failure sequences are incorporated into 
a polymer. The full-length sequences remain in solution. Extraction followed by 
nBuOH precipitation gives pure ODN. The polymerizable group we used is the 
methacrylamide group, which can be incorporated into a polyacrylamide gel. Four 
capping phosphoramidites (1.11-1.14) have been tested so far. All of them worked 
great. However 1.11-1.12 are preferred because they are easier to synthesize and 
cheaper. Scheme 1.2 illustrates how to cap the failure sequences with a polymerizable 
phosphoramidite while leaving the full-length sequences un-capped.  
                  
 
Figure 1.2. Capping reagents for catching failure sequences 
As shown in Scheme 1.2, after the coupling step, the failure sequences 1.6 are 
capped with polymerizable phosphoramidite 1.12. Instead of using acetic anhydride, 
the polymerizable phosphoramidite 1.12 is delivered to the column right after the 
coupling step. The failure sequences 1.6 react with 1.2 to give 1.15, which after the 
???
?
oxidation step, becomes 1.16. The failure sequences 1.16 now contain a 
methacrylamide polymerizable group. After synthesis, cleavage and deprotection, all 
failure sequences are depicted as 1.17 which contains a polymerizable group while 
full-length sequences 1.10 do not. The crude ODN is subjected into radical 
polymerization conditions. N,N-Dimethylacrylamide is used as the polymerization 
monomer and N,N-methylenebisacrylamide is used as a cross-linker. The 
polymerization is initiated with ammonium persulfate (APS) and N,N,N?,N?-
tetramethylethylenediamine (TMEDA). The failure sequences are incorporated into 
the polyacrylamide gel 1.18 (scheme 1.3). The full-length ODN 1.10 remains in the 
gel-matrix. The full-length ODN is extracted with water. At this stage, the full-length 
sequence is still contaminated with small molecules which are resulted from 
protecting groups. However, these small molecules are easily removed by 
precipitation of ODN from NH4OH solution with nBuOH (Scheme 1.3). This 
technology is useful to purify short ODNs because the failure sequences needs to be 
capped in each synthesis cycle and the capping agent is more expensive than acetic 
anhydride. We used this technology to purify different ODNs including short (20-
mer) and relatively longer ones (61-mer). This technology also works well to purify at 
large scales. We tested 3 μmol purification, the results were excellent. The ODNs 
purified by this method has high purity and good recovery yield (? 80%).  
???
?
?
Scheme 1.2. Acrylation of failure sequences using 1.12 during ODN synthesis 
???
?
 
Scheme 1.3. Catching failure sequences by polymerization 
1.6.2 Second Method: Catching Full-length Sequences by Polymerization 
?
The second method is called catching full-length sequences by 
polymerization. In this method, the full-length sequences are tagged with a 
polymerizable phosphoramidite. The failure sequences are capped with acetic 
anhydride. Thus the full-length sequences have a polymerizable group while failure 
sequences do not. The crude ODN is subjected to polymerization. The full-length 
sequences are incorporated into a polymer. The failure sequences remain in the gel-
matrix, which are removed by washing. The full-length ODN is cleaved from the gel 
???
?
using 80% acetic acid followed by extraction. Pure ODN is obtained by nBuOH 
precipitation from NH4OH. The polymerizable tagging agent 1.19 used to catch full-
length is used in our examples. It contains an alkyl trityl ether linkages, which is 
readily cleavable under weekly acidic conditions. The polymerizable group is the 
methacrylamide.  
 
Figure 1.3. Polymerizable tagging phosphoramidite with an acid cleavable linker 
Scheme 1.4 describes the procedure for tagging full-length sequences with a 
polymerizable linker 1.19. During ODN synthesis, failure sequences are capped with 
acetic anhydride in each synthesis cycle. At the end of synthesis, the full-length 
sequence is tagged with the polymerizable phosphoramidite 1.19. The 5? end of full-
length ODN then contains a polymerizable group 1.20. After cleavage and 
deprotection, the crude ODN contains a mixture of full-length ODN 1.21, which 
contains a polymerizable group and the failure sequences, which do not contain a 
polymerizable group.  
???
?
 
Scheme 1.4. Tagging of full-length sequences during ODN synthesis 
 
The crude ODN is subjected into radical polymerization conditions which are 
the same as described for the first purification method. The full-length sequences are 
???
?
incorporated into the polyacrylamide gel 1.24 (Scheme 1.5). The failure sequences 
and other impurities remain in the gel-matrix. The failure sequences and other 
impurities are washed away. The full length ODN is cleaved with 80% acetic acid. 
The full-length ODN is further extracted with water. Pure ODN is obtained after 
nBuOH precipitation from NH4OH.  
 
Scheme 1.5. Purification of ODN by catching full-length  
Using this technology, the polymerizable tagging agent is used only once at 
the last synthetic cycle of ODN synthesis. So the method is suitable to purify longer 
ODNs. In our examples, we used this technology to purify ODNs as long as (151 
mer) and at scales as large as 50 μmol. The purity and recovery yields are very good. 
We believe that the method can be further scaled up easily. 
???
?
1.7 Advantages of Our New Purification Methods 
?
Our new methods have significant advantages over all known ODN 
purification technologies. They do not need any chromatography. Purification is 
achieved by simple manipulations such as mixing, shaking, washing and extraction. 
They do not require large volumes of solvents and expensive column. The 
technologies use inexpensive materials and avoid expensive instrumentation.  As a 
result, they are suitable for large scale and high throughput purification. The ODNs 
purified by the methods have high purity and good recovery yields. The technologies 
use environmentally benign materials and save a substantial amount of energy, which 
are usually needed for solvent evaporation using methods such as RP HPLC. 
The advantages of our technologies over known are summarized in Table 1.1. 
 
 
 
 
 
 
 
 
???
?
Table 1.1. Advantages of the our purification techniques over known ones a 
?
Techniques 
Our methods RP 
HPLC 
IX 
HPLC 
PAGE Fluorous 
b 
Biotin-
Avidin c 
RP 
cartridge 
Expensive instrument No Yes Yes Medium No No No 
Expensive column No Yes Yes No Yes d No Yes d 
Expensive materials No No No No Yes d Yes d Yes d 
Scalability Excellent Medium  Medium No No No No 
High 
throughput 
purification 
Yes No No No No No No 
Desalting  No No Yes No No No No 
Automation Yes No No No No Possible No 
Labor intensive No Yes Yes Yes Medium Medium Medium 
Harmful solvent Minimal  Large  Large Small Small Minimal Medium 
Waste to product ratio 0.1K/1 200K/1 200K/1 50K/1 0.5K/1 0.2K/1 10K/1 
Energy demand e Low High High Low  Low Low High 
Environmental benign High Low f Low f Low g Low h - Low f 
Product purity i 98-100% 80-
100% 
80-
100% 
80-
100% 
85-
100% 
90-100% 70-100% 
Purity dependence  
on loading 
No High High High Low No High  
Recovery yield 80-99% ~70% ~65% ~50% ~80% ~80% ~60% 
Purification time j Fast Slow Slow Slow Fast Medium Fast 
Overall purification 
cost k 
~15% 100% ~120% ~400% ~200% ~250% ~70% 
 
a Information is based on our experience. We tried best to be fair. b Refers to 
fluorous affinity purification. c Refers to biotin-avidin affinity purification. 
dRefers to fluorous support, biotin and avidin, or C-18 silica. e Energy is needed 
for solvent evaporation. f Large amount of harmful solvents. g Large amount of 
acrylamide. h Fluorous materials are not environmental benign. i Purity is 
dependent on batch scale for known techs but not so for MTU techs. j Solvent 
evaporation time is not considered. k Relative to RP HPLC. 
A comarision of different techniques for oligonucleotide purification is shown 
in Table 1.2.  
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The specific details of new ODN purification methods are described in 
subsequent chapters. Purification of ODN by catching failure sequences is described 
in chapters 2 and 3. Chapter 2 describes the detailed investigation of this technology 
while in chapter 3 we highlight the optimization and refinements of this technology 
for practical use. In chapter 4 we describe the second method of purifications, which 
is catching full-length ODN by polymerization. An acid-cleavable linker is used in 
the examples. 
 
 
?
Table 1.2. Costs of different ON purification methods a 
?
Cost 0.2 μmol (~1 mg) 
1 μmol 
(~6 mg) 
10 μmol 
(~60 mg) 
1 mol 
(~6 kg) 
Electrophoresis $125 b $425 b c c 
RP HPLC $45 b $90 b $150 b c 
Fluorous method $18 d $22 d c c 
MTU methods $9 e $10 e $12 e $1,500 e 
Saving over HPLC 80% 88% 92% - 
?
a Based on 20-mer, which has a molecular weight of ~6 kg/mol. 
b Appromxiate Price.  
c No information on the web.  
d Price estimated from website;?????  labor not included. ?
e Estimated number; labor not included; not accurate. 
?
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Abstract
?
Oligodeoxynucleotide (ODN) purification was achieved by capping failure 
sequences with a polymerizable methacrylamide phosphoramidite during automated 
synthesis, polymerizing the failure sequences into an acrylamide gel after cleavage 
and deprotection, and extraction of full-length sequences with water. The details 
regarding the technology including the capping efficiency of four polymerizable 
phosphoramidites, optimal capping time, diffusion speeds of ODN from gels with 
different cross-linking ratios to solution, and the efficiency of ODN extraction from 
gel were investigated. In addition, the technology was tested for purification of a long 
sequence and purification on larger scales. We also found that polymerization of 
failure sequences in a centrifuge tube in air did not affect purification results. Finally, 
we provided additional evidences that ODNs are stable under radical polymerization 
conditions by complete digestion of ODN followed by reversed-phase HPLC analysis 
of nucleosides.  
???
?
2.1 Introduction 
?
 Applications such as total gene synthesis require the production of large 
numbers of short ODNs within a short time with high efficiency.[1-3] An ideal 
method to achieve this is through high throughput production. The high interest in 
using oligonucleotides (ONs) as therapeutic agents to cure human diseases generates 
a need for large quantities of ONs for preclinical research, clinical trial and patient 
use. This requires to develop technologies for large scale production of ON.[4] 
Currently, high throughput and large scale syntheses of ON are possible due to the 
commercialization of oligonucleotide microarray technologies,[5] high throughput 
automated solid phase synthesizer,? [1],? [6] and large scale synthesizer.[7] However, 
the products contain impurities, which must be removed before the applications. The 
impurities can be classified into three types. The first type is the truncated failure 
sequences generated in each synthetic cycle due to incomplete coupling of nucleoside 
phosphoramidite monomer. These failure sequences are capped usually with acetic 
anhydride to prevent them from growing in subsequent synthetic cycles and 
becoming the more difficult-to-remove deletion sequences. For a typical 20-mer 
ODN synthesis, they usually consist of 30-60% ODN content depending on the scale 
of synthesis, quality of reagents and solvents, and carefulness of the synthesizer 
operator to minimize exposure of reagents and solvents to air.[8] Because failure 
sequences have very similar physical properties as the desired full-length sequences, 
this class of impurities is challenging to remove. The second type of impurities is 
small organic molecules from protecting groups. These molecules are neutral, and 
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therefore are easy to remove from the negatively charged full-length sequences. The 
third type impurities include deletion sequences, addition sequences, and sequences 
resulted from depurination as well as other modifications during synthesis, cleavage 
and deprotection. Deletion sequences can be resulted from incomplete capping, and 
incomplete de-tritylation. Addition sequences can be resulted from premature de-
tritylation. Deletion and addition sequences are most difficult to remove. Fortunately, 
they only exist in minute quantities in crude ODN. In ODN production, it is best to 
tune synthesis, cleavage and deprotection conditions to avoid the third type 
impurities. As a result, the major task of ODN purification usually is the removal of 
failure sequences from the full-length sequences. 
 Current methods for ODN purification include gel electrophoresis, ion 
exchange HPLC, trityl-on reversed-phase (RP) HPLC, RP cartridge chromatography, 
hydrophobic RP chromatography,[9] fluorous affinity purification,[8, 10] biotin-
avidin based affinity purification [11-13] and reaction-based solid phase extraction.?
[14] The limitations of these methods in large scale ODN purification have been 
discussed earlier.[15-17] For applications in high throughput purification, gel 
electrophoresis and all chromatographic methods are not practical or highly 
expensive, affinity purification methods may be expensive, and to our best 
knowledge, reaction-based solid phase extraction methods have not been well 
developed. 
  Recently, we communicated our preliminary results on the development of a 
new ODN purification technology based on catching failure sequences by 
polymerization.?[16] Using this method, the failure sequences in crude ODN could be 
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simply removed by co-polymerizing them into an insoluble polymer, and pure ODN 
could be obtained by simple extraction followed by nBuOH  precipitation.[18] The 
method does not require any chromatography, and purification is achieved with 
simple manipulations such as mixing, shaking and extraction. As a result, it is 
potentially useful for large scale and high throughput ODN purification. In this 
article, we further report our detailed studies of the technology.  
2.2 Results and Discussion 
?
The working principle of the catching failure sequences by polymerization ODN 
purification method is detailed in Scheme 2.1. The entity 2.1 represents two of many 
n-mer ODNs on solid support (usually controlled pore glass, CPG) at the end of nth 
synthetic cycle, at which time the 5?-end DMTr (4,4?-dimethoxytrityl) group is 
removed (each cycle contains four steps: coupling, capping, oxidation and 
detritylation). Coupling 2.1 with excess phosphoramidite monomer 2.2 in the 
presence of an activator to generate (n+1)-mer is usually highly efficient, but it is 
inevitable for small amount of n-mer to fail the coupling and therefore generating 
failure sequences. The entity 2.3 represents one failure and one success sequences on 
solid support. Repeated coupling of 2.3 with 2.2 to complete the reaction is not a 
good option due to the expense of 2.2 and potential side reactions such as premature 
detritylation. However, if the failure sequences were carried on to the next synthetic 
cycles, they would become deletion sequences, which are highly challenging to 
remove during purification. As a result, they are usually capped with acetic 
anhydride. For using our catching failure sequences by polymerization ODN 
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purification technology, however, the capping agent is replaced with the 
polymerizable methacrylamide phosphoramidite 2.4, and the resulting material is 
depicted with 2.5. After oxidation and detritylation steps, 2.5 becomes 2.6. The 
synthesis is continued and the capping failure sequences with 2.4 is performed in each 
cycle.  
After cleavage and deprotection, there are mainly three entities in the crude 
product, the failure sequences that contain a methacrylamide group (2.7), the full-
length sequences that do not contain a methacrylamide group (2.8), and small 
organics from protecting groups. The crude product is subjected into radical 
polymerization conditions in the presence of additional polymerization monomer (e.g. 
N,N-dimethylacrylamide) and a cross-linker (e.g. N,N?-methylenebis(acrylamide)).  
The failure sequences are incorporated into an insoluble polymer (2.9). The full-
length sequences (2.8) and small organics remain in solution and are extracted with 
water. The small organics are neutral and soluble in nBuOH, while the full-length 
sequences are anionic and insoluble in nBuOH. The two are separated by 
precipitation of ODN 2.8 with nBuOH from a solution in concentrated NH4OH 
(Scheme 2.1).   
???
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Scheme 2.1. The catching failure sequences by polymerization ODN purification 
method 
Capping Efficiency of Four Methacrylamide Phosphoramidites and Optimal 
Capping Time 
 Previously, we used the methacrylamide phosphoramidite 2.10 as the reagent 
for capping failure sequences.[16] In the present study, we synthesized three more 
(2.11-2.13, Figure. 2.1). The capping efficiency of them and 2.10 were evaluated. 
Compared with 2.10, compound 2.11 has an ether oxygen atom in the linker, which 
may increase its solubility in polar organic solvents such as acetonitrile and have 
better reaction kinetics during capping. Compound 2.12 has two ether oxygen atoms 
in the linker and the linker is longer. These may offer benefits for reaction kinetics in 
both capping and polymerization steps. Compound 2.13 has an even longer linker, 
and in the linker, there is an amide bond. It was expected that the compound exist as a 
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solid at room temperature and therefore its purification and storage be more 
convenient. Compound 2.11 was simply synthesized from amino alcohol 2.14 in two 
steps in excellent yields (Scheme 2.2). The intermediate compound 2.15 is known,?
[19] but we used a different procedure for its preparation (see experimental section). 
Capping phosphoramidites 2.12-2.13 were prepared from 2.16, [20] and 2.18,? [21] 
respectively using the same procedures for preparing 2.11. The intermediate 
compound 2.17 was known,?[22] and 2.19 is new and was fully characterized. 
??? ?
Figure 2.1. Structures of polymerizable capping phosphoramidites. 
Scheme 2.2. Synthesis of polymerizable capping phosphoramidites. 
???
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In our initial studies, during automated ODN synthesis, capping failure 
sequences was performed after the oxidation step that oxidizes the newly formed 
phosphite triester bonds in the success sequences.[16] As a result, after capping, 
another oxidation step was needed to oxidize failure sequences. In the present study, 
we planned to simplify the process by omitting the first oxidation step and to oxidize 
the success and failure sequences in one single step. In addition, reduction of capping 
delivery time and the concentration of capping solutions were also planned. To test 
feasibility, the 20-mer ODN 2.20 was synthesized using a 0.15 M acetonitrile solution 
of 2.11 for capping. After the coupling steps, without oxidation, the capping solution 
was delivered to the synthesis column along with the activator 1H-tetrazole. 
?
 
Figure 2.2. Labelling of ODNs 
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The delivery time and manner were about the same as in the coupling step except that 
the reagents were delivered for two more times, and after each delivery a waiting step 
was added. More specifically, the reagents were delivered to the synthesis column for 
a total of four times (2.0 seconds, 1.5 seconds × 3). After each delivery the reagents 
remained in the column for 90 seconds (Cycle 1 in supporting information). These 
capping steps consumed less capping phosphoramidite compared with those used in 
our initial studies, which were 2.5 seconds, 1.5 seconds × 3 with 0.2 M solution.[16] 
After the capping steps, the column was washed with acetonitrile, and the synthesis 
was allowed to proceed as normal.  
The final detritylation, cleavage and deprotection were also carried out under 
commonly used conditions. The crude product, which was labeled as 2.20(c2.11l) 
(ODN labeling is summarized in Figure 2.2), was analyzed with RP HPLC (trace a, 
Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
???
Figure 2.3. RP HPLC profiles of ODN 2.20(c2.11l). (b) Crude ODN. (b) ODN 
purified with catching by polymerization 
The remaining crude 2.20(c2.11l) was subjected to radical acrylamide 
polymerization conditions widely used for the preparation of gels in electrophoresis 
experiments (Scheme 2.3).  
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Scheme 2.3. Purification of ODN 2.20 by polymerization of failure sequences 
 
Briefly, the crude ODN, which mainly contained the full-length sequences 
2.20, the failure sequences 2.21 and small organic molecules from protecting groups, 
was mixed with a pre- prepared polymerization solution containing the 
polymerization monomer N,N-dimethylacrylamide and the cross-linker N,N?-
methylenebis(acrylamide). Polymerization was then initiated under a nitrogen 
atmosphere with ammonium persulfate and N,N,N?,N?-tetramethylethylenediamine 
(TMEDA). 
The failure sequences were copolymerized into the acrylamide gel 2.22. The full-
length sequences (2.20) and small organics remained in solution, and were extracted 
???
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with water. After evaporation of volatiles and heating with concentrated NH4OH 
briefly, the ODN was precipitated with nBuOH.[16] The purified 2.20(c2.11l) was 
analyzed with RP HPLC (trace b, Figure. 2.3) and the purity was found to be 93%. 
The recovery yield of the purification process was estimated to be 93% by dividing 
the area of the peak at 19 minutes in trace b by that in trace a in Figure 2.3. The 
results indicate that the new agent 2.11 with the simplified capping procedure is 
capable of capping failure sequences completely. We also tested the capping agents 
2.10, 2.12 and 2.13 under the same new ODN synthesis and catching by 
polymerization purification conditions. All of them were found equally suitable for 
the application. The RP HPLC profiles for ODNs 2.20(c2.10l), 2.20(c2.12l) and 
2.20(c2.13l) are shown in supporting information. Their recovery yields and purity 
are shown in Table 2.1.   
In order to see if capping time could be further shortened and at the same time to 
distinguish the efficiency of the four capping reagents, the above ODN synthesis 
procedure was repeated with the capping conditions being changed from 
phosphoramidite and activator delivering time of 2.0 seconds, 1.5 seconds × 3, and 
waiting time of 90 seconds after each delivery to delivering time of 2.0 seconds, 1.5 
seconds × 2, and waiting time of 30 seconds (Cycle 2 in supporting information). 
After cleavage and deprotection, the four crude samples 2.20(c2.11s), 2.20(c2.10s), 
2.20(c2.12s) and 2.20(c2.13s) were purified using the same procedure as described 
above. The purified ODNs were analyzed with RP HPLC, and good purity and 
recovery yields were found (Table 2.1). Because the delivery time of capping 
reagents was almost the same as that of nucleoside phosphoramidite monomers in 
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typical coupling steps (2.0 seconds, 1.5 seconds), further shortening of capping time 
was not pursued. All the four capping phosphoramidites (2.10-2.13) performed 
equally well, and therefore any of them could be used for the catching by 
polymerization technology. However, compounds 2.12-2.13 are relatively more 
expensive to make. Compound 2.13 did not exist as a solid or foam at room 
temperature as we hoped, and moreover, it was found more prone to oxidation during 
purification. As a result, compounds 2.10-2.11 are preferred capping reagents for the 
catching failure sequences by polymerization purification technology. 
 
Table 2.1 ODN purity and recovery yielda
ODN Purity  Recovery yield 
2.20(c2.10l) 89% 92% 
2.20(c2.11l) 93% 93% 
2.20(c2.12l) 99% 72% 
2.20(c2.13l) 100% 81% 
2.20(c2.10s) 100% 82% 
2.20(c2.11s) 100% 86% 
2.20(c2.12s) 98% 95% 
2.20(c2.13s) 94% 70% 
2.23 92% 67% 
2.20(c2.11ls) 94% 73% 
2.20(c2.11dci) 100% 88% 
a Purity was calculated from the areas of ODN and impurity peaks in HPLC profile. Yield was calculated by dividing the area of 
ODN peak in HPLC profile of purified sample by that in the profile of crude sample.   
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Diffusion Speed of ODN From Gel and Extraction Efficiency 
The diffusion speed of ODN from the acrylamide gel to solution is an important 
factor to determine the efficiency of ODN extraction. The purification technology is 
most useful if the diffusion speed is high and ODN can be extracted with high 
efficiency and recovery yield. Our common sense was that gels with higher cross-
linking ratio [the mole ratio of N,N?-methylenebis(acrylamide) over N,N-
dimethylacrylamide] would result in lower diffusion speed and extraction efficiency. 
Gels with lower cross-linking ratio were expected to give better results. However, if 
the cross-linking ratio is too low, the gel may be too soft and therefore difficult to 
handle. We were interested to find a compromised point where the most common 20-
mer ODNs could be extracted with acceptable efficiency while the gel is hard enough 
to be easily handled. From experiments on ODN purification with polyacrylamide gel 
electrophoresis, it is known that gels with a cross-linking ratio of 1:25 are reasonably 
hard and 20-mer ODNs can be extracted from them with acceptable efficiency and 
yields. We therefore decided to start our experiments with this cross-linking ratio.  
???
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Table 2.2 Monitoring ODN diffusion from gels with different cross-linking ratios to 
supernatanta
Entry
Time 
(min) 
ODN Con. 
(ng/μL)b 
% of 
ODNb,g 
ODN Con. 
(ng/μL)c 
% of 
ODNc,g 
ODN Con. 
(ng/μL)d 
% of 
ODNd,g 
ODN Con. 
(ng/μL)e 
% of 
ODNe,g 
ODN Con. 
(ng/μL)f 
% of 
ODNf,g 
1 10 47.7 66.0 29.9 47.5 32.7 45.0 27.1 39.9 25.8 39.3 
2 20 53.3 73.7 37.8 60.1 40.9 56.3 36.0 53.0 34.7 52.9 
3 30 54.7 75.7 43.4 69.0 49.5 68.2 42.0 61.9 37.7 57.5 
4 40 58.6 81.1 48.6 77.3 53.4 73.6 46.9 69.1 42.8 65.2 
5 50 64.6 89.3 50.9 80.9 56.7 78.1 50.5 74.4 47.0 71.7 
6 60 65.1 90.0 54.6 86.8 59.2 81.5 53.3 78.5 50.0 76.2 
7 70 66.4 91.8 56.0 89.0 64.2 88.4 56.1 82.6 53.3 81.3 
8 80 67.6 93.5 58.0 92.2 64.6 89.0 59.7 87.9 56.0 85.4 
9 90 68.6 94.9 59.6 94.8 67.2 92.6 59.9 88.2 58.6 89.3 
10 100 70.9 98.1 61.2 97.3 68.0 93.7 64.0 94.3 59.8 91.2 
11 110 71.7 99.2 62.0 98.6 70.6 97.3 66.2 97.5 65.4 99.7 
12 120 72.3 100 62.9 100 72.6 100 67.9 100 65.6 100 
a Crude ODN containing 2.20 and 2.21 was copolymerized into gel. Water was added to extract 2.20. The concentration of 2.20 
in the supernatant was monitored with UV over a two-hour period. 
b-f In supernatants of gel with cross-linking ratio of 1:2, 1:7, 1:15, 1:25, 1:50, respectively. 
g Calculated by dividing ODN concentration at a specific time by that after 120 min. 
A portion of crude ODN 2.20(c2.11s), which contained 2.21, was subjected to 
polymerization using a polymerization solution that had a mole ratio of cross-linker 
over monomer of 1:25 (see details in Experimental section). Water was added to the 
gel, and small aliquots of supernatant were taken out every 10 min and the 
concentrations of ODN were determined with UV measurement. As shown in Table 
2.2, after 10 min, the concentration of ODN in the supernatant had reached about 
40% (entry 1) of the value at 2 h, at which time the diffusion was close to 
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equilibrium. For the concentration to reach 90% of equilibrium value, about 90 min 
were required (entry 9). To find out how many times were needed to extract all or 
most ODN from gel, after 2 h, the supernatant was removed completely (entry 12, 
Table 2.2 and entry 1, Table 2.3). To the gel, water was added again, and after 2 h, 
the supernatant was removed and its concentration was determined with UV 
measurement (entry 2, Table 2.3). The extraction and UV measurement were repeated 
for three additional times. As shown in Table 3, after two extractions, only about 3% 
extractable ODN remained in the gel (entry 3). After three extractions, the value 
lowered to 0.4% (entry 4). The results in Tables 2.2 and 2.3 indicate that ODN 
2.20(c2.11s) can be efficiently extracted from gel that has a cross-linking ratio of 1:25 
with water for three times in a total of 6 h. 
Table 2.3 Extraction efficiency of ODN from gela 
Entry
Time 
(h) 
ODN Con. 
(ng/μL)b 
% of 
ODNb,g 
ODN Con. 
(ng/μL)c 
% of 
ODNc,g 
ODN Con. 
(ng/μL)d 
% of 
ODNd,g 
ODN Con. 
(ng/μL)e 
% of 
ODNe,g 
ODN Con. 
(ng/μL)f 
% of 
ODNf,g 
1 2 72.3 85.5 62.9 82.4 72.6 77.2 67.9 71.7 65.6 63.3 
2 4 9.5 11.2 10.3 13.5 18.1 19.3 23.5 24.8 22.3 21.5 
3 6 2.8 3.3 3.1 4.1 3.3 3.51 2.6 2.8 13.2 12.7 
4 8 0.0 0.00 0.0 0.0 0.0 0.0 0.4 0.4 2.1 2.0 
5 10 0.0 0.00 0.0 0.0 0.0 0.0 0.3 0.3 0.4 0.4 
a The experiments in Table 2.1 were continued by removing the supernatant after 2 h. Water was added to the gels again, and 
supernatants were removed after 2 h. The extractions were repeated every 2 h for three additional times. 
b-f In supernatants of gel with cross-linking ratio of 1:2, 1:7, 1:15, 1:25, 1:50, respectively. 
g Calculated by dividing ODN concentration in each extract by that of the total amount of ODN extracted from the gel in the 
same volume of water. 
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To find out if a gel with lower cross-linking ratio could offer higher diffusion 
speed and better extraction efficiency, the above experiments were repeated with the 
exception of using a polymerization solution that had a cross-linking ratio of 1:50. As 
shown in Tables 2.2 and 2.3, the diffusion speed and extraction efficiency were not 
better, which was contrary to our prediction. Instead, the data showed a slightly 
slower diffusion speed and lower extraction efficiency although the differences were 
small (e.g. 39.3% vs. 39.9% at 10 min entry 1, and 91.2% vs. 94.3% at 100 min entry 
10, Table 2.2). Because gels with a higher cross-linking ratio gave slightly better 
results, we repeated the experiments with a cross-linking ratio of 1:15 (Tables 2.2 and 
2.3). According to the trend, the diffusion speed and extraction efficiency should 
become better, which was indeed the case although the difference was small again. 
For example, within 10 min, the concentration of ODN in the supernatant had reached 
about 45% of equilibrium value (entry 1). For the concentration to reach 90% of 
equilibrium value, about 80 min were required (entry 8). For extraction efficiency, 
after three extractions, no more ODN was detectable in additional extracts (entry 4, 
Table 2.3). We then further increased the cross-linking ratio to 1:7. The trends of 
diffusion speed and extraction efficiency changes were the same. Within 10 min, the 
concentration of ODN in the supernatant had reached 48% of equilibrium value (entry 
1). For the concentration to reach 90% of equilibrium value, about 70 min were 
needed (entry 7). When the cross-linking ratio was increased to 1:2, within 10 min, 
the concentration reached 66% (entry 1), and the time for reaching 90% was reduced 
to 60 min (entry 6). These results consistently show that the diffusion speed and ODN 
extraction efficiency increase with increased cross-linking ratio of gel. This is 
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significant for the technology because gels with higher cross-linking ratios are harder 
and therefore easier to handle. 
It was quite surprising to find that the ODN diffusion speed and extraction 
efficiency increase with cross-linking ratio. We had expected the contrary because 
gels with higher cross-linking ratio have smaller pores and ODN molecules would be 
more difficult to travel through them. Our explanation of the observed results is that 
the ODN molecules were not totally in the gel even though this seemed impossible 
because the gel with other contents including water and ODN looked like 
homogenous. Instead, when the polymers grew, ODN molecules were expelled or 
partially expelled out from the polymer matrix. With lower cross-linking ratio when 
the pores in polymer were larger, a higher portion of ODN molecules was in the 
polymer matrix, or all ODN molecules were not in the polymer matrix, but they could 
diffuse into it with relatively high rates. These resulted in seemingly lower diffusion 
speeds of ODN from gels to solution and lower extraction efficiency. With higher 
cross-linking ratio when the pores in the polymer were smaller, a lower portion of 
ODN molecules was in the polymer matrix, or all ODN molecules were not in the 
polymer matrix, and they could only diffuse into it with low rates. These resulted in 
seemingly higher diffusion speeds of ODN from gels to solution and higher extraction 
efficiency. 
Long Sequence Purification 
 For long sequence ODN purification, the catching failure sequences by 
polymerization method requires significant amount of polymerizable capping 
phosphoramidite, which is more expensive than acetic anhydride or phenoxyacetic 
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anhydride capping agents used in catching full-length sequences by polymerization 
method.[15] We therefore recommended the catching full-length sequences by 
polymerization method for long sequence purification.[16, 23] However, it is still 
interesting to test the suitability of the catching failure sequences method for ODN 
purification because it may be more convenient in certain applications such as high 
throughput purification. The 61-mer ODN 2.23, which is a portion of the HIV 
protease gene, was selected as the target. The synthesis was carried out on a 0.2 μmol 
scale using the procedure with shortened capping time. Polymerizable 
phosphoramidite 2.11 was used as the capping agent. In the coupling step, after 
finishing phosphoramidite and activator delivery, an additional waiting of 30 seconds 
was added to increase yields (Cycle 2 in supporting information with additional 
waiting after coupling). The crude ODN was purified by catching failure sequences 
by polymerization as we did for shorter sequences. RP HPLC analysis showed that 
the ODN had good purity and recovery yield (Table 2.1 and supporting information). 
The identity of purified ODN was confirmed with ESI-MS (supporting information).  
Purification at Larger Scales 
 After investigation of the effect of several additional factors such as capping 
agent storage time, radical scavenger, harsher deprotecting conditions, lower 
concentration of capping solution, polymerization in air (see supporting information), 
we decided to test the technology for larger scale purification. For this goal, ODN 
2.20 was synthesized on a 1 μmol scale. The synthesis conditions were only slightly 
different from those using shortened capping time described earlier, which was used 
for 0.2 μmol synthesis. The standard 1 μmol synthesis cycle provided by 
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manufacturer of the synthesizer was modified. The steps for capping with acetic 
anhydride were replaced with those for capping with polymerizable phosphoramidite. 
The latter was achieved by delivering the solution of 2.11 in acetonitrile and activator 
to the synthesis column in the same manner as in the coupling steps except that an 
additional delivery was added and a waiting of 30 seconds was added after each 
delivery (Cycle 3 in supporting information). At the end of synthesis, DMTr group 
was removed, and cleavage and deprotection were performed. The crude ODN was 
purified by catching failure sequences by polymerization using the same procedure 
described earlier. The only differences were that the 1 μmol ODN was purified in one 
batch,  the volume of the polymerization solution was increased to 10 times of that 
used in the general 0.05 μmol purification procedure, and the volume of extraction 
water was slightly larger. The ODN, which is labeled as 2.20(c2.11ls), was found to 
have good purity and recovery yield with RP HPLC (Table 2.1 and supporting 
information). It is remarkable that even though the purification scale was increased 
from 0.05 μmol to 1 μmol, which was 20 times, increasing the volume of 
polymerization solution to 10 times was sufficient to catch all the failure sequences. 
We further performed three 1 μmol syntheses simutaneously under conditions 
that are more close to actual large scale ODN production. Specifically, 1H-tetrazole is 
considered as an explosive and not recommended for large scale synthesis. Therefore, 
4,5-dicyanoimidazole (DCI) was used as activator. To save phosphoramidite 
monomers, their concentration was lowered from 0.1 M to 0.05 M. A 0.1 M solution 
of 2.11 in acetonitrile was used for capping. With these modifications, ODN 2.20 was 
synthesized under otherwise the same conditions for the synthesis of 2.20(c2.11ls). 
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According to trityl assay and RP HPLC analysis of crude ODN, the synthesis yields 
were not significantly different from synthesis under conditions without the above 
modifications. The 3 μmol ODN was purified in one batch under the same conditions 
described for purification of 2.20(c2.11ls) and is labeled as 2.20(c2.11dci). RP HPLC 
analysis indicated that the ODN was highly pure and had excellent recovery yield 
(Table 2.1 and supporting information). 
ODN Stability Under Radical Polymerization Conditions 
 A concern on the catching by polymerization purification technologies, which 
involves copolymerization of ODN into polymer under free radical conditions, is the 
potential damage of ODN under such conditions. Polymerization of ODN into 
polyacrylamide gels under radical conditions is known in the literature.[24-26] 
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Figure. 2.4 RP HPLC profiles of nucleosides from ODN enzymatic digestion essay. 
(a) Nucleosides from ODN 2.20(c2.11s), which was purified with the catching by 
polymerization technique. (b) Nucleosides from authentic ODN 2.20. (c) Nucleosides 
from ODN 2.24. (d) Nucleosides from the mixture ODN 2.25. The peaks in a-b and d 
correspond to dC, dG, dT and dA, respectively. Those in c correspond to dC, dG, 8-
oxo-dG, dT and dA, and 2-mercaptoethanol, respectively. The inconsistency of 
retention times in c with those in a-b and d is caused by the use of a different column. 
[min.]
Time
0 5 10 15 20 25
Ab
s (
26
0 n
m)
0
5
10
15
20
Mixture ODN + nucleases
? 
[min.]
Time
0 5 10 15 20 25
Ab
s (
26
0 n
m)
0
5
10
15
ODN 24 + nucleases
? 
[min.]
Time
0 5 10 15 20 25
Ab
s (
26
0 n
m)
-2
0
2
4
6
8
10
Control ODN + nucleases
? 
[min.]
Time
0 5 10 15 20 25
Ab
s (
26
0 n
m)
-2
0
2
4
6
8
10
Pure ODN + nucleases
? 
          ODN 2.24 + nucleases  
          Pure ODN + nucleases  
          Control ODN + nucleases  
          Mixture ODN  + nucleases  
???
?
However, to our best knowledge, detailed study of ODN stability in the presence 
of free radicals has not been reported. Certainly, RP HPLC analysis of ODNs purified 
with the catching by polymerization technologies by comparing with authentic ODN 
strongly supports that ODNs can survive such conditions. Another evidence of 
stability comes from mass spectrometry, which consistently gave molecular mass 
consistent with calculated values.??????? Further, we also subjected the nucleosides 
guanosine, adenosine, thymidine and cytidine to free radical acrylamide 
polymerization conditions, extracted them from the polymer, and analyzed them with 
RP HPLC. No damaged nucleoside was detected. Among the four nucleosides, 
guanosine oxidation is more common, and the oxidation product is 8-oxo-guanosine. 
We compared the guanosine from the polymer with authentic 8-oxo-guanosine by co-
injection into RP HPLC, the two were found to have different retention times, and no 
8-oxo-guanosine was detected in the sample from polymer.[15] However, concerns 
on ODN stability may still remain because this is so important an issue for 
purification, especially for ODN drug purification. For RP HPLC analysis, if only one 
of the 20 bases of a 20-mer ODN is damaged, and the physical properties of the 
damaged nucleobase are not changed significantly, the analysis may not be able to 
differentiate damaged ODN from authentic ODN. For mass spectrometry analysis, if 
only a minute portion of ODN is damaged, the method may not be sensitive enough 
for detection. For the experiments to test stability of nucleosides under radical 
conditions, the reactivity of nucleosides in an ODN may not be the same as individual 
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nucleosides. As a result, all the methods we used to support ODN stability under 
radical conditions are not conclusive. 
To obtain additional evidences on the stability of ODN under radical acrylamide 
polymerization conditions, we used ion exchange HPLC to analyze one of our 
samples purified with the catching failure sequences by polymerization process. It 
was expected that ion exchange HPLC have different resolution on potentially 
damaged ODNs than RP HPLC. To our satisfaction, we still did not found any 
damaged ODN, and only one peak was observed (supporting information). We also 
tried to find any impurity using RP HPLC by UV detecting at 210 nm instead of the 
usually used 260 nm; again, only one peak was observed (supporting information). 
Further, we performed an ODN enzymatic digestion essay to detect any damaged 
nucleosides.[27] A portion of the ODN sample 2.20(c2.11s) purified with the 
catching failure sequences by polymerization method was digested with Snake 
Venom Phosphodiesterase (SVP) into nucleotides, which were dephosphorylated to 
give nucleosides by Bacterial Alkaline Phosphatase (BAP). The neutral nucleosides 
were then separated from the highly polar species including inorganic salts and 
enzymes in the digestion mixture by precipitation of the latter materials by ethanol 
from a sodium acetate buffer. The nucleosides were soluble in ethanol and remained 
in the supernatant. The polar species were not soluble and were precipitated. The 
nucleosides were analyzed with RP HPLC. As shown in Figure 2.4, only four peaks, 
which correspond to the four natural nucleosides, were observed (trace a). No 
additional peaks that correspond to any damaged nucleosides were detected. An 
authentic ODN 2.20, which was from a commercial source and was purified with 
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preparative RP HPLC, was also subjected into the same digestion process. The 
resulting HPLC profile of nucleosides (trace b) was exactly the same as that from 
2.20(c2.21s). Another ODN (2.24), which is 2.20 with one dG being replaced with 8-
oxo-dG (Figure 2.2), was synthesized and purified by DMTr-on preparative RP 
HPLC (see supporting information for crude and pure HPLC profiles and MALDI-
TOF MS), and subjected to digestion.[28] The HPLC profile (trace c) showed five 
peaks besides a peak from 2-mercaptoethanol indicating that the essay could detect 
potentially damaged nucleosides. The relative retention times of the nucleosides 
including 8-oxo-dG were consistent with literature values.[27, 28] To address the 
concern that ODN damage may be dependent on the secondary structures resulted 
from different sequences, a complex mixture of 20-mer ODN (2.25), which contained 
419, theoretical sequences, were synthesized using a mixture of the four nucleoside 
phosphoramidite monomers. The synthesis procedure with a shortened capping time 
was used (Cycle 2 in supporting information), and the failure sequences were capped 
with methacrylamide phosphoramidite 2.11. The crude ODN was subjected to the 
general catching failure sequences by polymerization process (supporting 
information). The resulting mixture of full-length sequences was subjected to the 
same SVP digestion, BAP dephosphorylation, and RP HPLC analysis process (trace 
d, Figure 2.4). Only four peaks were observed. To confirm that the peaks were from 
ODN and not from SVP and BAP, the essay process was repeated without using any 
ODN. No nucleoside peaks were observed (supporting information). The four peaks 
in traces a-b and d correspond to dC, dG, dT and dA, respectively. The areas of them 
are consistent with calculated values (supporting information).? [27] These results 
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provide strong evidence that ODNs with different sequences are stable under the 
radical acrylamide polymerization conditions. Further analysis to detect any minute 
quantities of potentially damaged ODNs under the radical conditions is beyond the 
scope of this study. Future directions would be to use the purified ODNs in molecular 
biology experiments. 
2.3 Experimental 
?
General Methods 
Reagents and solvents commercially available were used as received unless 
otherwise noted. CH2Cl2 was distilled over CaH2 under a nitrogen atmosphere. 
Reactions were carried out under nitrogen in oven-dried glassware. Thin layer 
chromatography (TLC) was performed using TLC plates with silica gel 60F-254 over 
glass support, 0.25 μm thickness. Flash column chromatography was carried out 
using silica gel with particle size of 32 – 63 μm. 1H, 13C and 31P NMR spectra were 
measured at 400, 100 and 162 MHz, respectively. HRMS was obtained using a TOF 
mass analyzer. RP HPLC: A C-18 analytical column (5 μm diameter, 100 Å pore 
size, 250 × 3.2 mm dimension) was used. Solvent A: 0.1 M triethylammonium 
acetate, 5% acetonitrile. Solvent B: 90 % acetonitrile. Profiles were generated by 
detection of absorbance of ODN at 260 nm using the following gradient system 
unless indicated otherwise: solvent B (0%-45%) in solvent A over 60 min followed 
by solvent B (45%-100%) in solvent A over 20 min at a flow rate of 0.5 mL/min. Ion-
exchange HPLC: An analytical Gen-Pak FAX (100 × 4.6 mm) column was used. 
Solvent A: 25 mM Tris/Cl, 1 mM EDTA, pH 8.0. Solvent B: 25 mM Tris/Cl 1 mM 
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EDTA, 1.0 M NaCl, pH 8.0. The profile was generated by detection of absorbance of 
ODN at 260 nm using the gradient system: solvent B (10%-75%) in solvent A over 
30 min followed by solvent B (75%) in solvent A for 30 min at a flow rate of 0.5 
mL/min. Succinic ester linked DMTr-dT-lcaa-CPG (1000 Å pore size) and 5?-DMTr, 
2-cyanoethyl phosphoramidites Pac-dA, benzoyl-dA, acetyl-dC, 4-isopropyl-Pac-dG, 
isobutyryl-dG, dT and other commonly used reagents for solid phase ODN synthesis 
were from  commercial sources. The polymerization solution with a cross-linking 
ratio of 1:25 was used in all cases unless otherwise noted. The solution could be 
stored in a freezer at -20 ºC in dark for one month without affecting the results of 
catching by polymerization purification. High resolution MS and elemental analysis 
data for phosphoramidites were not collected due to their sensitivity to air and 
moisture. 
Methacrylamide 2.15 
 The compound is known,? [19] but a different procedure was used for its 
preparation.  To a round-bottomed flask under a nitrogen atmosphere was added 2.14 
(2.0 g, 19.0 mmol, 1.0 equiv), freshly distilled CH2Cl2 (60 mL), and saturated 
Na2CO3 (60 mL). The mixture was cooled to 0 oC, and methacrolyl chloride (1.86 
mL, 19.0 mmol, 1.0 equiv) was added via a syringe slowly with vigorous stirring. 
After addition, the reaction was allowed to proceed overnight while warming to rt 
gradually. The contents were then transferred into a separatory funnel. After 
removing the organic layer, the aqueous layer was extracted with CH2Cl2 (50 mL × 
3). The combined organic phase was dried over anhydrous Na2SO4, and filtered. 
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Volatiles were removed under reduced pressure. The crude product was purified with 
flash column chromatography (SiO2, CH2Cl2/CH3OH, 9:1) giving 2.15 as a colorless 
oil (3.12 g, 18.0 mmol, 95%): Rf  = 0.7 (SiO2, CH2Cl2/CH3OH, 9:1). 
Phosphoramidite 2.11 
 An oven-dried round-bottomed flask containing 2.15 (0.5 g, 2.89 mmol, 1.0 
equiv) and a magnetic stirring bar was evacuated and then refilled with nitrogen. The 
evacuation and nitrogen-filling cycle was repeated for three times. Freshly distilled 
CH2Cl2 (5 mL) was added via a syringe forming a light yellow solution. 2-
Cyanoethyl-N,N,N’,N’-tetraisopropylphosphoramidite (1.01 mL, 3.18 mmol, 1.1 
equiv) and 1H-tetrazole (0.45 M solution in CH3CN, 7.07 mL, 3.18 mmol, 1.1 equiv) 
were added slowly via syringes sequentially. After stirring at rt for 2 h, the reaction 
mixture was concentrated to dryness using a flow of nitrogen. The residue was 
purified with flash column chromatography (SiO2, hexanes/ethyl acetate/Et3N, 
1:3:0.2) to give 2.11 as a colorless oil (0.98 g, 2.62 mmol, 90%): Rf  = 0.7 (SiO2, 
hexanes/ethyl acetate/Et3N, 1:3:0.2); 1H NMR  (400 MHz, CDCl3) ? 6.29  (br s, 1H), 
5.61 (s, 1H), 5.24 (s, 1H), 3.81-3.60 (m, 4H), 3.57-3.50 (m, 6H), 3.45-3.40 (m, 2H),
2.56 (t, J = 6.4 Hz, 2H), 1.88 (s, 3H), 1.18-1.04 (m, 12H); 13C NMR (100 MHz, 
CDCl3) ? 168.6, 140.2, 119.6, 117.8, 71.2 (d, J = 7.6 Hz), 69.8, 62.9 (d, J = 16.7 Hz), 
58.6 (d, J = 19.7 Hz), 43.2 (d, J = 12.1 Hz), 39.6, 24.8, 24.7 × 2, 24.66, 20.55, 20.47, 
18.8; 31P NMR (162 MHz, CDCl3) ? 148.3. 
Methacrylamide 2.17 
 The compound is known,?[22] but a different procedure, which was the same 
as that for the synthesis of compound 2.15, was used for its preparation. Reaction of 
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compound 2.16, [20] (1.3 g, 8.71 mmol, 1.0 equiv) with methacrolyl chloride (851 
μL, 8.71 mmol, 1.0 equiv) in saturated Na2CO3 (40 mL) and CH2Cl2 (40 mL) gave 
2.17 as a colorless oil after flash column chromatography purification (SiO2, 
CH2Cl2/CH3OH, 9:1; 1.6 g, 7.37 mmol, 85%): Rf = 0.6 (SiO2, CH2Cl2/CH3OH, 9:1).
Phosphoramidite 2.12 
The same procedure for the synthesis of phosphoramidite 2.11 was followed. 
Thus compound 2.17 (500 mg, 2.30 mmol, 1.0 equiv), 2-cyanoethyl-N,N,N’,N’-
tetraisopropylphosphoramidite (0.80 mL, 2.53 mmol, 1.1 equiv) and 1H-tetrazole 
(0.45 M in CH3CN, 5.60 mL, 2.53 mmol, 1.1 equiv) in CH2Cl2 (5 mL) gave 
compound 2.12 as a colorless oil after flash column chromatography purification 
(SiO2, hexanes/ethyl acetate/Et3N, 1:3:0.2; 0.85 g, 2.04 mmol, 88%): Rf  = 0.7 (SiO2, 
hexanes/ethyl acetate/Et3N, 1:3:0.2); 1H NMR  (400 MHz, CDCl3) ? 6.33 (br s, 1H), 
5.61 (s, 1H), 5.22 (s, 1H), 3.76-3.70 (m, 4H), 3.58-3.49 (m, 10H), 3.43-3.38 (m, 2H), 
2.56 (t, J = 6.4 Hz, 2H), 1.86 (s, 3H), 1.10-1.07 (m, 12H); 13C NMR (100 MHz, 
CDCl3) ? 168.5, 140.2, 119.6, 117.9, 71.4 (d, J = 7.6 Hz), 70.7, 70.4, 69.8, 62.8 (d, J 
= 18.2 Hz), 58.6 (d, J = 18.2 Hz), 43.2 (d, J = 12.1 Hz), 39.5, 24.8, 24.7 × 2, 24.66, 
20.5, 20.4, 18.8; 31P NMR (162 MHz, CDCl3) ? 149.5. 
Methacrylamide 2.19 
The same procedure for the synthesis of compound 2.15 was followed. 
Reaction of 2.18[21] (2.0 g, 8.54 mmol, 1.0 equiv) with methacrolyl chloride (0.84 
mL, 8.54 mmol, 1.0 equiv) in CH2Cl2 (80 mL) and saturated Na2CO3 (60 mL) gave 
2.19 as a colorless oil (2.2 g, 7.28 mmol, 85%) after flash column chromatography 
purification (SiO2, CH2Cl2/CH3OH, 9:1): Rf  = 0.4 (SiO2, CH2Cl2/CH3OH, 9:1); 1H 
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NMR  (400 MHz, CDCl3) ? 6.94 (br s, 1H), 6.80 (br s, 1H) 5.58 (s, 1H), 5.19 (s, 1H),
3.53-3.44 (m, 6H), 3.43-3.32 (m, 4H), 3.30-3.24 (m, 4H), 2.19 (t, J = 7.0 Hz, 2H),
1.81 (s, 3H), 1.74-1.66 (m, 2H); 13C NMR (100 MHz, CDCl3) ? 174.1, 169.1, 139.9, 
120.1, 70.3, 69.92, 69.86, 61.7, 50.3, 39.6, 39.4, 33.4, 28.5, 18.7. HRMS (ESI, 
[M+H]+) m/z calcd for C14H27N2O5 303.1914, found 303.1918.
Phosphoramidite 2.13 
The same procedure for the synthesis of phosphoramidite 2.11 was followed. 
Thus compound 2.19 (0.5 g 1.65 mmol, 1.0 equiv), 2-cyanoethyl-N,N,N’,N’-
tetraisopropylphosphoramidite (0.58 mL, 1.82 mmol, 1.1 equiv) and 1H-tetrazole 
(0.45 M in CH3CN, 4.05 mL, 1.82 mmol, 1.1 equiv) in CH2Cl2 (5 mL) gave 
compound 2.13 as a colorless oil after flash column chromatography purification 
(SiO2, hexanes/ethyl acetate/Et3N, 1:3:0.2; 0.75 g, 1.49 mmol, 90%): Rf  = 0.65 (SiO2, 
hexanes/ethyl acetate/Et3N, 1:3:0.2); 1H NMR  (400 MHz, CDCl3) ? 6.40 (br s, 1H), 
6.22 (br s, 1H), 5.64 (s, 1H), 5.27 (s, 1H), 3.84-3.69 (m, 2H), 3.65-3.41 (m, 14H),
3.40-3.32 (m, 2H), 2.58 (t, J = 6.0 Hz, 2H), 2.24 (t, J = 7.4 Hz, 2H), 1.95-1.87 (m, 
5H), 1.16-1.08 (m, 12H); 13C NMR (100 MHz, CDCl3) ? 172.8, 168.6, 140.2, 119.7, 
118.0, 70.4, 69.9 (d, J = 18.3 Hz), 62.9 (d, J = 16.7 Hz), 58.4 (d, J = 19.8), 58.5, 45.5 
(d, J = 6.0 Hz), 43.1 (d, J = 10.6), 39.5, 39.3, 33.1, 27.3, 24.8 × 2, 23.11, 23.04, 20.6, 
20.3, 18.8; 31P NMR (162 MHz, CDCl3) ? 149.5. 
Synthesis of ODN 2.20 Using Polymerizable Phosphoramidites 2.10-2.13 to Cap 
Failure Sequences – The General ODN Synthesis Procedure 
The synthesis using 2.11 as the capping agent is described as an example. The 
phosphoramidite chemistry was used. CPG (1000 Å pore size) with a LCAA-succinyl 
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ester linkage was used as the solid support. The phosphoramidite monomers used 
were Pac-dA-CE, Ac-dC-CE, i-Pr-Pac-dG-CE and dT-CE. For capping failure 
sequences, a 0.15 M solution of 2.11 in dry acetonitrile (distilled under nitrogen or 
from a commercial source) was placed on the 5th phosphoramidite position. The two 
bottles normally used for storing Ac2O capping reagents were left empty. A new 
synthetic cycle was created by copying the standard 0.2 μmol synthesis cycle into a 
new file. The steps for capping failure sequences with Ac2O were deleted. After the 
coupling steps, new steps for delivering 2.11 from the 5th bottle position and 1H-
tetrazole solution from the 9th position (i.e. the same activator for the coupling steps) 
were added. These steps were the same as those in the coupling steps except that the 
base was from the 5th bottle, the reagents were delivered for two additional times, and 
after each delivery a waiting of 90 seconds was added. More specifically, the 
solutions of 2.11 and 1H-tetrazole were delivered to column for 2.0 seconds, 1.5 
seconds × 3, and after each delivery, the reagents remained in the column for 90 
seconds. After capping, steps for washing the column with acetonitrile and oxidation 
were added (Cycle 1 in supporting information). The synthesis was initiated using the 
above reagents and cycle on a 0.2 μmol scale. In the last synthetic cycle, the 5?-DMTr 
group was removed. Cleavage and deprotection were carried out on the synthesizer 
with concentrated NH4OH (900 min × 4) at rt. The synthesized ODN is labeled as 
2.10(c2.11l). The same sequence was synthesized under the same conditions using 
polymerizable phosphoramidites 2.10 and 2.12-2.13 as capping reagent giving 
2.20(c2.10l), 2.20(c2.12l) and 2.20(c2.13l), respectively. 
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Purification of ODN 2.20 by Polymerization of Failure Sequences – The General 
ODN Purification Procedure 
Purification of 2.20(c2.11l) is described as an example. The ODN solution 
from the synthesizer was divided equally into four portions and dried in centrifuge 
tubes in a centrifugal vacuum concentrator. One portion was dissolved in 150 μL 
water, 20 μL was injected into RP HPLC to generate trace a (Figure 2.3). The 
remaining 130 μL solution was transferred into a 25 mL 2-necked round-bottomed 
flask containing a magnetic stirring bar. The centrifuge tube was washed with water 
(40 μL × 3), and the washes were transferred to the same flask. A polymerization 
solution (250 μL, cross-linking ratio 1:25) was added via a pipette under positive 
nitrogen pressure. The solution was gently stirred under a nitrogen flow at rt. After 5 
min, the nitrogen flow was stopped but stirring was continued under a nitrogen 
atmosphere. The polymerization reaction was then initiated with (NH4)2S2O8 (10%, 5 
μL) and N,N,N?,N?-tetramethylethylenediamine (TMEDA, 5 μL), which were added 
sequentially via a pipette and a syringe, respectively. A clear gel was formed within 5 
min and stirring stopped automatically. The gel was allowed to stand for 1 h to ensure 
complete polymerization.
The gel was broken into about 4 pieces with a clean spatula or preferably a knife 
with a sharp blade that does not grind the gel into fine pieces. To the flask, sufficient 
water that could cover all the gel (~3 mL) was added. The mixture was stirred or 
shaken gently at rt for 3 h. The supernatant was separated from the gel. The gel was 
further extracted with water (3 mL × 3) under the same conditions. After the volume 
was reduced in a centrifugal vacuum concentrator, the extracts were filtered into one 
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1.5 mL centrifuge tube that has a spin filtration function. The extracts were 
evaporated into dryness. To the residue, concentrated NH4OH (100 μL) was added. 
The tube was closed. After vortexing and centrifuging briefly, it was kept for 25 min 
on a heating block that was pre-heated to 80 oC. The solution was then cooled to rt, 
and nBuOH (900 μL) was added. The tube was vortexed for 30 sec and centrifuged 
for 8 min at 14.1 relative centrifugal forces. The supernatant was removed carefully 
with a pipette. The residue was dried in a centrifugal vacuum concentrator shortly, 
and then dissolved in 130 μL water. After vortexing and centrifuging shortly, 20 μL 
was injected into RP HPLC to generate trace b (Figure 2.3). The recovery yield of the 
catching by polymerization process was estimated to be 93% by dividing the area of 
the peak at 19 min in trace b by that in trace a (Figure 2.3). Crude ODNs 2.20(c2.10l), 
2.20(c2.12l) and 2.20(c2.13l) were purified using the same procedure, and their 
recovery yields and purity are in Table 2.1. RP HPLC profiles are in supporting 
information. 
Synthesis of ODN 2.20 Using Polymerizable Phosphoramidites 2.10-2.13 to Cap 
Failure Sequences with Shorter Capping Time 
ODN 2.20 was synthesized again following the general ODN synthesis 
procedure described earlier on a 0.2 μmol scale except that the capping time was 
decreased from 2.0 seconds, 1.5 seconds × 3 deliveries and 90 seconds waiting after 
each delivery to 2.0 seconds, 1.5 seconds × 2 deliveries and 30 seconds waiting after 
each delivery (Cycle 2 in supporting information). The synthesized ODNs are labeled 
as 2.20(c2.10s), 2.20(c2.11s), 2.20(c2.12s) and 2.20(c2.13s). 
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Purification of ODN 2.20 Synthesized Using Shorter Capping Time by 
Polymerization of Failure Sequences 
The general ODN purification procedure described earlier was used. The RP 
HPLC profiles are in supporting information. The recovery yields and purity are in 
Table 2.1. 
Diffusion Speed of ODN From Acrylamide Gel and Extraction Efficiency 
One fourth of the crude ODN 2.20(c2.11s) was subjected into the radical 
acrylamide polymerization conditions in a 25 mL 2-necked round-bottomed flask as 
described in the general ODN purification procedure. The polymerization solution 
used in the procedure had a 1:25 cross-linking ratio between the cross-linker N,N?-
methylenebis(acrylamide) and the polymerization monomer N,N-dimethylacrylamide. 
After complete polymerization, the gel was broken into several pieces with a clean 
spatula. Water (3 mL) was added to the gel, and the mixture was stirred gently with 
magnetic stirring bar. The aliquots of supernatant (5 μL each) were taken out via a 
pipette in every 10 min until 2 h. The ODN concentrations in the aliquots were 
determined using a UV-Vis spectrophotometer at 260 nm (Table 2.2). At 2 h, all the 
remaining supernatant were taken out and transferred into clean centrifuge tubes. The 
ODN concentration in the supernatant was determined with UV. To the gel was added 
water (3 mL) again and the mixture was gently stirred. After 2 h, the supernatant was 
removed and the ODN concentration was determined with UV. The extraction and 
ODN quantification process was performed for three more times (Table 2.3). The 
ODN diffusion and extraction studies were repeated four more times using 
polymerization solutions with a different cross-linking ratio. One with a ratio of 1:50 
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between N,N?-methylenebis(acrylamide) and N,N-dimethylacrylamide, and the others 
1:15, 1:7 and 1:2. The data were recorded in Tables 2.2 and 2.3.    
Synthesis of Long Sequence ODN 2.23 
The 61-mer ODN 2.23 was synthesized on a 0.2 μmol scale using 
phosphoramidite 2.11 for capping failure sequences. The general synthesis procedure 
with shorter capping time (Cycle 2 in supporting information) was used except that a 
30 seconds additional waiting step was added after the coupling steps to increase 
coupling yields.   
Purification of ODN 2.23 by Polymerization of Failure Sequences 
 The general ODN purification procedure was used. The RP HPLC profiles 
from crude and purified ODN 2.23 were generated using a different buffer A that 
contained 10% urea under otherwise the same conditions described in the general 
methods section (supporting information). Recovery yield and purity are in Table 2.1. 
The purified 2.23 was analyzed with negative ESI MS using Waters’ Tofspec-2E, 
calcd for C599H749N235O361P60 18875.1, found 18875.1. Image of the MS is included 
in supporting information. 
Synthesis of ODN 2.20 on a Larger Scale 
 The general ODN synthesis procedure was followed except that a different 
synthesis cycle was used. To create the new cycle (Cycle 3 in supporting 
information), the standard 1 μmol synthesis cycle provided by the manufacturer of the 
synthesizer was copied into a new file. The steps for capping failure sequences with 
Ac2O were deleted. After the coupling steps, new steps for delivering polymerizable 
phosphoramidite 2.11 (0.15 M acetonitrile solution) from the 5th phosphoramidite 
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bottle position and 1H-tetrazole solution from the 9th position (i.e. the same activator 
for the coupling steps) were added. These steps were the same as those in the 
coupling steps except that the base was from the 5th bottle, one additional delivery of 
reagents was added, and after each delivery a waiting of 30 seconds was added. More 
specifically, the solutions of 2.11 and 1H-tetrazole were delivered to column for 2.5 
seconds × 3, and after each delivery, the reagents remained in the column for 30 
seconds. Other modifications of the cycle were the same as detailed in the general 
synthesis procedure. The synthesis was performed using this new cycle at 1 μmol 
scale following the conditions described in the general synthesis procedure. The ODN 
is labeled as 2.20(c2.11ls) 
Purification of 2.20(c2.11ls) by Polymerization of Failure Sequences 
 The general ODN purification procedure was followed. The 1 μmol ODN was 
purified in one batch. The volume of the polymerization solution was 10 times of that 
used in 0.05 μmol scale purification described in the general procedure. Extraction of 
full-length sequences from gel was achieved by water (4 mL × 4). HPLC profiles are 
in supporting information. Recovery yield and purity are in Table 2.1. 
Synthesis of ODN 2.20 with DCI as Activator 
 ODN 2.20 was synthesized under the same conditions described for the 
synthesis of 2.20(c2.11ls) except for the following modifications. DCI (0.25 M in 
acetonitrile) instead of 1H-tetrazole was used as the activator for coupling and 
capping. The concentration of phosphoramidite monomers was lowered from 1.0 M 
to 0.05 M. Capping was performed using a 0.1 M acetonitrile solution of 2.11. The 
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synthesis was performed in three 1 μmol columns simultaneously. The ODN is 
labeled as 2.20(c2.11dci). 
Purification of 2.20(c2.11dci) by Polymerization of Failure Sequences 
 The 3 μmol ODN was purified in one batch following the procedure for the 
purification of 2.20(c2.11ls). The volumes of the polymerization solution and 
extraction solutions were increased proportionally (i.e. 3 times of those for the 1 μmol 
2.20(c2.11ls) purification). The volumes of the polymerization initiators and the 
reagents for ODN precipitation from NH4OH solution by nBuOH were not changed. 
The RP HPLC profiles from crude and purified ODN 2.20(c2.11dci) including one 
that was generated by UV detection at 210 nm from the purified ODN are included in 
supporting information. Recovery yields and purity are in Table 2.1. 
Synthesis of Mixture ODN 2.25 
The general ODN synthesis procedure with a shorter capping time was 
followed (Cycle 2 in supporting information). The synthesis was carried out on a 0.2 
μmol scale using polymerizable phosphoramidite 2.11 for capping failure sequences. 
To synthesize the mixture ODN, the solution of Pac-dA-CE, Ac-dC-CE, i-Pr-Pac-dG-
CE and dT-CE in 1:1:1:1 mole ratio was used as the phosphoramidite monomers in 
the coupling steps in all synthesis cycles. The cycle was executed 20 times to give the 
20-mer ODN mixture 2.25. At the end of synthesis, the DMTr group was removed. 
The ODN were cleaved and deprotected with concentrated NH4OH at rt on 
synthesizer. 
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?
Purification of ODN Mixture 2.25 by Polymerization of Failure Sequences 
 The general ODN purification procedure was used to remove failure 
sequences. The RP HPLC profiles from crude and purified ODN 2.25 (only failure 
sequences were removed; theoretically it still contained 419 sequences) are included in 
supporting information. The recovery yield of the purification process was estimated 
to be 78%. 
ODN Stability Studies Through Nuclease Digestion Followed by RP HPLC 
Analysis
To a 1.5 mL centrifuge tube, which contained 18 μg ODN 2.20 purified by 
catching failure sequences by polymerization, was added 29 μL master mixture 
solution containing 16.45 unit SVP (Worthington Biochemical Corporation), 0.4 unit 
BAP (TaKaRa Bio Inc.), and 1× of BAP buffer. The tube was vortexed and 
centrifuged briefly to mix thoroughly and to bring the master mixture to the bottom of 
the tube. The mixture was then incubated at 37 ºC for 24 h. The digested ODN was 
then prepared for RP HPLC analysis following reported procedure.[27] Briefly, 
sodium acetate buffer (3 M, 4 μL) and ethanol (100 μL) were added into the tube. 
The tube was then vortexed shortly and chilled on dry ice for 10 min. After 
centrifuging for 5 min at 14.1 relative centrifugal force, the supernatant was carefully 
transferred into another 1.5 mL centrifuge tube. To the tube was added ethanol (300 
μL), and the contents were vortexed and chilled on dry ice again for 10 min. The tube 
was centrifuged for 5 min, and the supernatant was transferred into a new 1.5 mL 
centrifuge tube. After drying in a centrifugal vacuum concentrator, the nucleosides 
were dissolved in water (30 μL). The sample (20 μL) was analyzed with RP HPLC 
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under the conditions described in the General section except that the gradient system 
was changed to: solvent A (100%) for 5 min, solvent B (0%-10%) in solvent A over 
30 min, followed by solvent B (10%-100%) in solvent A over 25 min. The resulting 
profile is shown in Figure. 2.4 (trace a). The same ODN digestion and RP HPLC 
analysis procedure was applied to a control ODN (18 μg) from a commercial source 
purified with preparative RP HPLC (trace b), the mixture ODN 2.25 (33 μg, trace d), 
and a blank control (supporting information). The control ODN 2.24 (9 μg) was 
synthesized and digested following known procedure (trace c).[28]  
Effect of One-Month Old Capping Agent on Purification 
 For the catching by polymerization purification technology to be practically 
useful, it is important that capping phosphoramidites stored for a reasonable time 
have a similar capping efficiency as freshly prepared ones. For this reason, we stored 
compound 2.11 in a freezer under a nitrogen atmosphere at -20 ºC. After one month, 
its acetonitrile solution was prepared and used for the synthesis ODN 2.20 for 
capping failure sequences. The synthesis procedure with shortened capping time 
(Cycle 2) was used. The crude ODN, which is labeled as 2.20(c2.11o), was purified 
with the catching failure sequences by polymerization method. RP HPLC analysis 
(see this supporting information) indicated that the purification results were the same 
as with freshly prepared capping agents. The recovery yield of the purification 
process was estimated to be 87%. The purity is 92%. 
Effect of Radical Scavenger on Purification 
 For one time, when pure phosphoramidite 2.10, which was a thick oil, was 
dried under high vacuum at room temperature overnight, it became a gel. The reason 
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is that under such conditions, the amount of oxygen, which serves as a radical 
scavenger, was significantly reduced, and radical polymerization occurred. To avoid 
premature radical polymerization, since then all capping phosphoramidites (2.10-
2.13) were dried over drierite in a dessicator under a relatively low vacuum (achieved 
using an oil pump for an appropriate time and then close the dessicator) at -20 ºC in a 
freezer overnight. With the new drying method, we never met premature 
polymerization problem again. In the case of the solution of the methacrylamide 
phosphoramidites (2.10-2.13) in acetonitrile, premature polymerization never 
occurred in our hands. They are stable for at least three days on a synthesizer or in a 
freezer (-20 ºC) under nitrogen. Despite these favorable observations, potential users 
of the technology may still be interested to know if the capping steps during ODN 
synthesis are compatible with radical polymerization inhibitors in the capping 
solution. To clarify, ODN 2.20 was synthesized using the procedure with shortened 
capping time (Cycle 2). The solution of 2.11 (0.15 M) in acetonitrile with 500 ppm 
2,6-di-tert-4-methylphenol was used for capping. The crude ODN was purified by 
catching failure sequences in the usual way. RP HPLC analysis (see this supporting 
information) revealed that the ODN, which is labeled as 2.20(c2.11i), was pure 
indicating that the radical scavenger studied did not adversely affect the purification 
results. The recovery yield of the purification process was estimated to be 97%. The 
purity is 98%. 
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Effect of Harsher Deprotecting Conditions on Purification 
 In our studies so far, the exo-amino groups on adenine and guanine were 
protected with phenoxyacetyl (Pac) and isopropyl-phenoxyacetyl (i -Pr-Pac) groups, 
respectively. These groups along with the acetyl group on cytosine were removed 
with concentrated NH4OH at room temperature after synthesis. This protecting 
strategy has the advantage of avoiding deprotection under ammonia pressure in a 
sealed vial at elevated temperature. In the less expensive and more commonly used 
ODN synthesis methods, adenine and guanine are protected with benzoyl and 
isobutyryl groups, respectively, and deprotection are usually achieved with 
concentrated NH4OH at elevated temperature. Previously, we showed that the harsher 
deprotecting conditions were compatible with the catching full-length sequences by 
polymerization ODN purification technology (Y. Yuan et al, RSC Adv., 2012, 2, 
2803). Here, we show that the conditions are also compatible with the catching failure 
sequences method. The ODN 2.20 was synthesized on a 0.2 μmol scale using the 
more commonly used protecting strategy (benzoyl for dA, isobutyryl for dG, and Ac 
for dC). The synthetic cycle with shortened capping time described earlier (Cycle 2) 
was used for the synthesis, and phosphoramidite 2.11 was employed for capping 
failure sequences. At the end of synthesis, DMTr group was removed, and cleavage 
was performed on the synthesizer with concentrated NH4OH (900 min × 4) at rt. 
Deprotection was achieved by heating the concentrated NH4OH solution in a screw 
capped vial at 65 ºC for 8 h. The ODN, which was labeled as 2.20(c2.11c), was 
purified by catching failure sequences by polymerization as usual. RP HPLC analysis 
showed that the ODN was pure (see this supporting information). The recovery yield 
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of the purification process was estimated to be 76%. The purity is 93%. The results 
indicate that the catching failure sequences by polymerization purification method is 
equally effective when protecting groups that require harsher deprotecting conditions 
are used during ODN synthesis. 
Capping with Lower Concentration Polymerizable Phosphoramidite Solution 
 In our preliminary communication, we used a capping solution with a 
concentration of 0.2 M to cap failure sequences (S. Fang et al, Chem. Commun., 
2011, 47, 1345). In the present work, we reduced the concentration of capping 
solution to 0.15 M. Good purification results were obtained in both cases. In the 
coupling steps, the concentration of nucleoside phosphoramidite monomers we used 
was 0.1 M. We were interested in further reducing the concentration of the capping 
solution to this value. For the purpose, ODN 2.20 was synthesized using the 
procedure with shortened capping time (Cycle 2). Capping failure sequences was 
performed with a 0.1 M solution of 2.10. The resulting ODN, which is labeled as 
2.20(c2.10lc), was purified by catching failure sequences by polymerization as usual. 
RP HPLC analysis showed that the ODN was equally pure (see this supporting 
information). The recovery yield of ODN was estimated to be 90%. The purity is 
99%. 
Purification by Polymerization in Air 
 So far in all of our studies, the polymerization step, in which failure sequences 
were incorporated into a polyacrylamide gel, was performed under a nitrogen 
atmosphere to minimize the chances of termination of polymerization by oxygen. 
This may not be convenient for some applications such as high throughput 
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purification. Noting that excess initiators were used and cross-linking could connect 
terminated polymer segments, we tested to perform the step in air in a 1.5 mL 
centrifuge tube. A portion of ODN 2.20(c2.11s) in a centrifuge tube was simply 
dissolved in water and polymerized by adding polymerization solution and initiators 
to the tube directly. Interestingly, the polymerization speed was not found slower than 
that under nitrogen atmosphere, and the gel was formed within 5 min. After waiting 
for complete polymerization for 1 h, extraction of full-length sequences with water 
was also carried out directly in the same tube. The remaining steps were the same as 
in the general purification procedure. RP HPLC showed that the ODN was equally 
pure (see this supporting information). The recovery yield was estimated to be 87%. 
The purity is 100%. Polymerization under nitrogen in large scale purifications should 
be quite convenient, and is not expected to add any significant cost to the process. 
However, for high throughput purification, handling many samples at the same time 
under a nitrogen atmosphere may require special equipment. Therefore, the results are 
important for applying the technology in high throughput ODN purification.  
2.4 Conclusion 
?
Several details of the catching failure sequences by polymerization ODN 
purification technology were investigated. We found that the four methacrylamide 
phosphoramidites 2.10-2.13 were similarly effective for capping failure sequences in 
the purification technique. However, because 2.10 and 2.11 are easier to prepare, they 
are the best choices. The studies on the diffusion speeds of ODN from 
polyacrylamide gel to solution indicate that extraction of ODN from gel is efficient. 
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Normally, three extractions will recover more than 90% ODN. Contrary to our 
prediction, ODN extraction efficiency is higher in the case of gels with higher cross-
linking. This is a favorable finding for the technology because gels with higher cross-
linking are harder and easier to work with. The technology was successfully applied 
for the purification of a long sequence and purification at a larger scale. Capping 
failure sequences with older methacrylamide phosphoramidite and phosphoramidite 
solution containing a radical scavenger were also studied and were found that they 
have little adverse effects on the purification results. The more commonly used exo-
amino nucleobases protecting groups that require harsher conditions to remove were 
tested in the ODN purification method. They were found equally compatible with the 
technology as the more labile phenoxyacetyl protecting groups. Polymerization in air 
is more convenient than under a nitrogen atmosphere. This is especially important for 
high throughput purification. We demonstrated that it does not affect purification 
results. Finally and most importantly, we provided further evidences to support that 
ODNs are stable under free radical acrylamide polymerization conditions. This study 
is most important in the context of ODN drug purification. 
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Abstract
?
Purification of synthetic oligodeoxynucleotides (ODNs) is simply achieved by 
capping failure sequences with a polymerizable phosphoramidite followed by 
polymerization. In this article, the reduction of the amount of polymerization 
monomer to drastically increase ODN extraction efficiency, the use of a centrifugal 
filter unit to ease the extraction process and the notification of using fresh 
phosphoramidite solutions are described. In addition, further evidence to support the 
purity of ODN and discussions of ODN stability under radical polymerization 
conditions are provided. 
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3.1 Introduction 
?
Synthetic oligodeoxynucleotides (ODNs) have found wide applications in 
areas such as molecular biology, synthetic biology and antisense drug 
development.[1] Their syntheses have been automated. Large scale and high 
throughput syntheses are both possible.[2-6] During synthesis, the first nucleoside is 
attached to a solid support. Subsequent nucleosides are added sequentially to give the 
full-length ODN. The coupling reactions are highly efficient, but cannot be 100%, 
which inevitably generates failure sequences. These failure sequences are usually 
capped with acetic anhydride to ease purification. At the end of synthesis, the ODN is 
cleaved from support and fully deprotected. The product contains failure sequences 
and small molecules besides full-length sequences, and has to be purified for most 
applications and ideally for all applications. The small molecules are easy to remove 
because they are neutral and ODNs are anionic. Removal of failure sequences is, 
however, more difficult. Currently, the most widely used method is HPLC. 
Drawbacks include high cost of instrument and column, labor intensiveness, and high 
waste to product ratio. The method is difficult to automate, expensive to scale up, and 
unsuitable for high throughput purification. Other methods have been developed to 
solve the problems[7-13], but still have various shortcomings.[14]  
 We recently reported a catching failure sequences by polymerization method 
for ODN purification.[14, 15] In this method, the failure sequences are capped with a 
polymerizable phosphoramidite such as 3.1 (Figure 3.1). Purification is achieved by 
copolymerization with N,N-dimethylacrylamide. The failure sequences are 
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incorporated into polymer. The full-length sequences and small molecules remain in 
solution and polymer matrix. Extraction with water and nBuOH precipitation gives 
pure ODN. In this letter, we report several highly important refinements of the 
technology. In our initial procedure, large excess of polymerization monomer was 
used. One refinement is to reduce this amount. This refinement drastically increased 
the extraction efficiency of ODN from polymer. Previously, extraction of ODN was 
accomplished by pipetting supernatant, which was inconvenient. The second 
refinement is to carry out polymerization in a centrifugal filter unit and to perform 
extraction by simple spins. Besides these refinements, further evidences to prove the 
purity of ODN, and the explanation of the stability of ODN under radical 
polymerization conditions are provided.  
 The greatly simplified procedure is demonstrated by the purification of the 20-
mer ODN 5?-TCA TTG CTG CTT AGA CCG CT-3? (3.2). The ODN synthesis 
procedure, which includes capping failure sequences by 3.1, was similar as previously 
described.[15] Briefly, the synthesizer manufacturer (ABI 394) suggested 1 μmol 
DNA synthesis cycle was copied to create a new cycle. The steps for capping with 
acetic anhydride were replaced with those for capping with 1, which were achieved 
by delivering 3.1 and activator to column. The delivery method was the same as the 
coupling steps except that an additional delivery was added (2.5 seconds × 3) and 
after each delivery a wait of 30 seconds was added. Following capping, three washes 
(acetonitrile to column, 10 seconds; reverse flush, 6 seconds) were added. The 
synthesis was set up as usual with 3.1 (0.1 M in acetonitrile)[15] being placed in 
bottle 5. 4,5-Dicyanoimidazole (0.25 M in acetonitrile) was used as activator. 
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Because the catching by polymerization method can isolate full-length ODN from 
very complex mixture, we lowered the concentration of phosphoramidite monomer 
(Pac-dA, acetyl-dC, 4-isopropyl-Pac-dG, dT) solutions from the usually used 0.1 M 
to 0.05 M (in acetonitrile). At the end of synthesis, detritylation was performed. 
Cleavage and deprotection were carried out with concentrated NH4OH at room 
temperature on synthesizer (15 min × 4, then 2 h). The solution was divided into four 
portions and dried in 1.5 centrifugal tubes. One portion was dissolved in 600 μL 
water, 20 μL was injected in to HPLC to give the crude profile (trace A, Figure 3.2). 
Another portion of the crude 3.2 (~0.25 μmol) was dissolved in 50 μL water. 
Short vortex and spin were performed to ensure complete dissolution and bring down 
solution to bottom. To the solution was added 6 μL polymerization solution (0.37 M 
N,N?-methylenebisacrylamide and 3.7 M N,N-dimethylacrylamide) followed by a 
short vortex and spin. The molar ratio of the polymerization monomer over ODN is 
~100/1. The initiators (NH4)2S2O8 (5%, 5 μL) and TMEDA (0.66 M, 5 μL) were then 
added. After a short vortex and spin, the mixture was transferred to the center of the 
filter in a centrifugal filter unit (2 mL, pore size 7-20 μm, Aldrich) immediately in 
one portion (Figure 3.1).[16] 
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Figure 3.1. The catching failure sequences by polymerization ODN purification 
technology. (A) Working principle. (B) Picture of centrifugal filter units. (C) 
Workflow: (a) To crude ODN in a centrifugal tube are added polymerization 
monomer, cross-linker and initiators. After mixing, the contents are transferred to the 
upper tube of a centrifugal filter unit. (b) The cap is closed and the mixture is allowed 
to polymerize for 1 h. (c) The gel is cut into several pieces and the supernatant is 
collected in the lower tube by spin. To the gel was added water. After standing at 
room temperature for 10 min, spin again. The extraction is repeated two more times. 
(d) The upper tube is removed, and the filtrate is evaporated to dryness. (e) To the 
residue is added concentrated NH4OH,  warmed for 15 min at 80 ºC in a heating 
block. After cooling to room temperature, nBuOH is added. The mixture is vortexed 
and then spun for 2 min. (f) The supernatant is removed by a pipette. 
???
Figure 3.2. HPLC profiles of ODN 3.2. Conditions: column, C-18, 5 μm, 100 Å, 250 
× 3.20 mm; solvent A, 0.1 M triethylammonium acetate, 5% acetonitrile; solvent B, 
90% acetonitrile; gradient, solvent B (0%-45%) in solvent A over 60 min; flow rate, 
0.5 mL/min; detection, 260 nm. 
It is suggested to close the bottom of the tube, but we found that the solution 
would not leak even without closing. Care needs to be taken to transfer all contents 
and to avoid splashing, which is easily achievable by manipulating the pipette with a 
steady force as opposed to abrupt sucking and pushing. The unit was closed and the 
mixture was allowed to polymerize for 1 hour. The gel was cut into about four pieces, 
and the bottom of the upper tube was opened. The unit was spun for about 30 
seconds, which separated the supernatant from gel. To the upper tube was added 50 
μL water, which should cover all the gel. After standing for 10 minutes, the unit was 
spun. The extraction was repeated two more times. The supernatants were evaporated 
to dryness. To the residue, 100 μL concentrated NH4OH was added, and the mixture 
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was heated to 80 ºC for 15 minutes on a heating block (CAUTION: safety goggles 
and face shield are needed for potential explosion). After cooling to room 
temperature, 900 μL nBuOH was added. The mixture was vortexed shortly and spun 
for 2 minutes. The supernatant was removed with a pipette. The white flake was pure 
ODN. To determine purity and recovery yield, it was dissolved in 600 μL water, and 
20 μL was injected into HPLC to give trace B (Figure 3.2). The ODN was 100% 
pure. The recovery yield was estimated to be 97% by dividing the area of the peak at 
15.5 minutes in trace B by that in trace A. To see if more ODN could be obtained 
from the gel, the extraction and precipitation process was repeated. HPLC analysis 
did not show any ODN (supporting information), which indicated that three 
extractions in a time as short as 30 minutes were sufficient. We also performed a 
blank control experiment in which no ODN was used. We did not see any residue. 
HPLC analysis did not found any UV active material.  
 To confirm that the ODN peak in trace B does not contain any failure 
sequences, we synthesized the 19-mer ODN 5?-CAT TGC TGC TTA GAC CGC T-3? 
(3.3), which was identical to 3.2 except that the 20th base was not added. The ODN 
was purified by catching by polymerization. Co-injection of 3.2 and 3.3 gave a 
broadened peak. When a slower gradient was used, the two were well-resolved. With 
the same slower gradient, 3.2 did not show any 19-mer failure sequence (supporting 
information). Because 19-mer failure sequence is most difficult to resolve from the 
full-length 20-mer sequence, it is conclusive that all failure sequences can be 
removed by the catching by polymerization purification technique. Another potential 
impurity in 3.2 may be the one from oxidation of dG to 8-oxo-dG, and this could not 
???
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be detected by HPLC. We had described the synthesis of the same 20-mer sequence 
of 3.2 with one dG being replaced with 8-oxo-dG 5?-TCA TTG CT(8-oxo-dG) CTT 
AGA CCG CT-3? (3.4), and its digestion to nucleosides. We found that 8-oxo-dG 
could be detected by HPLC. In contrast, 8-oxo-dG could not be detected from 
nucleosides from digesting 3.2.[15] In addition, we had subjected the G nucleoside 
into the radical polymerization conditions and found that it was stable.[16] Here, we 
provide further evidence that dG is stable under radical acrylamide polymerzation 
conditions. When ODN 3.4, which contains 8-oxo-dG, was exposed to concentrated 
NH4OH at elevated temperature, multiple peaks were observed in HPLC profile 
(supporting information). This observation indicated that ODNs containing 8-oxo-dG 
is unstable under such conditions.  Because our purification procedure involves in 
heating ODN in concentrated NH4OH, and HPLC analysis showed single peak, we 
can conlude that ODNs purified with the catching by polymerization technology do 
not contain 8-oxo-dG.  
 It is interesting to note that radicals can damage DNA.[17] Then, why is ODN 
stable under the radical acrylamide polymerization conditions? To anwser this 
question, we need to consider the fact that DNA damage is mostly caused by the 
highly reactive hydroxyl radical. This radical is so reactive that it breaks carbon-
hydrogen bonds with little selectivity. The radical used to initiate the acrylamide 
polymerization reaction is the sulfate radical, which was reported to be 3,000 times 
less reactive than the hydroxyl radical.[18] In addition, under the polymerization 
conditions used for purification, large excess of acrylamide is used. This acrylamide 
could serve as a radical scavenger like vitamin E in the biological system. Once the 
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sulfate radical is formed in the initiation stage of polymerization, it is quickly 
converted to the carbon radical of acrylamide. This radical is stabilized by the amide 
group through resonance, and may not be reactive enough to damage ODN, which 
requires abstraction of hydrogen atom from a carbon-hydrogen bond or breaking 
aromaticity of nucleoside bases by adding a radical to an aromatic ring. 
 For using the catching by polymerization method for ODN purification, one 
very important lesson we learned in the past few years is that fresh nucleoside 
phosphoramidite solutions need to be used for ODN synthesis. Otherwise, the purity 
of product may be lower. For example, to reduce costs, in some of our previous 
experiments, phosphoramidite solutions that were stored in a freezer under nitrogen in 
jars containing Drierite over half a year were used. The ODNs purified by catching by 
ploymerization were found contaminated with small amount of unidentifiable 
impurities.[15] After realizing this, we always used phosphoramidite solutions 
prepared within one week and found that ODN purity was consistently 100% after 
purification by polymerization. Leaving the solutions on the synthesizer for one week 
was found having no adverse effects on the purification results. It should be noted 
that the phosphoramidites do not need to be freshly purchased. In fact, the ones we 
used were usually stored in a freezer for more than six months.  
The above refinements including using less acrylamide polymerization 
solution, using a centrifugal filter unit, and using fresher phosphoramidite solutions 
are critical for the catching by polymerization purification technology to be 
practically useful. The resulted improvements are summarized in Table 3.1. For 
example, in previous procedure, we used large excess of polymerization monomer. 
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Therefore, we had to extract 0.25 μmol ODN from more than 500 μL gel.[14, 15] In 
the improved procedure, we only used 6 μL monomer solution and the gel volume is 
less than 20 μL. Importantly, we observed supernatant over the gel, which may 
contain a large portion of ODN. In contrast, using previous procedure, there was only 
one phase. Due to the reduced gel volume and the existence of supernatant, the 
efficiency of ODN extraction is drastically improved. Previously, we had to be very 
careful to suck up the supernatant by pipette during extraction.[14, 15] It was 
inconvenient because gel fragments occasionally block pipette tip, and fine fragments 
can be sucked up, which contaminate ODN. With a centrifugal filter unit, extraction 
can be carried out by short spins.  
3.2 Conclusion 
?
In conclusion, several very important refinements of the catching failure 
sequences by polymerization ODN purification technology are presented. These 
refinements are critical for the technology to be practically useful. In addition, to 
demonstrate the purity of ODN, we synthesized a 19-mer failure sequence and proved 
that HPLC can resolve it from the 20-mer full-length sequence. The observation of 
ODN that contains 8-oxo-dG is unstable under the purification conditions further 
confirmed that ODN is stable under the acrylamide radical polymerization conditions. 
The reasons for the stability are discussed. With these new results and findings, we 
are now very confident that the catching by polymerization purification method is 
highly convenient and highly reliable. We expect that it be widely used for small 
scale, large scale, and high throughput purification. 
???
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Table 3.1. Summary of advantages of improved procedure over previous procedure 
 
Entry Items Previous procedure Improved procedure
1 Polymerization 
solution 
250 μL 6 μL. Save monomers and reduce gel 
volume
2 ODN solution 250 μL 50 μL
3 Gel volume ?500 μL. Larger volume makes 
extraction less efficient 
< 20 μl. Smaller volume makes 
extraction more efficient
4 Supernatant No. All ODN in gel, difficult to 
extract 
Yes. Most ODN in supernatant, easier 
to extract
5 Water for extraction 12 mL (3 mL x 4). Needs more time 
to evaporate 
0.15 mL (50 μL × 3). Needs less  time 
to evaporate
6 Extraction time 12 h (3 h x 4). Cannot finish in one 
day 
30 min (10 min × 3)
7 Extraction method Pipetting supernatant. Difficult to 
tip blockage by gel. Each extraction 
takes ~ 20 min. Not suitable for 
high throughput purification 
Spin. Each extraction takes 10 sec. 
Suitable for high throughput 
purification 
8 Extract May contain gel, which needs 
additional removal and reduces 
recovery yield
No gel fragments, and very clean
9 Recovery yield 70-95% >95%
10 ODN Purity 92-100% 100%. due to fresher    
phosphoramidite solution
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Abstract
?
 A methacrylation phosphoramidite containing a linker cleavable with acetic 
acid was synthesized, and used for synthetic oligodeoxynucleotide (ODN) 
purification. During automated synthesis, the full-length ODN was tagged with the 
phosphoramidite. The failure sequences were not. In purification, the full-length 
ODN was co-polymerized into a polyacrylamide gel, and the failure sequences and 
other impurities were removed by washing. Pure ODN was cleaved from the gel with 
acetic acid. Using the method, purification of sequences as long as 151-mer and at 
scales as high as 50 ?mol was demonstrated. The products have high purity and good 
recovery yields. The method does not involve in any type of chromatography and 
purification is achieved through simple manipulations such as shaking and filtration. 
Compared with gel electrophoresis and HPLC purification methods, the new 
technology is less labor-demanding and more amendable for automation, consumes 
minimal amount of environmentally harmful organic solvents and requires little 
energy for solvent evaporation. Therefore, it is ideal for high throughput purification 
and large scale ODN-based drug purification as well as small scale purification.  
?
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4.1 Introduction 
?
Synthetic ODNs have found wide applications.[1-5] Important recent 
examples include total gene synthesis for genome construction in synthetic biology 
projects,[6-11] and oligonucleotide-based drug development.[12-16] Gene synthesis 
requires hundreds of ODNs. In order for the synthetic genes to be affordable, the 
ODNs should be produced in a high throughput fashion. Due to automated ODN 
synthesis either using modern column-based synthesizers or microarray technologies, 
large numbers of ODNs can be synthesized simultaneously.[6-11] For gene assembly, 
it is crucial that the ODNs are highly pure. Currently, the ODNs are mostly purified 
using gel electrophoresis or HPLC. However, using these technologies purification in 
a highly parallel fashion is challenging, and high throughput ODN purification 
remains a bottle-neck for gene synthesis and synthetic genome construction. For 
oligonucleotide-based drug development, kilograms to metric tons of oligos are 
needed for clinical trials and patient use after the drugs are marketed. This requires 
large scale oligo production, which includes synthesis and purification. The 
challenges for large scale oligo synthesis have been largely overcome,[12, 13] but 
large scale purification remains a bottle-neck.[13-16] Currently, the most widely used 
technology for large scale purification of oligonucleotide-based drugs is reversed-
phase (RP) HPLC. The method is expensive to scale up, consumes large volumes of 
environmentally harmful organic solvents, and takes significant energy for solvent 
evaporation. The waste to product mass ratio can be as high as 105:1. 
???
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In order to overcome the challenges currently existed in high throughput and 
large scale ODN purifications, we recently reported a new technology using the 
concept of catching by polymerization.[17-21] In one instance, during automated 
synthesis, the failure sequences were capped with acetic anhydride in each synthetic 
cycle, and the full-length sequences were tagged with a polymerizable 
methacrylamide group using a methacrylation phosphoramidite that contained a 
cleavable linker. At purification, the crude product was simply subjected to 
acrylamide polymerization conditions. The full-length sequences were co-
polymerized into the polyacrylamide gel, leaving the failure sequences and other 
impurities in solution, which were removed by washing. The full-length ODN was 
then cleaved from the polymer, and extracted with water. Highly pure ODN was 
obtained with excellent recovery yields.[18] The new purification technology does 
not involve any types of chromatography, and purification is achieved with simple 
manipulations such as shaking and filtration. The waste to product mass ratio can be 
as low as 1:1. As a result, the technology is highly suitable for high throughput and 
large scale purification. However, in our earlier studies, the linker we used in our 
methacrylation phosphoramidite for tagging full-length sequences was a 
diisopropylsilyl acetal function, and the highly toxic and corrosive hydrogen fluoride 
had to be used for cleaving the full-length sequences from the polyacrylamide gel. In 
addition, before cleavage the gel had to be dried under vacuum, which was energy-
demanding and time-consuming. Furthermore, the cleaving reaction was carried out 
in DMF, which is expensive for large scale purification and difficult to evaporate due 
to its high boiling point.[18] In this Paper, we report the synthesis of a new 
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methacrylation phosphoramidite, which contains a linker that can be readily cleaved 
with the more environmentally benign 80% acetic acid, and its application in ODN 
purification using the catching full-length sequences by polymerization approach. We 
demonstrate that even for purification of sequences as long as 151-mer and at scales 
as high as 50 ?mol, the purification procedure requires little modification, and the 
technology is still highly efficient.
4.2 Results and Discussion 
?
Synthesis of Methacrylation Phosphoramidite 1 
The phosphoramidite (4.1), which contains a polymerizable methacrylamide 
group and an acid-labile alkyl trityl ether linker, was synthesized according to 
Scheme 4.1. The commercially available 4-hydroxybenzophenone (4.2) was reacted 
with methyl 6-bromohexanoate in the presence of potassium carbonate to give 4.3. 
Compound 4.3 was treated with 4-methoxyphenylmagnesium bromide to give 4.4, 
which was conveniently converted to 4.5 by simply heating with 2,2?-
(ethylenedioxy)bis(ethylamine) in water. Under these conditions, mono-acylation was 
favored over di-acylation, which is a common side reaction for mono-acylation of 
symmetric diamines.[22, 23] Compound 4.5 was acylated with methacrolyl chloride 
using DIEA as base to give 4.6. Converting 4.6 to 4.7 was achieved by first treating 
4.6 with excess acetyl chloride. After removing volatiles, without purification, the 
intermediate trityl chloride was used directly to react with thymidine in pyridine. 
Product 4.7 was obtained in 77% isolated yield.[24] Phosphinylation of 4.7 using 2-
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cyanoethyl N,N,N?,N?-tetraisopropylphosphordiamidite with diisopropylammonium 
tetrazolide as activator gave compound 4.1 in 87% yield. All the reactions are simple, 
and the reagents are inexpensive or can be replaced with cheaper ones. We expect 
that the synthesis could be easily scaled up to kilograms.  
Scheme 4.1. Synthesis of methacrylation phosphoramidite 1. Reagents and 
conditions: (a) Br(CH2)5CO2CH3 (1.0 equiv), K2CO3 (4.0 equiv), acetone, reflux, 12 
h, 85%; (b) p-H3COPhMgBr (3.0), -78 °C to rt, 4 h, 56%; (c) [CH2O(CH2)2NH2]2 (3.0 
equiv), H2O, 85 C, 12 h, 75%; (d) methacrolyl chloride (1.0 equiv), DIEA (3.0 equiv), 
CH2Cl2, 0 °C to rt, 12 h, 88%; (e) acetyl chloride, rt, 2 h; then thymidine (1.0 equiv), 
pyridine, rt, 18 h, 77%; (f) (iPr2N)2PO(CH2)2CN (1.1 equiv), diisopropylammonium 
tetrazolide (1.0 equiv), rt, 5 h, 87%.
???
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Purification at Small Scales 
Table 4.1. ODN sequences 
 
ODN Length Sequences 
4.8 20-mer 5?-T CAT TGC TGCT TAG ACC GCT-3?  
4.9 31-mer 5?-T CGG ATT ATG TCG ATA TTA GGA GAA TGG TAT-3?  
4.10 37-mer 5?-T ATA CCA TTC TCC TAA TAT CGA CAT AAT CCG TCG ATC-3? 
4.11 61-mer 5'-T AAA GCT ATA GGT ACA GTA TTA GTA GGA CCT ACA CCT 
GTC AAG ATA ATG GTC CAG GTC GGT-3' 
4.12 151-mer 5'-T CAA CAA AAT CAT TTT GCA CCA TGT GGA GCA CCT CCA 
AAT AAC ACC TTT ATA ACC CAT GTG GCG TAA TCA TTG TTT 
TCC ATC CTA GAA AGC TCA TAC AAT GCG TTT TTC ATG AGT 
TTA TTT TCA TGC TCT AGT TTA GTC ATC TTC TTT TCT-3' 
The 20-mer ODN sequence 4.8 (see Table 4.1 for ODN sequences) was used 
to demonstrate the convenience of the new technology for the purification of short 
ODNs on small scales. The ODN was synthesized on a 1 ?mol scale under standard 
conditions using phosphoramidite chemistry. The synthesizer manufacturer suggested 
cycle was slightly modified so that the methacrylation phosphoramidite 4.1 could be 
coupled to the 5?-end of full-length sequences on the synthesizer automatically 
(Figure 4.1). If one does not prefer to spend time on cycle modification, manual 
coupling can also be used. For automated coupling, the standard cycle was copied to a 
new file. After the coupling steps and before the capping steps, a 180 second waiting 
step was inserted, and was set to be active only for base 5. The solution of 4.1 in 
acetonitrile at the same concentration (0.1 M) as other standard phosphoramidite 
monomers was attached to this bottle position. In the sequence, the nucleotide at the 
5?-end was edited to be 5, which in the example here incorporated the nucleotide dT 
while tagging the ODN with a methacrylamide group. Except for these modifications, 
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all other synthesis, deprotection and cleavage conditions were standard. Briefly, CPG 
with a succinyl ester linker was used as solid support. The phosphoramidite 
monomers were 5?-DMTr 2-cyanoethyl benzoyl-dA, acetyl-dC, isobutyryl-dG, and 
dT. Their 0.1 M solutions in acetonitrile were used for coupling with DCI as the 
activator. Failure sequences were capped with acetic anhydride in each synthetic 
cycle. At the end of synthesis, detritylation was not carried out as this would remove 
the methacrylamide tag. Cleavage was carried out on the synthesizer with 
concentrated ammonium hydroxide. Deprotection was achieved by heating the 
ammonium hydroxide solution to 55 °C for 15 hours. After adding ~200 ?L DIEA, 
the solutions were divided into five equal portions, and evaporated to dryness under 
vacuum. One portion was dissolved in 300 ?L water, and 20 ?L was injected into RP 
HPLC to give trace a (Figure 4.2). 
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?
Figure 4.1. The catching full-length sequences by polymerization ODN purification 
technology. (A) Principle. (B) Workflow: (a) Add polymerization monomer and 
initiators to crude ODN, and transfer to a centrifugal filter unit. (b) Wait for 
polymerization. (c) Spin, add water, and spin. (d) Add 80% AcOH. (e) Spin, add 
water, spin, evaporate filtrate, and precipitate with nBuOH. (f) Remove supernatant.?
Once the full-length sequences were tagged with a methacrylamide group, 
purification was very simple (Figure 4.1). To the second portion of the crude ODN 
(~0.2 ?mol), small amounts of water (50 ?L), polymerization solution containing 
N,N-dimethylacrylamide and N,N?-methylenebis(acrylamide) (12 ?L, see supporting 
information for recipe), 5% ammonium peroxide (5 ?L) and 0.66 M TMEDA 
solutions (5 ?L) were added sequentially. For convenient filtration during subsequent 
washing, cleavage and extraction, before polymerization the solution was transferred 
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into the top compartment of a centrifugal filtering unit using a pipette. The solution 
could stay above the filter disc even without stopping the bottom of the compartment. 
The polymerization occurred quickly within 15 minutes, but it was allowed to 
proceed for 1 hour to ensure completion (Figure 4.1). The full-length sequences were 
covalently linked to polymer, and failure sequences remained in solution. The 
polyacrylamide gel was loosened with a clean spatula, and water containing 5% Et3N 
was added to wash away impurities including failure sequences and small molecules. 
The wash was very convenient because the supernatant could be removed by a simple 
spin. So, it was carried out for six times. A final wash with pure water was performed 
to rinse away residue Et3N. To cleave the full-length sequences from the polymer, 
minimum amount of 80% acetic acid that could cover the gel (120 ?L) was added, 
and the mixture was incubated for 5 minutes. The supernatant was removed by spin, 
and the cleavage was repeated for two times. To extract remaining ODN, minimum 
amount of water that could cover the gel (120 ?L) was added, and the supernatant 
was collected by spin. This was repeated for four times. The acetic acid and water 
extracts were combined and evaporated to dryness. The residue was dissolved in 100 
?L concentrated ammonium hydroxide and precipitated with 900 ?l nBuOH. Pure 
ODN 4.8 was dissolved in 300 ?L, and 20 ?L was injected into RP HPLC to give 
trace b (Figure 4.2). As shown, the ODN was 100% pure. Because the theoretical 
amount of ODN for generating traces a and b were equal, the recovery yield of the 
purification process was easily determined to be 68% by dividing the area of the peak 
in trace b at 19 minutes by that in trace a at 45 minutes.  
????
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To demonstrate the simplicity and effectiveness of the purification procedure 
with more examples, the slightly longer ODNs 4.9 (31-mer) and 4.10 (37-mer) were 
synthesized and purified. ODN 4.9 was synthesized at 1 ?mol scale under the same 
conditions described for 4.8, and 4.10 was synthesized at 10 μmol scale described in 
the section of large scale purification. For cleavage and deprotection, we tested 
different conditions. The mixture of concentrated ammonium hydroxide and 
methylamine solutions at 1:1 volume ratio was used in both cases. This reagent 
cleaved the ODN from CPG and removed all protecting groups at room temperature 
in three hours, and therefore the procedure was more convenient. The purification 
procedures were similar to that for purifying 4.8 with only slight modifications (see 
experimental section). Both ODNs were obtained in 100% purity, and the recovery 
yields were high. RP HPLC profiles are in supporting information. 
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Figure 4.2. RP HPLC profiles of ODNs; (a) crude 4.8 (b) pure 4.8 (c) crude 4.10 (d) 
pure 4.10 (e) crude 4.12 (f) pure 4.12
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Purification at Larger Scales 
A major application of the technique is the purification of ODNs on large 
scales, which is important for large scale ODN-based drug production. To 
demonstrate the suitability of our method for this purpose, we decided to carry out a 
purification on a 50 ?mol scale using ODN 4.10 as the example. The ODN was 
synthesized in five 10 ?mol columns with 1000 Å CPG. The same procedure and 
reagents for synthesizing 4.8 were used except that the synthesis cycle was modified 
from 10 ?mol cycle. According to trityl essay before the cycle for attaching 4.1, the 
average yield of 36-mer for the five synthesis was 50%. Cleavage and deprotection 
were achieved using the mixture of concentrated ammonium hydroxide and 
methylamine. RP HPLC analysis of the crude indicated that only about 50% of the 
36-mer intermediate was successfully methacrylated with 4.1 (trace c, Figure 4.2). As 
a result, the synthesis yield of the 37-mer was 25%. In the future, the synthesis should 
be improved by increasing coupling time and capping time, and by coupling 4.1 for 
one more time or allowing it to proceed longer. These modifications are expected to 
give higher synthesis yield. For purification, the crude ODN was dissolved in 1.25 
mL water in a 25 mL round-bottomed flask, and polymerization was carried out using 
as little as 1.25 mL polymerization solution. The gel was transferred into a 15 mL 
Büchner funnel with a sintered glass disc and broken into several pieces with a 
spatula. Washing failure sequences and other impurities were simply achieved using 
water containing Et3N followed by water. The wash was convenient because the 
solutions could be easily removed by applying vacuum. Cleaving the full-length 
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sequences from gel was achieved under the same conditions in small scale 
purifications with only a slightly larger volume of 80% AcOH (~4 mL). Extraction of 
full-length sequences and precipitation with nBuOH were also very convenient (see 
experimental section). Pure ODN 4.10 was obtained as nice white cotton-like fluffy 
fibers (see picture in supporting information). The weight was 98 mg, which 
corresponds to a 70% recovery yield of the purification process. RP HPLC analysis 
showed that the ODN was 100% pure (trace d, Figure 4.2). The images 1H NMR are 
in supporting information.
Long Sequence Purification 
Another important application of the technique is long ODN purification, 
which is especially important for total gene synthesis. Because long ODNs can 
usually assume secondary structures and the hydrophobicity of DMTr group becomes 
less distinctive as the length increases, they are challenging to purify with other 
methods including trityl-on RP HPLC. Because our catching by polymerization 
technology attaches the full-length sequences to a polymer gel covalently, in 
principle, there is no limit on the length of ODN that can be purified using the 
method. To demonstrate the power of the technique, the 61-mer 4.11 and the 151-mer 
4.12 were synthesized and purified. ODN 4.11 was synthesized on 1 ?mol scale using 
the conditions for 4.9 on 1000 Å CPG. ODNs 4.12 was synthesized on 0.2 ?mol scale 
using 2000 Å CPG. To increase recovery yield and capping efficiency, additional 
coupling and capping times were added in the synthetic cycle (see experimental 
section). In addition, before the synthesis, the CPG was subjected to the capping 
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conditions for 20 minutes. All other conditions were the same as for the synthesis of 
4.8 (see experimental section). The synthesis yields as indicated by trityl assay before 
the last cycle for coupling 4.1 were 83% (for 4.11) and 22% (for 4.12). Cleavage and 
deprotection were achieved using the mixture of concentrated ammonium hydroxide 
and methylamine. Purification was carried out at 0.2 ?mol (for 4.11) and 0.04 ?mol 
(for 4.12) scales. Polymerization was achieved under the same conditions described 
for 4.8 using the same amount of polymerization reagents even though the 
purification scales and sequence lengths were different. For washing failure 
sequences from gel, the same conditions for 4.9 were used for 4.11. For the longer 
ODNs 4.12, 3.0 M NaOAc was used to increase washing efficiency. The residue 
NaOAc was removed by washing with 1% Et3N and water sequentially. Cleavage of 
ODN from gel, extraction and nBuOH precipitation were carried out under the same 
conditions described for 4.8. Recovery yields were determined to be 83% (for 4.11) 
and 50% (for 4.12) by comparing areas of pure and crude HPLC peaks. All ODNs 
were 100% pure. The crude and pure HPLC profiles for 4.12 are shown in Figure 4.2. 
Those for 4.11 are in supporting information. 
Reagent Mass Considerations 
A major advantage of the catching by polymerization purification technology 
compared to the most widely used RP HPLC is the low waste to product ratio. In the 
above purification processes, for small scale purifications including 0.2 ?mol scale 
purification of 20-mer 4.8, 0.2 ?mol scale purification of 31-mer 4.9, 0.2 ?mol scale 
purification of 61-mer 4.11, and 0.04 ?mol scale purification of 151-mer 4.12, we 
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consistently used 12 ?l polymerization solution [3.7 M N,N-dimethylacrylamide and 
0.37 M N,N?-methylenebis(acrylamide)]. The molar ratio of polymerization 
monomers [moles of N,N-dimethylacrylamide and N,N?-methylenebis(acrylamide)] 
over the nucleotides in the ODNs (moles of ODN times the number of nucleosides) 
were 12.2 (for 0.2 ?mol 4.8), 7.9 (for 0.2 ?mol 4.9), 4.0 (for 0.2 ?mol 4.11), and 8.1 
(for 0.04 ?mol 4.12). For the 1 ?mol scale purification of 37-mer 4.10, 24 ?l 
polymerization solution was used, the molar ratio was 2.6. For the 50 ?mol 
purification of 37-mer 4.10, 1.25 mL polymerization solution was used, and the molar 
ratio was 2.8. Our guideline is that the molar ratio of polymerization monomer over 
nucleotides in the ODN should be equal to or slightly higher than 2.5. If we assume 
that an ODN contains equal numbers of the four nucleotides, the mass ratio of 
polymerization monomers over ODN is around 0.83, which means that purification of 
one gram of ODN requires less than one gram of polymerization monomers. Molar 
ratio lower than 2.5 is not suggested because the full-length sequences may not be 
caught completely and the polymerization may not be efficient due to diluted 
polymerization monomer concentration. For small scale purification of short 
sequences, when the molar ratio of 2.5 is used, the volume of polymerization solution 
may be too tiny for convenient manipulation. As a result, a larger ratio is suggested. 
In our examples, 12 ?L polymerization solution was consistently used in the 
purification of 4.8 (0.2 ?mol), 4.9 (0.2 ?mol), 4.11 (0.2 ?mol), and 4.12 (0.04 ?mol). 
For larger scale purification, molar ratio much higher than 2.5 is not recommended 
even though the polymerization monomers are inexpensive. With large amount of gel, 
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extraction of ODN after washing failure sequences requires relatively more water, 
which consumes energy for evaporation.  
Besides the mass ratio of polymerization monomers over ODN, there are other 
mass ratios that need to be decided although these ratios are not critical for the 
success of purification. In all the above purification examples, the molar ratio of N,N-
dimethylacrylamide over N,N?-methylenebis(acrylamide) was set to be 10:1. Other 
ratios could also be used, but ratios higher than 40:1 give gels that are too soft for 
convenient handling and ratios lower than 5:1 may reduce ODN extraction efficiency. 
For the volume of water used to dissolve ODN before adding polymerization 
solution, it can also be varied but should not be too far away from our examples. The 
ones we used ranged from one (50 ?mol purification of 4.10) to four (0.2 ?mol 
purification of 4.8) times of that of polymerization solution. The initiators are usually 
more than enough even though only 5 ?l of each were used in most of our examples. 
For the 50 ?mol purification of 4.10, we used 10 ?l of each to ensure efficient 
polymerization. The molar ratio of TMEDA over ammonium persulfate was set to be 
3:1 in our examples, but this is not a requirement. For washing failure sequences from 
gel, we used water containing bases such as Et3N and, NaOAc followed by pure 
water. Adding bases can ensure the stability of the trityl alkyl ether linkage for 
anchoring full-length sequences to gel and is expected to increase washing efficiency. 
The volume of the washing solutions can be large because the solutions are 
inexpensive and not harmful to environment, and do not require evaporation. For 
cleaving and extraction full-length sequences from gel, minimum amount of 80% 
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AcOH and water that can cover gel should be used. Efficiency should not be achieved 
using large amount of solutions, instead it should be achieved through repetitions. 
Minimizing the total volume is important for saving time and energy for evaporation. 
4.3 Experimental Section 
?
General Procedures 
All reagents and solvents were used from commercial sources as received 
unless otherwise indicated. Dry THF and CH2Cl2 were from Innovative Technology’s 
PureSolv™ system. Dry pyridine was obtained from distillation over CaH2 under 
nitrogen. All reactions were carried in oven-dried glassware under nitrogen. 1H, 13C 
and 31P NMR spectra were measured on a Varian UNITY INOVA spectrometer at 
400, 100 and 162 MHz, respectively. High resolution mass spectra were obtained on 
an Agilent Q-TOF system using a dual electrospray ionization source. MALDI-TOF 
mass spectrometry experiments were performed on Waters’ Tofspec-2E. ODNs were 
synthesized on an ABI 394 solid phase synthesizer. RP HPLC was carried out using 
the JASCO LC-2000Plus System with the pump PU-2089Plus Quaternary Gradient; 
detector UV-2075Plus; column C-18 analytical (5 μm diameter, 100 Å, 250 × 4.6 
mm); solvent A, 0.1 M triethylammonium acetate, 5% acetonitrile; and solvent B, 90 
% acetonitrile. Profiles were generated by detection of absorbance of ODN at 260 nm 
using the gradient system, solvent B (0%-45%) in solvent A over 60 min followed by 
solvent B (45%-100%) in solvent A over 20 min at a flow rate of 1 mL/min unless 
otherwise noted. In all purification examples, the solution that contains 3.7 M N,N-
dimethylacrylamide and 0.37 M N,N?-methylenebis(acrylamide), which had a cross-
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linking ratio of 10:1, was used as the polymerization solution for catching full-length 
sequences. Solutions of 5% (NH4)2S2O8 and 0.66 M TMEDA were used as 
polymerization initiators. 
Compound 4.3 
Compound 4.2 (5.0 g, 25.24 mmol, 1.0 equiv), methyl 6-bromohexanoate (4.1 
mL, 25.24 mmol, 1.0 equiv) and K2CO3 (14.0 g, 100.96 mmol, 4.0 equiv) was 
charged to a round-bottomed flask. About 80 mL of acetone was added which was 
previously passed through anhydrous sodium sulfate. The mixture was refluxed for 
overnight. After cooling to rt, the mixture was concentrated under reduced pressure to 
remove acetone. The remaining contents were transferred into a separatory funnel and 
partitioned between ethyl acetate and water. The organic phase was dried over 
anhydrous Na2SO4, filtered and the filtrate was concentrated to dryness under reduced 
pressure and the residue was recrystallized between ethyl acetate and hexane giving 
pure 4.3 as a white solid. (7.0 g, 21.44 mmol, 85%): Rf = 0.5 (Hexane/EtOAc, 3:1); 
1H NMR  (400 MHz, CDCl3) ? 7.80-7.71 (m, 4H), 7.56-7.51 (m, 1H) 7.47-7.43 (m, 
2H), 6.93-6.90 (m, 2H), 4.02 (t, J = 7.2 Hz, 2H), 3.66 (s, 3H), 2.34 (t, J = 7.2 Hz  2H),
1.86-1.79 (m, 2H), 1.74-1.66 (m, 2H), 1.55-1.49 (m, 2H); 13C NMR (100 MHz, 
CDCl3) ? 195.7, 174.1, 162.9, 138.5, 132.8, 132.0, 130.2, 129.9, 128.4, 114.2, 68.1, 
51.7, 34.1, 29.0, 25.8, 24.8.
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Compound 4.4 
Compound 4.3 (5.0 g, 15.31 mmol, 1.0 equiv) in a round-bottomed flask was 
stored over Drierite under vacuum in a dessicator overnight. The flask was then 
connected to a nitrogen atmosphere via a Schlenk manifold. Freshly distilled THF (60 
mL) was added. After cooling to -78 °C, the solution of 4-methoxyphenymagnesium 
bromide in THF (0.5 M, 92 mL, 45.95 mmol, 3.0 equiv) was added slowly via a 
syringe. After addition, the mixture was allowed to warm up to rt gradually. After a 
total of 4 h, the reaction was quenched with water, and THF was evaporated under 
reduced pressure. The remaining contents were transferred into a separatory funnel 
and partitioned between ethyl acetate and 5% NaHCO3. The organic phase was dried 
over anhydrous Na2SO4, filtered and the filtrate was concentrated to dryness under 
reduced pressure. The product was purified with flash column chromatography (SiO2, 
hexanes/EtOAc/Et3N, 3:1:0.2) giving 4.4 as a thick oil (3.7 g, 8.52 mmol, 56%): Rf = 
0.4 (hexanes/EtOAc/Et3N, 3:1:0.4); 1H NMR  (400 MHz, CDCl3) ? 7.30-7.15 (m, 
9H), 6.84-6.40 (m, 4H) 3.91 (t, J = 6.4 Hz 2H), 3.71 (s, 3H), 3.61 (s, 3H), 3.49 (br s, 
1H), 2.30 (t, J = 7.2 Hz 2H), 1.78-1.63 (m, 4H), 1.51-1.46 (m, 2H); 13C NMR (100 
MHz, CDCl3) ? 174.3, 158.8, 158.3, 147.9 139.9, 139.8, 129.5, 128.1, 128.0, 127.2, 
113.9, 113.3, 81.6, 67.8, 55.4, 51.7, 34.1, 29.2, 25.9, 24.9; HRMS (ESI, [M+Na]+) 
m/z calcd for C27H30NaO5 457.1991, found 457.1989.
Compound 4.5 
Compound 4.4 (3.0 g, 6.91 mmol, 1.0 equiv), 2,2?-
(ethylenedioxy)bis(ethylamine) (3.1 mL, 20.73 mmol, 3.0 equiv) and water (700 μL ) 
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was charged to a round-bottomed flask. The mixture was stirred under nitrogen at 85 
°C overnight. After cooling to rt, the mixture was concentrated and the residue was 
purified by flash column chromatography (SiO2, Et2O/MeOH/Et3N, 3:2:0.2) giving 5 
as a thick oil (2.85 g, 5.18 mmol, 75%): Rf = 0.5 (Et2O/MeCN/MeOH/Et3N, 5:2:2:1); 
1H NMR  (400 MHz, CDCl3) ? 7.24-7.08 (m, 9H), 6.80-6.70 (m, 4H) 6.39 (br s, 1H),
3.86 (t, J = 6.4 Hz 2H), 3.71 (s, 3H), 3.53-3.46 (m, 6H), 3.39-3.34 (m,  4H), 2.75-2.65 
(m, 4H), 2.10 (t, J = 7.2 Hz 2H), 1.74-1.58 (m, 4H), 1.44-1.37 (m, 2H); 13C NMR 
(100 MHz, CDCl3) ? 173.3, 158.6, 158.1, 147.9 140.1, 139.9, 128.4, 128.0, 127.9, 
126.9, 113.7, 113.2, 81.3, 72.8, 70.3, 70.2, 70.1, 67.8, 55.4, 41.5, 39.3, 36.5, 29.2, 
25.9, 25.6, HRMS (ESI, [M+H]+) m/z calcd for C32H43N2O6 551.3121, found 
551.3126.  
Compound 4.6 
To an oven-dried round-bottomed flask under nitrogen was added 4.5 (2.7 g, 
4.91 mmol, 1.0 equiv), dry CH2Cl2 (40 mL) and DIEA (2.6 mL, 14.73 mmol, 3.0 
equiv). After cooling to 0 °C, methacrolyl chloride (479 μL, 4.91 mmol, 1.0 equiv) 
was mixed with 10 mL CH2Cl2 then added via an addition funnel slowly with 
vigorous stirring. After addition, the reaction flask was disconnected from the 
nitrogen manifold and connected to air through a Drierite tube. The mixture was then 
stirred at rt overnight. The contents were transferred into a separatory funnel and 
partitioned between 10% Na2CO3 and CH2Cl2. The organic phase was dried over 
anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The 
crude product was purified by flash column chromatography (SiO2, 
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hexanes/EtOAc/Et3N, 1:5:0.2) giving 6 as a colorless oil (2.65 g, 4.29 mmol, 87%): 
Rf = 0.3 (hexanes/EtOAc/Et3N, 1:5:0.6); 1H NMR  (400 MHz, CDCl3) ? 7.25-7.08 (m, 
9H), 6.80-6.72 (m, 4H) 6.34 (br s, 1H), 6.12 (br s, 1H), 5.64 (s, 1H), 5.27 (s, 1H),
3.88 (t, J = 6.4 Hz, 2H), 3.74 (s, 3H), 3.56-3.35 (m, 12H), 2.14 (t, J = 6.4 Hz, 2H),
1.90 (s, 1H), 1.76-1.58 (m, 4H), 1.50-1.40 (m, 2H); 13C NMR (100 MHz, CDCl3) ? 
173.2, 168.7, 158.7, 158.2, 147.7 140.1, 139.8, 139.7, 129.4, 128.0, 127.9, 127.1, 
119.8, 113.8, 113.3, 81.5, 70.4, 70.3, 70.1, 69.9, 67.8, 55.3, 39.5, 39.3, 36.7, 29.2, 
25.9, 25.6, 18.8; HRMS (ESI, [M+Na]+) m/z calcd for C36H46N2NaO7 641.3203, 
found 641.3209.  
Compound 4.7 
Compound 4.6 (2.0 g, 3.23 mmol, 1.0 equiv) in a round-bottomed flask was 
stored in a dessicator over Drierite under vacuum overnight. Thymidine (782.8 mg, 
3.23 mmol , 1.0 equiv) in a round-bottomed flask was dried in the same way. The 
flasks were connected to a Schlenk manifold under nitrogen and the contents were 
further dried through multiple cycles of evacuation and nitrogen filling. To the flask 
containing compound 4.6, acetyl chloride (4 mL) was added, and the mixture was 
stirred at rt for 2 h. Most of acetyl chloride was evaporated by a nitrogen flow or 
under vacuum. Freshly distilled hexane from the Innovative Technology’s 
PureSolv™ system was added to precipitate the product. The hexane was removed by 
syringe or cannula. The residue was washed with hexane one more time, and then 
dried under vacuum for 1 h. Freshly distilled pyridine 10 mL was added, and the 
solution was transferred via a cannula to the flask containing thymidine. The reaction 
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mixture was stirred at rt overnight. Volatiles were evaporated under reduced pressure. 
The residue was transferred into a separatory funnel and partitioned between ethyl 
acetate and 10% Na2CO3. The organic phase was dried over anhydrous Na2SO4 and 
filtered. Volatiles were removed under reduced pressure. The product was purified 
with flash column chromatography (SiO2, EtOAc/MeOH/Et3N, 9.5:0.5:0.2) giving 4.7 
as a white foam (2.1 g, 2.50 mmol, 77%): Rf = 0.4 (EtOAc/MeOH/Et3N, 9:1:0.1); 1H 
NMR  (400 MHz, acetone-d6) ? 7.62 (s, 1H), 7.49-7.46 (m, 2H), 7.36-7.20 (m, 6H), 
6.89-6.86 (m, 5H), 6.36 (t, J = 6.0 Hz, 1H), 5.69 (s, 1H), 5.29 (s, 1H), 4.59 (br s, 1H), 
4.06-4.01 (m, 2H), 3.96 (t, J = 6.0 Hz, 2H), 3.76 (s, 3H), 3.56-3.30 (m, 16H), 2.38-
2.28 (m, 2H), 2.18 (t, J = 7.2 Hz, 2H), 1.95 (s, 3H), 1.89 (s, 1H), 1.45 (s, 3H), 1.19-
1.36 (m, 2H); 13C NMR (100 MHz, Acetone-d6) ? 172.6, 168.0, 163.7, 159.0, 158.7, 
158.5, 150.6, 145.2, 140.8, 135.9, 130.3, 128.3, 128.0, 127.0, 118.6, 113.8, 113.3, 
110.2, 86.7, 86.5, 84.6, 71.8, 70.3, 70.2, 69.9, 69.5, 67.6, 64.1, 59.9, 54.9, 40.5, 39.4, 
39.1, 35.9, 25.7, 25.5, 20.1, 18.2, 13.8; HRMS (ESI, [M+H]+) m/z calcd for 
C47H59N4NaO11 865.4000, found 865.3998.  
Phosphoramidite 4.1 
An oven-dried round-bottomed flask containing 4.7 (0.7 g, 0.83 mmol, 1.0 
equiv) was evacuated then refilled with nitrogen. The evacuation and nitrogen-filling 
cycle was repeated for three times. Freshly distilled CH2Cl2 (3 mL) was added via a 
syringe. 2-Cyanoethyl-N,N,N’,N’-tetraisopropylphosphoramidite (292.2 μL, 0.92 
mmol, 1.1 equiv) and diisopropyl ammonium tetrazolide (142.2 mg, 0.83 mmol, 1.0 
equiv) were added sequentially. After stirring at rt for 5 h the mixture was 
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concentrated to dryness with a nitrogen flow. The residue was purified by flash 
column chromatography (SiO2, EtOAc/Et3N, 9.5:0.5) to give 6 as a white foam (0.75 
g, 0.72 mmol, 87%): Rf = 0.5 (EtOAc/acetone/Et3N, 7:3:0.1); 1H NMR  (400 MHz, 
acetone-d6) ? 7.62 (m, 1H), 7.50-7.47 (m, 2H), 7.38-7.10 (m, 6H), 6.91-6.87 (m, 5H), 
6.36 (m, 1H), 5.69 (s, 1H), 5.29 (s, 1H), 4.76 (br s,1H), 3.98-3.80 (m, 2H), 3.78 (s, 
6H), 3.6-3.20 (m, 8H), 2.75 (t, J = 6.0 Hz 2H), 2.61 (t, J = 6.4 Hz, 2H) 2.53-2.44 (m, 
2H), 2.18 (t, J = 7.2 Hz, 2H), 1.90 (s, 3H), 1.86-1.60 (m, 4H), 1.48-1.47 (m, 6H), 
1.27-1.14 (m, 12H); 13C NMR (100 MHz, Acetone-d6) ? 172.4, 167.9, 163.7, 159.1, 
158.6, 150.6, 145.1, 140.8, 130.4, 128.4, 128.0, 127.1, 118.5, 113.9, 113.4, 110.5, 
94.6, 86.8, 85.5, 84.6, 73.8, 70.4, 70.2, 69.9, 69.6, 67.8, 63.6, 58.9, 54.9, 43.3, 43.2, 
39.4, 39.1, 35.9, 25.8, 25.5, 24.3, 20.0, 18.3, 11.6; 31P NMR (160 MHz, acetone-d6) ? 
149.3, 149.2, LRMS (ESI, [M+Na]+) m/z calcd for C55H75N6NaO12P 1065.5, found 
1065.4 
Procedure for Small Scale ODN Purification 
ODN Synthesis 
The 20-mer ODN 4.8 was used as an example. Its synthesis was carried out on 
a 1 ?mol scale under standard conditions using phosphoramidite chemistry. The 
synthesizer manufacturer suggested 1 ?mol synthetic cycle was copied to a new file. 
After the coupling steps and before the capping steps, a 180 second waiting step was 
inserted, and was set to be active only for base 5. The 0.1 M solution of 4.1 in dry 
acetonitrile was attached to bottle position 5. The volume should be around 600 ?L, 
which was needed for running the bottle exchange cycle, the begin cycle, as well as 
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the coupling steps in one cycle. When editing sequence, the dT at the 5?-end was 
input as 5. CPG with a long chain alkylamine succinyl ester linker and a glass pore 
size of 500 Å was used as solid support. The 5?-DMTr 2-cyanoethyl benzoyl-dA, 
isobutyryl-dG, acetyl-dC, and dT phosphoramidites (0.1 M acetonitrile solutions) 
were used as coupling monomers. The 0.25 M DCI solution in acetonitrile was used 
as activator. Failure sequences were capped with Ac2O in each synthetic cycle. At the 
end of synthesis, detritylation was not carried out as this would remove the 
methacrylamide tag. Cleavage was carried out on the synthesizer with concentrated 
NH4OH. Deprotection was achieved by heating the solution to 55 °C for 25 h. After 
cooling to rt, 200 ?L DIEA was added. The solution was divided into 5 equal 
portions, and evaporated to dryness under vacuum. One portion (~0.2 μmol) was 
dissolved in 300 μL water, 20 μL was injected into RP HPLC to generate trace a 
(Figure 4.2). 
Polymerization
To the second portion (~0.2 μmol) of ODN in a centrifuge tube was added 50 
μL water. The tube was vortexed and spun shortly for efficient dissolution. 
Polymerization solution [12 μL, 44.4 ?mol N,N-dimethylacrylamide, 4.4 ?mol N,N?-
methylenebis(acrylamide)], and initiators (NH4)2S2O8 (5%, 5 ?L, 1.1 ?mol) and 
TMEDA (0.66 M, 5 ?L, 3.3 ?mol) were added sequentially. The mixture was 
vortexed and spun briefly, and then transferred immediately into the top compartment 
of a centrifugal filter unit. The bottom of the compartment could be stopped with a 
cap or parafilm, but the solution will not pass through the filter disc even without 
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stopping. Care needs to be taken to transfer all solution to the center of the filter disc, 
which can be achieved with steady releasing and pushing the pipette. Washing the 
residue solution to the compartment is not recommended. The solution was allowed 
to stand at rt with the cap of the unit closed. A gel was formed in ~15 min, but the 
polymerization was allowed to continue for 1 h. 
Washing
The gel was loosened with a clean spatula, and water containing 5% Et3N 
(~200 μL) was added. After 3 min, the liquid was removed with a spin. The washing 
was repeated for 7 times with the last wash using pure water.  
Cleavage and Extraction 
A minimum amount of AcOH solution (80%) that could cover the gel (~120 
?L) was added. After 5 min, the liquid was collected with a spin. The procedure was 
repeated for two more times. A minimum amount of water that could cover the gel 
(~120 μL) was added, and the extract was collected with a spin. The extraction was 
repeated for four times. The extracts including those of AcOH solution and water 
were combined and evaporated to dryness. To the residue, concentrated NH4OH (100 
μL) was added. After a short vortex, the closed tube was heated at 80 oC for 15 min. 
The tube was cooled to rt, and nBuOH (900 μL) was added. The mixture was 
vortexed for 30 sec and centrifuged for 3 min at 14.1K. The supernatant was carefully 
removed with a pipette, and the residue, which was the pure ODN, was dried under 
vacuum to evaporate residue nBuOH. The ODN was dissolved in 300 μL water, 
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vortexed, and spun, and 20 μL was injected into RP HPLC to generate traces b 
(Figure 2). The recovery yield of the ODN was determined to be 68% by dividing the 
area of the peak in trace b at 19 minutes by that in trace a at 45 minutes. 
The 31-mer ODN 4.9 was synthesized under the same conditions as describe 
for 4.8 except that cleavage and deprotection were achieved using a mixture of 
concentrated NH4OH and MeNH2 solutions (1:1 v/v) at rt for 3 h. The ODN was 
purified at 0.2 ?mol scale using the same procedure and the same amount of reagents 
for purifying 4.8. The RP HPLC traces for crude and pure ODNs are in supporting 
information. The recovery yield of purification was determined to be 71% by 
comparing areas of peaks in the HPLC profiles of pure and crude ODN. The 37-mer 
ODN 4.10 was also purified at 1 ?mol scale using the same procedure with slightly 
different amount of reagents: 50 ?L water for dissolving crude ODN, 24 ?L 
polymerization solution for catching full-length sequences, 5 ?L (NH4)2S2O4 and 
TMEDA solutions for initiating polymerization, and minimum amount of solutions 
that could cover gel for washing failure sequences and for cleavage and extraction. 
RP HPLC profiles for crude and pure ODN are in supporting information. Recovery 
yield was determined to be 83% by comparing areas of peaks in the HPLC profiles of 
pure and crude ODN. 
Procedure for Large Scale Purification 
The 37-mer ODN 4.10 was used as an example. Its synthesis was achieved in 
five 10 ?mol columns with 1000 Å CPG. The same procedure and reagents for 
synthesizing 4.8 were used except that a different synthetic cycle was used. The 
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standard 10 ?mol synthesis cycle was copied into a new file. After the coupling steps 
and before the capping steps, a 180-second waiting step was inserted, and was set to 
be active only for base 5. Approximately, a total of 5.9 mL of 0.08 M solution of 4.1 
was used for tagging full-length sequences. According to trityl essay before the cycle 
for attaching 4.1, the average yield of 36-mer for the five synthesis was 50%. 
Cleavage and deprotection were achieved under the same conditions for 4.9. DIEA 
(~500 ?L) was added to minimize the possibility of premature tag cleavage during 
evaporation. RP HPLC analysis of the crude indicated that only about 50% of the 36-
mer intermediate was successfully methacrylated with 4.1 (trace c, Figure 2). As a 
result, the synthesis yield of the 37-mer was 50%. For purification, the crude ODN 
was dissolved in 1.25 mL water in a 25 mL round-bottomed flask, which was flushed 
with nitrogen. Polymerization solution (1.25 mL) and initiator solutions (10 ?L each) 
were added sequentially. The flask was hand-shaken briefly, and polymerization was 
allowed to proceed at rt for 1 h. The gel was transferred into a 15 mL Büchner funnel 
with a sintered glass disc and broken into several pieces with a spatula. Water (~4 
mL) containing 5% Et3N was added to the gel. After 3 min, vacuum was applied and 
the liquid was removed. The washing was repeated for 4 times. The gel was further 
washed with water (~4 mL) containing 1% Et3N for 4 times without waiting between 
the washes, and finally, the gel was washed with pure water (~ 4 mL). For cleaving 
full-length sequences, 80% AcOH (~4 mL) was added into the funnel. After 5 min, 
vacuum was applied and the extract was collected in a centrifuge tube placed in the 
filter flask. The procedure was repeated for two times. The gel was further washed 
with water (4 mL × 5) without waiting between washes. The extracts including AcOH 
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solution and water were combined and evaporated to dryness under vacuum. The 
residue was dissolved in 1 mL concentrated NH4OH and heated at 80 ºC for 15 min. 
After cooling to rt, 9 mL nBuOH was added, and the mixture was vortexed for 30 sec 
and centrifuged for 3 min. The supernatant was removed, and the residue was dried 
under vacuum. Pure ODN was obtained as white cotton-like fluffy fibers (see picture 
in supporting information). The weight was 98 mg, which corresponds to a 70% 
recovery yield of the purification procedure. A portion of the ODN was dissolved in 
water, and analyzed with RP HPLC (trace d, Figure 2), which indicated 100% purity. 
The images of 1H NMR of the pure ODN are in supporting information.
Procedure for Long Sequence Purification 
The sequences 4.11 (61-mer) and 4.12 (151-mer) were used to demonstrate 
the power of the technique for purification of long ODN sequences. ODN 4.12 is used 
for the description of the procedure. The ODN was synthesized at 0.2 ?mol scale 
under similar conditions described for 8 with slight modifications. The standard 0.2 
?mol (instead of 1 ?mol) synthetic cycle was used to create the new cycle. After 
coupling and capping steps, additional waiting steps of 45 sec and 30 sec were added, 
respectively. CPG with a pore size of 2000 Å was used as solid support. Before 
synthesis, the capping solutions were manually delivered to fill the column, and the 
mixture was allowed to stand at rt for 20 min. The CPG was then washed with 
acetonitrile. All other conditions were the same as for 4.8. The synthesis yield before 
the last cycle was 22% according to trityl essay. The ODN was cleaved and 
deprotected using the mixture of concentrated NH4OH and MeNH2 (1:1 v/v) at rt for 
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3 h. About 200 ?L DIEA was added, and the solution was divided into five equal 
portions, which were evaporated to dryness under vacuum. One portion was dissolved 
in 150 ?L water, and 20 ?L was injected into RP HPC to generate trace e (Figure 
4.2). A second portion was used for purification. The polymerization step including 
reagent volumes were exactly the same as for 4.8. In the washing step, 3.0 M NaOAc 
(200 ?L × 6 with 3 min waiting between the washes), water containing 1% Et3N (200 
?L × 1) and pure water (200 ?L × 1) were used, sequentially. Cleavage, extraction, 
and precipitation were carried out under the same conditions for 4.8. The pure ODN 
was dissolved in 150 μL water, and 20 μL was injected into RP HPLC (flow rate 2 
mL/min, column temperature 55 °C) to give trace f. The recovery yield of the 
purification process was determined to be 50% by comparing the area of peaks of 
crude trace (37 min) with that of pure one (18 min).  
The sequence 4.11 was synthesized at 1 ?mol scale under the conditions for 
4.9 using 1000 Å CPG. Purification was carried out at 0.2 ?mol scale under the same 
conditions described for 4.9. The recovery yield was determined to be 83% by 
comparing the area of peaks of crude trace (40 min) with that of pure one (20 min).  
HPLC images of 11 and 13 are in supporting information. 
4.4 Conclusion 
A new methacrylation phosphoramidite that contains a linker cleavable with 
acetic acid solution has been synthesized, and used for the purification of ODN using 
the catching full-length sequences by polymerization approach. The simplicity, 
convenience, and suitability of the technology with the new linker for small scale 
????
?
purification, large scale purification and long sequence purification have been 
demonstrated. Because acetic acid solution is much more environmentally benign 
than the previously used hydrogen fluoride for the same purpose, we believe that the 
work described in this paper will promote wide adoptions of the ODN purification 
technology in academic labs, biotechnology companies and pharmaceutical industry.  
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Chapter 5 
Introduction to Peptide Purification
5.1 Peptides 
?
Peptides are short polymers of amino acids monomers. The amino acids are 
linked together by amide bonds from a dehydration reaction between a carboxylic 
group of one amino acid and amino group of another amino acid. A general structure 
of peptides is shown in Figure 5.1 (5.1). Depending on the number of amino acid 
monomers, peptides are classified as dipeptides, tripeptides, tetrapeptides and so on. 
Peptides with 10 or less number of amino acid are known as oligopeptides while the 
longer peptides (more than 100 amino acids) are called proteins. The carboxylic end 
of a peptide is termed as its C-terminal and amino end is N-terminal.  
?
Figure 5.1. Peptide structure 
5.2 Applications of Peptides 
?
Synthetic peptides have a wide range of application in therapeutics, 
biochemistry, molecular biology and immunology.[1] One of the most important 
applications of peptides is to use as medicine. There are about 60 peptide drugs on the 
market and more than 500 are in different stages of clinical and pre-clinical trials. It is 
estimated the global annual sale of peptide drugs in 2010 to be $13 billion? [2]. 
Peptide drugs have several advantages over traditional small molecule drugs. They 
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usually have high affinity, and selectivity to biological targets, and therefore have 
high potency and low toxicity. Another reason for low toxicity of peptide drugs is 
because the degradation products of peptide drug are amino acids, which are known 
non-toxic molecules in the nature.[3] Currently, peptide based drugs are used to treat 
different types of cancer, cardiovascular diseases and other diseases. They are also 
used as vaccines for immunization against hepatitis A and B, insulin for diabetes and 
some growth hormones.[4] It is estimated that the annual sale of peptide drugs is 20 
billion  USD in 2012, which is about 2% of total drug product. Currently, the annual 
growth rate of peptide based drug sale is 7.5-10%.[5] 
5.3 Peptide Synthesis 
Peptides are synthesized by coupling of the carboxylic group of one amino 
acid with the amino group of another amino acid. Two types of methods are 
commonly used. One is solution-phase synthesis. This method is classical. It needs 
intensive labor to purify intermediate products. It is still widely used. However, the 
most commonly used method, which is the second method, is solid-phase synthesis. 
This method was first developed by Bruce Merrifield in 1963.[6] Using this method, 
the first amino acid is anchored to a solid support, usually polystyrene beads. Peptides 
are assembled by stepwise addition of amino-protected amino acid monomers. 
Because the desired peptide intermediates are anchored to the solid support, after 
each reaction during the multiple step synthesis, excess reagents and side products are 
conveniently removed by simple washing. As a result solid-phase synthesis is rapid 
and can be automated. Nowadays, solid support with first amino acid being attached 
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is commercially available. Scheme 5.1 illustrates the typical solid phase peptide 
synthesis cycle that are responsible for attaching one amino acid to the nascent 
peptides on solid support. The cycle consists of three steps which are deprotection, 
coupling and capping.  They are described in following paragraphs.?
?
Scheme 5.1. Synthesis cycle of solid-phase peptide synthesis. 
5.3.1 Side-Chain Functional Group Protection 
????
?
Some amino acids contain a side chain functional group. They have to be 
protected during the peptide synthesis. These protecting groups should remain intact 
throughout the synthesis and must be readily removable after synthesis. Most 
commonly used side chain protecting groups are tert-butyloxycarbonyl (Boc), trityl, 
benzoyloxymethyl and tert-butylether. Nowadays, side-chain protected amino acids 
are commercially available. 
5.3.2 Deprotection 
This is the first step of a peptide synthesis cycle. As shown in scheme 5.1, in 
this step, 5.2, which is the first amino acid anchored to solid support with its amino 
group being protected with a Fmoc group, is converted to 5.3. The Fmoc group is an 
abbreviation of 9-fluorenylmethoxycarbonyl group. This step is usually achieved with 
the mild base piperidine, usually a 20% solution in dimethyl formamide (DMF). The 
acid-labile protecting group used for side chain protection are all stable under the 
conditions. Fmoc is the most widely used amino protecting group. Besides the Fmoc 
group, the Boc group which is an abbreviation of tert-butyloxycarbonyl is also widely 
used. Boc group is removed under acidic conditions. The side chain protecting groups 
are also removed under acidic conditions but this needs harsher conditions. After this 
step, the amino group in 5.3 is free of protecting group and the solid support is now 
ready for the next step, which is coupling.  
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5.3.3 Coupling 
The second step in a peptide synthesis cycle is coupling. As shown in scheme 
5.1, this step couples 5.3 with the Fmoc-protected amino acid monomer 5.4 to give 
5.5. This step requires activation of carboxylic group of the amino acid 5.4. Most 
commonly used coupling reagents include N,N'-dicyclohexylcarbodiimide (DCC) 
5.12 and diisopropylcarbodiimide (DIC) 5.13. Recently, O-(7-azabenzotriazol-1-yl)-
N,N,N?,N?-tetramethyluronium hexafluorophosphate (HATU) 5.14 O-(benzotriazol-1-
yl)-N,N,N?,N?-tetramethyluronium hexaflurophosphate (HBTU) 5.15  are widely used 
because these reagents reduce racemization.[7] These coupling reagents form highly 
reactive intermediates with the carboxylic acid group of amino acid monomer (5.4), 
which react with 5.3 to form the peptide bond in 5.5. 
?
Figure 5.2. Example peptide coupling reagents 
????
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5.3.4 Capping 
The third step in a peptide synthesis is capping. The coupling step is usually 
very efficient but it may be incomplete. The unreacted amino group in 5.3 if not 
capped, can participate in the coupling reactions in the next synthesis cycle. This 
generates deletion sequences. Deletion sequences are very difficult to remove during 
purification. To solve the problem, the unreacted amino groups are capped with large 
excess of acetic anhydride right after each coupling step to give 5.7. Products 5.7 are 
called failure sequences. They cannot participate in next coupling reactions.  
The synthesizer repeats the steps deprotection, coupling and capping, which is 
responsible to add one amino acid in each synthesis cycle until desired length of 
peptide is obtained. 
5.3.5 Cleavage and Deprotection 
Once the peptide synthesis is complete, the product is cleaved from solid 
support. Cleavage is usually achieved with an acid. In the example we shown in 
chapter 6, we used the 2-chlorotrityl linker to anchor nascent peptides to solid 
support. The cleaving agent is 1.0% solution of trifluoroacetic acid (TFA) in 
dichloromethane. Under these conditions, side chain protecting groups are not 
removed. To remove side chain protecting group, usually the TFA cocktail containing 
81.5% TFA, 1.0% triisopropylsilane, 5.0% water, 2.5% ethane dithiol, 5.0% 
thioanisole  and 5.0% phenol is used. This cocktail is much more acidic and can 
remove all side chain protecting groups. Because the side products of the deprotection 
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reactions include highly reactive cationic species, the cocktail contains scavengers, 
which prevents reactive cationic species from reacting with deprotected peptides. 
5.4 Impurities 
?
After synthesis, cleavage and deprotection, the crude peptide contains the 
desired full-length sequence and impurities including failure sequences. The 
impurities are divided into different classes. They have to be removed before most of 
the applications.  
The first type of impurities is the failure sequences. They are generated from 
incomplete coupling of amino acid monomer during synthesis.  Incomplete removal 
of Fmoc group in the deprotection step in a synthesis cycle also results in failure 
sequences.[8] Because the failure-sequences have similar physical properties as the 
full-length peptides, they are difficult to remove. The major challenge of peptide 
purification is to remove the failure-sequences. 
The second type of impurities include deletion and addition sequences. The 
deletion sequences are resulted from incomplete capping. The unreacted amino group 
can couple with amino acid in the next synthesis cycle. The deletion sequence lacks 
one or more amino acids in the peptide chain. The addition sequences are resulted 
from premature removal of Fmoc group. The addition sequences have at least one or 
more amino acids. Both deletion and addition sequences are challenge to remove 
during purification. The best strategy is to minimize their quantity to close to zero by 
tuning the reaction conditions during synthesis.  
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The third type of impurities is small organic molecules from side chain 
protecting groups. These impurities can be removed easily by precipitation with cold 
diethyl ether from TFA solution. The peptides are not soluble in cold ether, and are 
precipitated. The small organic molecules are soluble in ether, and remain in solution. 
Other impurities include diasteromers which are resulted from racemization. 
Some impurities are generated from modification of functional groups.[9] These 
impurities should be minimized by tuning the condition during synthesis, cleavage 
and deprotection. They are challenging to remove using any purification methods. 
5.5 Current Methods of Purification 
?
Currently, several methods are extensively studied for peptide purification. 
These methods include reversed-phase (RP) HPLC, fluorous affinity purification, 
polyacrylamide gel-electrophoresis, size-exclusion chromatography, and ion-
exchange chromatography. The principles of the methods have been introduced in 
Chapter 1. When they are applied to peptide purification, advantages and 
disadvantages similar to ODN purification exist. Briefly the disadvantages include 
high labor demand, unamenable for automation, requiring expensive instrument and 
column consuming large volumes of harmful organic solvents, expensive to scale up, 
and harmful to environment. 
5.6 Our Peptide Purification Method 
?
To overcome the problems associated with known peptide purification 
methods, we developed a simple and convenient method for peptide purification. This 
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method utilizes the same principle as discussed in previous chapters for ODN 
purification, which is catching by polymerization.  In this method, a compound 
containing polymerizable methacrylamide group and a cleavable linker (5.16) is 
attached to the amino terminus of full-length peptide. The failure sequences are not 
tagged with the compound. During purification, the crude product is subjected to 
polymerization. The full-length sequences are incorporated into polymer. The failure 
sequences are removed by washing. The full-length sequences are then cleaved from 
the polymer. The compound we used for the application is 5.16. It contains a 
methacrylamide polymerizable group and an acid-cleavable linker. The following 
paragraph explains how to tag the full-length sequence while leaving failure 
sequences free of the methacrylamide tag.  
 
Figure 5.3. Polymerizable linker 
As shown in Scheme 5.2, at the end of peptide synthesis, the full-length 
peptide on solid support (5.9) is reacted with the polymerizable tagging agent 5.16 to 
give 5.17. The failure sequences on the solid support 5.8 do not react because their 
amino groups are capped with acetic anhydride in capping step. The peptide including 
full-length sequences and failure sequences are cleaved from the solid support. The 
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cleavage reagent we used is 1% TFA. The linker shown in 5.16 and side chain 
protecting groups are stable under this condition.  
?
Scheme 5.2. Acrylation of full-length peptide by polymerizable linker 5.16 
????
?
After peptide synthesis and cleavage, the crude peptide mainly contains the 
methacrylamide-tagged full-length sequence 5.18, the failure sequences 5.11 and 
other impurities. It is subjected into a polymerization mixture containing N,N-
dimethylacrylamide 5.19 and N,N-methylenebisacrylamide 5.20. The polymerization 
reaction is initiated with ammonium persulfate (APS) and N,N,N?,N?-
tetramethylethylenediamine (TMEDA). The full-length peptide 5.18 is incorporated 
into the polymer gel 5.21. The failure sequences 5.11 and other impurities remain in 
solution. The failure sequences and other impurities are washed away. The full-length 
peptide is cleaved with TFA cocktail solution, which also removes the side chain 
protecting groups. The full-length peptide is further extracted with TFA. Small 
molecule impurities are removed by precipitation of peptides with diethyl ether from 
the TFA solution. The small molecules are in solution. The peptide is not soluble in 
ether and is precipitated. 
 
Scheme 5.3. The catching full-length sequence by polymerization peptide 
purification method 
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5.7 Advantages of Our New Peptide Purification Method 
?
Our new peptide purification method has significant advantages over all 
known purification methods. The method does not involve any chromatography and 
purification is achieved through simple manipulation such as mixing, shaking, 
filtration and extraction. It does not need any expensive reagents, instruments and 
column. Therefore it is highly suitable for large scale purification including large 
scale peptide based drug purification. 
The advantages of our technology to purify ODN are presented in Table 1.1 
and Table 1.2 of chapter 1. The tables can be used to compare the advatages of our 
technology for peptide purification. 
The detailed information on peptide purification using the catching full-length 
sequence by polymerization method is presented in Chapter 6. 
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Abstract
?
During automated solid phase peptide synthesis, failure sequences were 
capped with acetic anhydride. After synthesis, a polymerizable methacrylamide tag 
was attached to the full-length sequences. Peptide purification was then achieved by 
polymerizing the full-length sequences, washing away impurities, and cleaving the 
peptide product from the polymer 
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6.1 Introduction 
?
Synthetic peptides have wide applications. For example, there are 65 therapeutic 
peptides on the market and around 270 peptides in clinical trials.[1, 2] Peptides are 
mostly synthesized on a solid support by stepwise addition of amino-protected amino 
acid (aa) monomers. Each synthetic cycle accomplishes the addition of one aa. It 
usually consists of three steps, which are coupling, capping and deprotection. Excess 
reagents and side products in each step are removed by washing. After synthesis, the 
product is cleaved from the support and fully deprotected. Besides the desired full-
length peptide, the major impurities in the crude product include failure sequences 
and small molecules from side chain protecting groups. The latter can usually be 
removed by precipitation with cold diethyl ether from a trifluoroacetic acid (TFA) 
solution. However, the failure sequences have physical properties similar to those of 
full-length peptide, and cannot be removed in the process.  
Currently, the first industrial choice for peptide purification is reversed-phase (RP) 
HPLC. However, it has limitations. For example, in the manufacture of enfuvirtide, 
which is a 36-aa peptide used to treat HIV infection, RP HPLC is the primary tool for 
purification. When a linear solid phase synthesis method was used, the purity of the 
crude product was 30-40%, which is acceptable considering the length of the 
synthesis and the convenience of the procedure. Unfortunately, the product had to be 
purified by a complicated procedure involving difficult, low-concentration, low-
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throughput, and two-pass HPLC.[3] To ease purification, later a combined solid phase 
and solution phase synthesis method was developed, and the purity of product was 
improved to ~75%. However, the purification was not much easier. The product was 
loaded in multiple portions onto a column for preparative HPLC.[3] In general, the 
disadvantages of HPLC for large scale purification include high capital costs on 
instrument and column, labor intensiveness, high energy demand for solvent 
evaporation, and inability to resolve peptides with multiple higher order structures. 
Most importantly, HPLC consumes large volumes of harmful solvents, which results 
in high waste to product ratios, usually more than 1,000. Other methods for peptide 
purification include fluorous affinity purification,[4-10] antigen-antibody affinity 
purification,[11, 12] covalent capture with a solid matrix,[13-15] and lipophilic tag 
assisted chromatography.[16] All these methods are extensively studied, but are still 
not ideal for large scale peptide drug purification. 
6.2 Results and Discussion 
?
Recently, we reported a catching by polymerization strategy for purification of 
oligodeoxynucleotides (ODN).[17-19] In one method, at the end of automated 
synthesis, a polymerizable methacrylamide group is attached to the full-length 
sequence. ODN purification is then achieved by polymerizing the full-length 
sequences, washing away failure sequences and other impurities, and cleaving 
product from the polymer.[17] The method avoided many drawbacks associated with 
chromatography and other known methods, and could be used for large scale and high 
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throughput ODN purification. Here we report our results on using the strategy for 
synthetic peptide purification. 
To demonstrate feasibility, compound 6.1, which contains an acid-labile linker and 
a reactive 4-nitrophenyl carbonate function, was designed. Because we planned to use 
the commercially available 2-Cl-trityl polystyrene resin as the solid support for 
peptide synthesis, the linker must be stable in 1% TFA, which are the conditions for 
cleaving peptides from the resin.[3, 20-23] However, the linker must be readily 
cleavable under more acidic conditions to obtain good recovery yield in the 
purification process. These goals were achieved by careful tuning the electron density 
of the benzene ring in the linker. The molecule was also designed to be easy to 
synthesize. As shown in Scheme 1, 4-hydroxybenzyl alcohol was alkylated with  
methyl chloroacetate to give 6.2,[24] which was reacted at room temperature with 
2,2?-(ethylenedioxy)bis(ethylamine) to give 6.3.[25] Methacrylation of 6.3 gave 
compound 6.4, which was converted to 6.1 by reacting with 4-
nitrophenylchloroformate. The synthesis did not use any expensive and highly 
reactive reagents, and is expected to be readily scalable. 
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 Scheme 6.1. Synthesis of compound 6.1 
Since peptide synthesis and purification are much more complicated than 
ODN, at the beginning of the project, we used the short 6-aa peptide 6.5 (LWTRFA) 
to demonstrate the feasibility of the concept. The 2-Cl-trityl polystyrene resin 
preloaded with Ala was selected as the solid support. The Fmoc-protected Phe, 
Arg(Pbf), Thr(tBu), Trp(Boc) and Leu were used as aa monomers. Synthesis was 
carried out on an automated synthesizer. In the coupling steps, only 2.1 equivalents of 
monomers were used, which was lower than the amounts usually suggested by 
manufacturers of peptide synthesizers. The lowered amount was expected to generate 
more failure sequences and to better show the effectiveness of the new purification 
method. After coupling, failure sequences were capped with excess acetic anhydride. 
The steps for removing Fmoc protecting group were normal. After assembling the 
sequence, the full-length peptide was reacted with compound 6.1 in the presence of a 
base at room temperature overnight to give 6.6 (see Scheme 6.2). The failure 
sequences (6.7) could not react because they were capped with acetic anhydride. The 
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crude product, which mainly contained 6.6 and 6.7, were cleaved from the resin using 
1% TFA to give full-length peptide 6.8 and failure sequences 6.9. Under these 
conditions, the side chain protecting groups and the 4-hydroxybenzyl alcohol linker 
were stable.[3] The mixture was analysed with RP HPLC (trace a, Figure 6.1). The 
full-length peptide appeared at 61 minutes. To generate a control HPLC profile, a 
portion of the crude was treated with a TFA cocktail containing 81.5% TFA, 1.0% 
triisopropylsilane (TIPS), 5.0% water, 2.5% ethane dithiol (EDT), 5.0% thioanisole, 
and 5.0% phenol to globally remove protecting groups and to cleave the 
methacrylamide tag. After Et2O precipitation, the crude product was analysed with 
RP HPLC (trace b). The fully deprotected full-length peptide (6.5) appeared at 23 
minutes. 
????
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Scheme 6.2. Peptide cleavage from resin and purification by catching full-length    
sequence by polymerization 
Another portion of the crude containing 6.8 and 6.9 (with side chain 
protecting groups and methacrylamide tag not removed) was subjected to 
polymerization under typical polyacrylamide gel formation conditions [N,N-
dimethylacrylamide, N,N?-methylenebis(acrylamide), (NH4)2S2O8, TMEDA]. The 
full-length peptide 6.8 was incorporated into the polymer 6.10. The failure sequences 
6.9 and other impurities remained in solution (Scheme 6.2). The gel was washed 
????
extensively with solvents such as water, DMF and MeCN to remove impurities. Full-
length peptide was then cleaved from the gel and fully deprotected by 
 
Figure 6.1. RP HPLC profiles of peptides. (a) Crude 6-aa peptide containing full-
length sequences 6.8 and failure sequences 6.9, the side chain protecting groups and 
the methacrylamide tag on 6.8 were on; (b) crude peptide with side chain protecting 
groups and methacrylamide tag removed; (c) peptide 6.5 purified using the catching 
full-length sequences by polymerization approach.  
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treating with the TFA cocktail described above. At this stage, the peptide was still 
contaminated with small molecules from side chain protecting groups and the 
cocktail. Removing them was achieved by precipitation of peptide with cold Et2O. 
The pure peptide 6.5 was analysed with RP HPLC (trace c, Figure 6.1). The purity of 
the peptide was more than 98%. The recovery yield of the purification process was 
estimated to be 66% by comparing the areas of the peaks at 23 minutes in traces b and 
c. The identity of the peptide was confirmed with ESI-MS and NMR (see Supporting 
Information).  
To further demonstrate the effectiveness of the purification technique, the 16-aa 
peptide 6.11 (KNRWEDPGKQLYNVEA), which is a peptide derived from human 
C3d and carries the LYNVEA CR2 binding sequence,[26] was synthesized under 
similar conditions described for 6.5. Fmoc aa Glu(OtBu), Val, Asn(Trt), Tyr(tBu), 
Leu, Gln(Trt), Lys(Boc), Gly, Pro, Asp(OtBu), Trp(Boc) and Arg(Pbf) were used as 
the monomers. To further increase the difficulty of the purification task, the amount 
of aa monomers was lowered to 1.5 equivalents. The purification process was exactly 
the same. The RP HPLC profiles for the crude peptide with the methacrylamide tag 
and side chain protecting groups on, that with tag and protecting groups removed, and 
purified full-length peptide are included in Supporting Information. The purity of the 
peptide (6.11) is more than 96%. The recovery yield was estimated to be 73%. The 
identity of 6.11 was confirmed with ESI MS and NMR. 
The catching by polymerization peptide purification method has significant 
advantages over other techniques. Compared with chromatographic methods such as 
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HPLC and lipophilic tag assisted purification,[16] the method does not need any 
expensive instrument, column, or large volumes of harmful solvents. Compared with 
RP cartridge, fluorous and antigen-antibody affinity purification methods,[4-12] the 
method does not require a disposable column. Compared with the methods using 
covalent capture,[13-15] the method does not need a functionalized solid matrix. 
Importantly, using the method, purification is achieved by simple manipulations such 
as shaking, washing, extraction and precipitation. As a result, it is expected to be 
particularly useful for large scale peptide drug purification. Some drugs need to be 
purified for more than one time, and ideally, each time uses a different purification 
technique. The catching by polymerization method may be an excellent choice for 
initial removal of large quantities of failure sequences. This is predicted to be 
particularly useful for the purification of peptide sequences that have inherently low 
coupling yields in certain cycles. Furthermore, due to the ease of  removal of failure 
sequences using the method, it is possible for drug manufacturers to reduce the 
equivalents of aa monomers and their activators during synthesis. The re-balance of 
reagent costs and purification costs will provide new opportunities to lower the 
overall expenses of drug production.  
6.3 Experimental Section 
?
General Experimental 
All reactions were performed in oven-dried glassware under a nitrogen 
atmosphere using standard Schlenk techniques. Reagents and solvents available from 
commercial sources were used as received unless otherwise noted. Pyridine and 
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CH2Cl2 were distilled over CaH2 under nitrogen. Thin layer chromatography (TLC) 
was performed using plates with silica gel 60F-254 over glass support, 0.25 μm 
thickness. Flash column chromatography was performed using silica gel with particle 
size 32-63 μm. 1H and 13C NMR spectra were measured at 400 and 100 MHz, 
respectively on a Varian 400 MHz spectrometer. Chemical shifts (?) were reported in 
reference to solvent peaks (residue CHCl3 at ? 7.24 ppm for 1H and CDCl3 at ? 77.00 
ppm for 13C, and residue CHD2OD at ? 3.31 ppm for 1H and CD3OD at ? 49.00 ppm 
for 13C). ESI-MS for small molecules were obtained on an Agilent Q-TOF System; 
those for peptides were obtained on a Thermo Finnigan LCQ Advantage 
spectrometer. H-Ala-2-Cl-Trt polystyrene resin (1% DVB cross-linking, 100-200 
mesh, ~0.56 mmol/g loading for the synthesis of 6.5 and ~0.80 mmol/g for 6.11), 
Fmoc protected amino acids, N-hydroxybenzotriazole (HOBt·H2O), N,N'-
diisopropylcarbodiimide (DIC), piperidine, and N,N-diisopropylethylamine(DIEA) 
were purchased from AAPPTec (Louisville, USA). RP HPLC was performed on a 
JASCO LC-2000Plus System: pump, PU-2089Plus Quaternary Gradient; detector 
UV-2075Plus. RP analytical columns XBridgeTM, C18, 5.0 ?m diameter, 3.0 mm × 
250 mm (for 6-amino acid peptide 6.5); and XBridgeTM, C18, 5.0 ?m diameter, 4.6 
mm × 150 mm (for 16-amino acid peptide 6.11) were used. Solvent A: 0.05% 
trifluoroacetic acid (TFA) in water. Solvent B: 0.05% TFA in acetonitrile. All profiles 
were generated by detection of absorbance of peptide at 214 nm using the linear 
gradient solvent system: solvent B (0%-15%) in solvent A over 9 min followed by 
solvent B (15%-100%) in solvent A over 71 min at flow rates of 1.0 mL/min (4.6 mm 
× 150 mm column) and 0.5 mL/min (3.0 mm × 250 mm column).  
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Synthesis and Characterization of Compounds 
Compound 6.3 
To a round-bottomed flask under a nitrogen atmosphere was added 6.2 (2.48 
g, 12.64 mmol, 1.0 equiv.), water (1 mL) and 2,2’-(ethylenedioxy)bis(ethylamine) 
(5.6 mL, 38 mmol, 3.0 equiv.). The reaction mixture was stirred for 5 h at rt. The 
crude was loaded onto a flash chromatography column (SiO2). Eluting with the 
solvent mixture  Et2O/MeOH/MeCN/Et3N (v/v/v/v 5:2:2:1) gave 6.3 as a sticky solid 
(2.78 g, 8.89 mmol, 70%): Rf = 0.32 (Et2O/MeOH/MeCN/Et3N, 5:2:2:1); 1H NMR  
(400 MHz, CD3OD) ? 7.28 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 4.51 (s, 2H), 
4.47 (s, 2H), 3.65-3.43 (m, 10H), 2.75 (t, J = 5.2 Hz, 2H); 13C NMR (100 MHz, 
CD3OD) ? 169.9, 157.3, 135.1, 128.5, 114.6, 72.4, 70.1, 69.2, 67.2, 63.5, 40.8, 38.8;
HRMS (ESI) calcd for C15H25N2O5 [M+H]+ m/z 313.1763, found 313.1762.
Compound 6.4 
To a round-bottomed flask under a nitrogen atmosphere was added 6.3 (4.5 g, 
14.41 mmol, 1.0 equiv.), freshly distilled CH2Cl2 (100 mL), N,N-
diisopropylethylamine (7.5 mL, 43.23 mmol, 3.0 equiv.), and methacrolyl chloride 
(1.34 mL, 13.69 mmol, 0.95 equiv.). The reaction mixture was stirred at rt overnight. 
The contents were transferred into a separatory funnel and extracted with EtOAc (50 
mL × 3). The combined organic phase was dried over anhydrous Na2SO4, and 
filtered. Volatiles were removed under reduced pressure. The crude product was 
purified by flash column chromatography (SiO2, EtOAc/acetone, 7:3) giving 6.4 as a 
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light yellow oil (4.53 g, 11.91 mmol, 82%): Rf = 0.24 (EtOAc/acetone, 7:3); 1H NMR  
(400 MHz, CDCl3) ? 7.25 (d, J = 8.8 Hz, 2H), 6.95 (br s, 1H), 6.82 (d, J = 8.8 Hz, 
2H), 6.36 (br s, 1H), 5.63 (s, 1H), 5.26 (s, 1H), 4.56 (s, 2H), 4.39 (s, 2H), 3.59-3.36 
(m, 12H), 2.88 (br s 1H), 1.88 (s, 3H); 13C NMR (100 MHz, CDCl3) ? 168.7, 168.6, 
156.8, 140.1, 135.4, 128.8, 119.8, 114.8, 70.4, 70.3, 69.9, 69.8, 67.7, 64.6, 39.5, 38.9, 
18.8; HRMS (ESI) calcd for C19H28N2NaO6 [M+Na]+ m/z 403.1845, found 403.1844. 
Compound 6.1 
To a round-bottomed flask under a nitrogen atmosphere was added 6.4 (1.1 g, 
2.89 mmol, 1.0 equiv.), freshly distilled CH2Cl2 (100 mL), freshly distilled pyridine 
(1.16 mL, 14.45 mmol, 5.0 equiv.), and 4-nitrophenyl chloroformate (728.2 mg, 3.61 
mmol, 1.25 equiv.). The reaction mixture was stirred at rt for 1 h. The contents were 
transferred into a separatory funnel and partitioned between sat. NH4Cl and CH2Cl2 
(50 mL). The aqueous phase was further extracted with CH2Cl2 (50 mL × 2). The 
combined organic phase was dried over anhydrous Na2SO4 and filtered. Volatiles 
were removed under reduced pressure. The crude product was purified by flash 
column chromatography (SiO2, EtOAc/acetone, 7:3) giving 6.1 as a light yellow solid 
(1.37 g, 2.51 mmol 86%): Rf = 0.37 (EtOAc/acetone, 7:3); m.p. 81.2 ºC; 1H NMR  
(400 MHz, CDCl3) ? 8.24 (d, J = 9.2 Hz, 2H), 7.42-7.32 (m, 4H), 6.92 (d, J = 8.8 Hz, 
2H), 6.25 (br s, 1H), 5.66 (s, 1H), 5.28 (s, 1H), 5.21 (s, 2H), 4.48 (s, 2H), 3.58-3.46 
(m, 12H), 1.91 (s, 3H); 13C NMR (100 MHz, CDCl3) ? 168.6, 168.1, 157.9, 155.7, 
152.6, 145.6, 140.2, 131.1, 128.1, 125.5, 121.9, 119.8, 115.2, 70.7, 70.5, 70.4, 70.0, 
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69.9, 67.6, 39.5, 38.9, 18.8; HRMS (ESI) calcd for C26H31N3NaO10 [M+Na]+ m/z 
568.1907, found 568.1903.  
Peptide Synthesis, Acrylation and Cleavage 
Peptide Synthesis:  
The 6-amino acid peptide 6.5 (H2N-LWTRFA-CO2H) was synthesized on an 
automated solid phase synthesizer using the Fmoc protecting strategy. The 2-Chloro-
Trityl-Ala-H polystyrene resin (with 1% DVB cross-linking, 0.56 mmol/g loading, 
0.39 mmol, 0.70 g) was swollen by soaking in CH2Cl2 (25 mL) at rt for 45 min. The 
solvent was removed. The resin was washed with DMF for 3 times and finally the 
DMF was removed. Coupling was then carried out. To the amino acid tube on the 
synthesizer containing Fmoc-Phe-OH (2.1 eq, 0.84 mmol, 0.32 g) and HOBt·H2O 
(2.1 eq, 0.84 mmol, 0.13 g) was added DMF (3.5 mL). The mixture was dissolved by 
bubbling nitrogen. After 5 min, DIC (2.1 eq, 0.84 mmol) in 3.5 mL DMF was added. 
Pre-activation of the amino acid was proceeded at rt for 20 min. The mixture 
containing the activated ester was added to the reaction flask containing the resin. 
Coupling was allowed to proceed at rt for 60 min. The reagents were removed. The 
resin was washed with DMF (10 mL × 4). Capping failure sequences was then 
performed. First a solution of DIEA (1.5 M) in DMF, and then the solution of Ac2O 
(1.0 M) also in DMF were delivered to the reaction flask. The ratio of the volumes of 
the two solutions was approximately 1:1, and the total volume of the two solutions 
was approximately 10 mL, which could cover the entire resin. The mixture was 
allowed to react at rt for 30 min. The reagents were removed and the resin was 
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washed with DMF (10 mL ×2). The process was repeated for three more times under 
the same conditions with the exception of reducing the capping time from 30 min to 
15 min. The resin was washed with DMF (10 mL × 4). Removal of Fmoc group was 
then carried out. A solution of piperidine in DMF (20%, 10 mL) was delivered to the 
reaction flask, and the mixture was allowed to react at rt for 3 min. The reagents were 
removed. The process was repeated for two more times. The resin was washed with 
DMF (10 mL × 4 times). This completed one synthesis cycle, in which one amino 
acid was added to the elongating peptide. The synthesis cycle was repeated with the 
Fmoc amino acid monomers Arg(Pbf), Thr(tBu), Trp(Boc) (120 min for coupling), 
and Leu sequentially. At the end of the synthesis, the Fmoc group was removed. 
Acrylation of the Full-Length Peptide 
The solutions of compound 6.1 (3.1 eq, 1.23 mmol, 0.67g) in DMF (2.0 mL), 
and DIEA (10%) in DMF (2.0 mL) were combined, and then added to the resin 
manually via a pipette. The reaction was allowed to proceed at rt overnight. The resin 
was filtered, and washed with DMF (2.0 mL × 4) and CH2Cl2 (2.0 mL × 4), and then 
dried under vacuum. The thoroughly dried resin (0.95 g) was stored at -20 ºC under 
inert atmosphere. 
Cleaving the Peptide From the Resin and HPLC Analysis of Crude Peptide 
A portion of the resin (0.12 g) was swollen in CH2Cl2 (3.0 mL) at rt for 45 
min. The solvent was removed with a pipette, and the resin was treated with a 
solution of 1% TFA in CH2Cl2 (1.0 mL) at rt. After 30 min, the mixture was filtered. 
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The resin was washed with 1% TFA in CH2Cl2 (200 μL × 2). To the combined 
solution was added Et2O (12 mL). The mixture was vortexed and spun briefly to 
bring down contents to the bottom of the tube, and cooled to -70 ºC. After 1 h, the 
mixture was centrifuged for 3 min (at ~10 ºC). The supernatant was removed with a 
pipette. The residue was washed with cold Et2O (1 mL × 3, -70 ºC). After washing, 
residue Et2O was allowed to evaporate in air. The crude product (26.7 mg), which 
contained the full-length sequences 6.8, failure sequences 6.9 and other impurities, 
was obtained as an amorphous solid. A portion (10 mg) was dissolved in 60% 
CH3CN (1.0 mL). From the solution, 20 μL was injected into RP HPLC to generate 
trace a (Figure 6.1). From the remaining solution (980 μL) was drawn 100 μL, and 
evaporated to dryness in a centrifugal vacuum concentrator. The residue was treated 
with a TFA cocktail (100 μL), which contained 81.5% TFA, 1.0% triisopropylsilane 
(TIPS), 5.0% water, 2.5% ethane dithiol (EDT), 5.0% thioanisole, and 5.0% phenol, 
at rt for 100 min. To the solution was added Et2O (900 μL). The mixture was 
vortexed and spun briefly, and cooled to -70 ºC. After 1 h, the mixture was 
centrifuged for 3 min (at ~10 ºC). The supernatant was removed with a pipette. The 
residue was washed with cold Et2O (1 mL × 3, -70 ºC). Residue Et2O was allowed to 
evaporate in air. The solid was dissolved in 100 μL 50% CH3CN, 20 μL was injected 
into RP HPLC to generate trace b (Figure 6.1). 
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Purification by Catching Full-Length Sequences by Polymerization 
Catching Full-Length Peptide by Polymerization 
Purification was carried out with the side chain protected peptide to avoid side 
reactions between peptide and acrylamide. An additional benefit is that protected 
peptide must be soluble at least in the solvent in which it is synthesized. This will 
ensure that other peptides could be purified using the method. Thus, from the above 
remaining solution (~880 μL) of crude peptide containing 6.8 and 6.9 with side chain 
protected, 100 μL was transferred into a 25 mL 2-necked round bottomed flask. To 
the same flask, 150 μL CH3CN, 270 μL water, and 520 μL polymerization solution, 
which contained N,N-dimethylacrylamide (1.69 M) and N,N?-
methylenebis(acrylamide) (0.068 M) in DMF, were added. The mixture was stirred 
using a magnetic stirring bar while a gentle nitrogen flow passed over the liquid 
surface. After 5 min, a solution of (NH4)2S2O8 (10%, 5 μL) and TMEDA (3.5 μL) 
were added sequentially via a pipette and a syringe, respectively, under positive 
nitrogen pressure. The solution was stirred gently under nitrogen at rt for 1 min to 
mix the materials, and then stirring was stopped. The mixture was allowed to stand 
under nitrogen. The gel 6.10 was formed within 30 min. To ensure complete 
polymerization, the gel was left under nitrogen for 2 h or longer. 
Removing Failure Sequences and Other Impurities by Washing 
To the flask containing the gel was added 3 mL water via a pipette. The flask 
was moved onto an orbital shaker and shaken at rt for 2 h. The supernatant was 
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removed with a pipette. The gel was further washed with water (3 mL × 2, 2 h each 
time), DMF (3 mL × 3, 2 h each time), 50% CH3CN (3 mL × 3, 2 h each time), and 
CH3CN (3 mL × 3, 2 h each time) to ensure complete removal of failure sequences 
and other impurities. The gel 6.10 was then dried under vacuum. 
Cleaving Full-Length Peptide From Gel and Global Peptide Deprotection 
To the flask containing gel 6.10 was added 2.0 mL TFA cocktail (81.5% TFA, 
1.0% TIPS, 5.0% water, 2.5% EDT, 5.0% thioanisole, and 5.0% phenol) via a pipette. 
The flask was gently shaken at rt for 100 min. The supernatant, which contained the 
full-length peptide 6.5 and small molecules from side chain deprotection, was 
transferred to a 45 mL centrifuge tube using a pipette. The gel was further washed 
with the TFA cocktail (2.0 mL, 1 h), pure TFA (2.0 mL, 2 h; 1.0 mL × 3, 1 h each 
time) to ensure complete extraction of full-length sequences. The last extract was 
concentrated and precipitated with Et2O at -70 ºC, and analyzed with HPLC. No 
peptide was detected, which indicates that the extraction process could be simplified. 
All other extracts were combined into the same 45 mL centrifuge tube, and 
concentrated to about 2.5 mL with a flow of nitrogen. To the solution was added Et2O 
(22.5 mL). The mixture was vortexed and spun briefly to bring down contents to the 
bottom of the tube, and cooled to -70 ºC. After 1 h, the mixture was centrifuged for 3 
min (at ~10 ºC). The supernatant was removed with a pipette. The residue was 
washed with cold Et2O (1 mL × 3, -70 ºC). After washing, residue Et2O was allowed 
to evaporate in air. The solid, which was the pure fully deprotected peptide 6.5, was 
dissolved in 100 μL 50% CH3CN, 20 μL was injected into RP HPLC to generate 
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trace c (Figure 6.1). Occasionally, small impurities were observed in HPLC profiles. 
These were caused by small molecules that were not completely removed by the 
precipitation process. We were able to remove them by re-dissolving the peptide in a 
minimum amount of 50% CH3CN followed by evaporation in a centrifugal vacuum 
concentrator. The recovery yield of the catching by polymerization purification 
process was estimated to be 66% by comparing the area of the peak at 23 min in trace 
c with that in trace b. The identity of the peptide was established with ESI-MS using a 
50% acetonitrile solution, calcd for [M+H]+ m/z 793.9, found 793.5. The image of the 
spectrum is shown in this Supporting Information. To obtain sufficient peptide for 
NMR experiment, the purification was repeated with peptides cleaved from 26.5 mg 
of resin, which theoretically contains 10.9 μmol peptide. The product was obtained as 
a white powder (5.5 mg, 6.9 μmol, 63% combined yield for synthesis and 
purification). 1H NMR  (400 MHz, 50% CD3CN in D2O) ? 7.98 (d, J = 7.2 Hz, 1H, 
H-1, see following structure for proton assignment), 7.79 (d, J = 8 Hz, 1H, H-2), 
7.71-7.58 (m, 6H, H-3), 7.55 (t, J = 8 Hz, 1H, H-4), 7.46 (t, J = 8 Hz, 1H, H-5), 5.10 
(t, J = 7.6 Hz, 1H, H-6), 4.96 (m, 1H, H-7), 4.80-4.40 (buried in solvent peak, 2H, H-
8), 4.26 (t, J = 7.6 Hz, 1H, H-9), 3.70-3.20 (m, 7H, H-10), 2.20-1.85 (m, 3H, H-11), 
1.78-1.63 (m, 7H, H-12), 1.37 (d, J = 6.4 Hz, 3H, H-13), 1.30-1.20 (m, 6H, H-14). 
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Figure 6.2. The 6-aa peptide 6.5 and proton numbering for NMR signal assignment
Purification of the 16-Amino Acid Peptide 6.11 
The 16-amino acid peptide 6.11 (H2N-KNRWEDPGKQLYNVEA-CO2H) 
was synthesized using Fmoc amino acid monomers Glu(OtBu), Val, Asn(Trt), 
Tyr(tBu), Leu, Gln(Trt), Lys(Boc), Gly, Pro, Asp(OtBu), Trp(Boc) and Arg(Pbf), 
under the similar conditions on the same resin with a loading of 0.80 mmol/g, and  
using 1.5 equivalents amino acid monomers and activating agents in the coupling 
steps. The catching by polymerization purification process was exactly the same as 
described for purification of peptide 6.5. The RP HPLC profiles for the crude peptide 
with the methacrylamide tag and side protecting groups on, the crude peptide with tag 
and protecting groups removed, and full-length peptide purified with the catching 
full-length sequences by polymerization approach are shown in this Supporting 
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Information. The recovery yield of the purification process was estimated to be 73% 
by comparing the area of the peak at 17 min in the HPLC profiles of purified and 
crude peptide. The image of ESI MS for the purified peptide, calcd for [M+2H]2+ m/z 
974.5, found 974.3, are shown in this Supporting Information. To obtain sufficient 
peptide for NMR experiment, the purification was repeated with peptides cleaved 
from 85.4 mg of resin, which theoretically contains 12.6 μmol peptide. The product 
was obtained as a white powder (16.9 mg, 8.7 μmol, 69% combined yield for 
synthesis and purification). 1H NMR (400 MHz, 50% CD3CN in D2O) ? 7.97 (d, J = 8 
Hz, 1H, H-1, see following structure for proton assignment), 7.80 (d, J = 8.4 Hz, 1H, 
H-2), 7.60-7.40 (m, 5H, H-3), 7.13 (d, J = 8.0 Hz, 2H, H-4), 5.20 (t, J = 7.2 Hz, 1H, 
H-5), 5.04 (t, J = 6.8 Hz, 2H, H-5), 4.97 (t, J = 8.4, 1H, H-5), 4.88-4.85 (m, 1H, H-5), 
4.75-4.44 (buried in solvent peak, 6H, H-6), 4.34 (t, J = 6.0 Hz, 1H, H-6), 4.26 (br s, 
2H, H-7), 4.16-4.08 (m, 2H, H-6), 3.70-1.60 (m, 58H, H-8), 1.30 (d, J = 6.0 Hz, 3H, 
H-9), 1.27 (d, J = 6.0 Hz, 3H, H-9), 1.23 (d, J = 6.0 Hz, 3H, H-9), 1.17 (d, J = 6.0 Hz, 
3H, H-9). 
 
Figure 6.3. The 16-aa peptide 6.11 and proton numbering for NMR signal 
assignment
????
?
6.4 Conclusion 
?
In conclusion, we have successfully developed a new method for peptide 
purification. The method used a concept that is completely different from any 
previously reported peptide purification techniques. It is easy to use and readily 
scalable, and gives peptides with good purity and recovery yields. Adapting the 
method for purification of several peptide drugs such as Bivalirudin (20 aa),[27] 
Ziconotide (25 aa),[28] Thymalfasin (28 aa),[29] Enfuvirtide (36 aa)[30] and 
Pramlintide (39 aa)[31] is underway.  
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Chapter 7 
Future Research Plan
?
Synthetic ODNs and peptides have wide applications in therapeutics, 
genomics and forensic science. In the previous chapters, we described the novel 
technologies for ODN and peptide purification. We used catching by polymerization 
approach to purify these biooligomers. The result of the technology is satisfactory. In 
future, our efforts may be directed to extend the catching failure sequences by 
polymerization approach to peptide purification, using the catching-full length 
sequence by polymerization approach to purify peptides of much longer sequences 
and specific drugs at large scales, using the catching by polymerization methods to 
purify RNA, phosphorothioates, and other modified nucleic acids, and adopt the 
technologies for high throughput purification of ODNs. 
7.1 For Peptide Purification 
?
7.1.1 Catching Failure Sequences by Polymerization 
In chapter 6, we discussed the purification of peptide by polymerizing full-
length sequences. Despite the satisfactory result, the peptide must be cleaved from the 
gel during purification. We proposed a purification method by catching failure 
sequences which does not need a cleavage step. Failure sequences are capped right 
after each synthetic cycle by suitable reagents containing polymerizable group. We 
designed two capping reagents; the first one is methacrylic anhydride 7.1. The second 
reagent is the pentafluro compound 7.2. 
????
?
 
 
Figure 7.1. Proposed capping reagents 
The failure sequences will be capped with 7.1 or 7.2 during automated synthesis. 
After cleavage, they will be polymerized leaving full-length peptide in solution, 
which will be extracted with suitable solvents. Small molecules will be removed by 
precipitation of the full-length sequences from a TFA solution with cold ether. The 
peptides, which normally carry positive charges under these conditions, are not 
soluble in ether, while small molecules, which are neutral, are soluble in ether. 
7.1.2 Purification of Longer Sequences and at Large Scale 
We purified peptides that contain 6 and 16 amino acids by the catching full-
length sequence by polymerization approach. In this method, a polymerizable tag is 
attached only once at the end of the amino terminus so it is suitable for longer peptide 
purification. We will use the method to purify peptides that have more than 30 amino 
acids. We will also use the technique to purify specific peptide durgs such as 
Bivalirudin,[1] Ziconotide,[2] Thymalfasin,[3] Enfuvirtide,[4] and Pramlintide[5]. 
Further, we will use the method to purify at scales that can afford gram quantities of 
pure peptides. 
????
?
7.2 For ODN  and RNA Purification 
?
7.2.1 RNA Purification 
Purification of oligoribonucleotides is also highly important because of their 
wide applications in medicine and biology. RNA purification is more challenging due 
to the ubiquitous enzyme known as RNAse. We propose the purification of 
oligoribonucleotide using the catching by polymerization ODN purification 
technologies. Both technologies of ODN purification can be used to purify 
oligoribonucleotide by slight modification of the current methods. 
7.2.2 Longer Sequence Purification, Large Scale Purification and High 
Throughput Purification 
In chapter 4, we discussed the purification of a 151 mer ODN by catching 
full-length sequence polymerization. We propose to purify even longer ODNs such as 
those that are as long as 200 mer. This method is suitable to purify longer ODNs 
because tagging with an expensive polymerizable phosphoramidite is only required at 
the end of synthesis. Because of the high demand for pure ODN in industrial scales, 
we propose to test the suitability of the technology to purify ODNs at gram scales.  
????
?
7.2.3 Purification of Phosphorothioates
Phosphorothioates have increasing applications in therapeutics. In 
phosphorothioates 7.4, the oxygen atom in the phosphate backbone is replaced with a 
sulfur atom. This structure change makes the ODN more resistant to enzymatic 
hydrolysis (Figure 7.2).[6] The delivery of this modified ODN to the interior of cell is 
more efficient than normal ODN. Because of the applications of phosphorathioates, 
we propose to purify phosphorothioates by the catching polymerization approach. 
 
Figure 7.2. Phosphodiester and phosphorothioate linkages 
?
?
?
????
?
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Synthetic Oligodeoxynucleotide Purification by Capping Failure 
Sequences with a Methacrylamide Phosphoramidite Followed by 
Polymerization 
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Figure A.1. 1H NMR of compound 2.11 
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Figure A.2. 13C NMR of compound 2.11  
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Figure A.3. 31P NMR of compound 2.11 
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Figure A.4. 1H NMR of compound 2.12  
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Figure A.5. 13C NMR of compound 2.12 
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Figure A.6. 31P NMR of compound 2.12
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Figure A.7. 1H NMR of compound 2.13  
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Figure A.8. 13C NMR of compound 2.13  
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Figure A.9. 13P NMR of compound 2.13  
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Figure A.10. 1H NMR of compound 2.15  
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Figure A.11. 13C NMR of compound 2.15  
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Figure A.12. 1H NMR of compound 2.17  
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Figure A.13. 13C NMR of compound 2.17  
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Figure A.14. 1H NMR of compound 2.19  
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Figure A.15. 13C NMR of compound 2.19 
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Figure A.16. ESI MS of compound 2.19 
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Figure A.17. LC MS of ODN 2.23 (continued next page) 
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Figure A.17. LC MS of ODN 2.23 (continued)
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Figure A.18. MALDI-TOF MS of ODN 2.24
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Figure A.19. RP HPLC profile of crude ODN 2.20(c2.10l)  
Figure A.20. RP HPLC profile of ODN 2.20(c2.10l) purified by catching by 
polymerization 
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Figure A.21. RP HPLC profile of crude ODN 2.20(c2.12l) 
 
Figure A.22. HPLC profile of ODN 2.20(c2.12l) purified by catching by 
polymerization   
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Figure A.23.  RP HPLC profile of crude ODN 2.20(c2.13l) 
?
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Figure A.24.  RP HPLC profile of ODN 2.20(c2.13l) purified by catching by 
polymerization 
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Figure A.25.   RP HPLC profile of crude ODN 2.20(c2.10s) 
Figure A.26. RP HPLC profile of ODN 2.20(c2.10s) purified by catching by 
polymerization 
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Figure A.27. RP HPLC profile of crude ODN 2.20(c2.11s) 
Figure A.28. RP HPLC profile of ODN 2.20(c2.11s) purified by catching by 
polymerization
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Figure A.29. RP HPLC profile of crude ODN 2.20(c2.12s) 
Figure A.30. RP HPLC profile of ODN 2.20(c2.12s) purified by catching by 
polymerization 
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Figure A.31. RP HPLC profile of crude ODN 2.20(c2.13s) 
Figure A.32. RP HPLC profile of ODN 2.20(c13s) purified by catching by 
polymerization 
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Figure A.33. RP HPLC profile of crude ODN 2.23 
Figure A.34. RP HPLC profile of ODN 2.23 purified by catching by polymerization 
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Figure A.35. RP HPLC profile of crude ODN 2.20(c2.11o) 
Figure A.36. RP HPLC profile of ODN 2.20(c2.11o) purified by catching by 
polymerization  
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Figure A.37. RP HPLC profile of crude ODN 2.20(c2.21i) 
Figure A.38. RP HPLC profile of ODN 2.20(c2.11i) purified by catching by 
polymerization 
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Figure A.39. RP HPLC profile of crude ODN 2.20(c2.11c) 
Figure A.40. RP HPLC profile of ODN 2.20(c2.11c) purified by catching by 
polymerization 
??????
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Figure A.41. RP HPLC profile of crude ODN 2.20(c2.11lc) 
Figure A.42. RP HPLC profile of ODN 2.20(c2.11lc) purified by catching by 
polymerization  
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Figure A.43. RP HPLC profile of ODN 2.20 purified by catching by polymerization; 
the polymerization step was carried in air in a centrifuge tube 
Figure A.44. RP HPLC profile of crude ODN 2.20(c2.11ls) 
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Figure A.45. RP HPLC profile of ODN 2.20(c2.11ls) purified by catching by 
polymerization 
Figure A.46. RP HPLC profile of crude ODN 2.20(c2.11dci) purified at 3 μmol scale 
using the catching failure sequences by polymerization method?
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Figure A.47. RP HPLC profile of ODN 2.20 (c2.11dci) purified at 3 μmol scale 
using the catching failure sequences by polymerization method  
Figure A.48. RP HPLC profile of ODN 2.20(c2.11dci) purified at 3 μmol scale using 
the catching failure sequences by polymerization method; the profile was generated 
by UV detection at 210 nm 
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Figure A.49. Ion-exchange HPLC analysis of ODN 2.20. The conditions described in 
the general methods section were used. For analysis, 20 μL solution from the 
remaining ODN 2.20 (c2.12s) solution in the purification by catching failure 
sequences by polymerization experiment following the general ODN purification 
procedure was injected into HPLC.
Figure A.50. RP HPLC profile of crude ODN 2.24
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Figure A.51. RP HPLC profile of pure ODN 2.24
 
Figure A.52. RP HPLC profile of crude ODN mixture 2.25 
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Figure A.53. RP HPLC profile of ODN 2.25 that went through catching by 
polymerization
Figure A.54. RP HPLC profile of nucleosides from ODN enzymatic digestion essay 
for ODNs that do not contain 8-oxo-dG—the blank control 
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Figure A.55. RP HPLC profile of nucleosides from ODN enzymatic digestion essay 
for ODN that contain 8-oxo-dG—the blank control; the peak at 11 minutes is resulted 
from 2-mercaptoethanol added to prevent oxidation of 8-oxo-dG
[min.]
Time
0 5 10 15 20 25
Ab
s 
(2
60
 n
m
)
-2
0
2
4
6
8
10
Blank + nuclease
????
?
Table A.1. Nucleoside peak areas in HPLC profiles of SVP and BAP digested ODNs 
* Calculated based on the relative nucleoside extinction coefficients of dC/dG/dT/dA 
1.0:1.6:1.2:2.1 from Current Protocols in Nucleic Acid Chemistry, Unit 10.6, DOI: 
10.1002/0471142700.nc1006s01. 
Table A.2. Recipes for the preparation of polymerization solutions
ODN 20 Authentic 20 24 
 
Base dC dG dT dA dC dG dT dA dC dG dT dA 
8-
Oxo-
dG 
Number 
of base 6 4 7 3 6 4 7 3 6 3 7 3 1 
Calcd 
relative 
area* 
6.0 6.4 8.5 6.3 6.0 6.4 8.5 6.3 6.0 4.8 8.5 6.3 - 
Meaured 
relative 
area 
6.0 7.1 7.8 5.7 6.0 7.0 7.5 5.6 6.0 5.3 7.6 6.3 1.1 
Cross-linking 
ratio 
N,N?-Methylenebis(acrylamide) N,N-Dimethylacrylamide 
Water (mL) 
Mass (mmol) Weight (mg) Mass (mmol) Volume (μL) 
1:50 0.169 26.05 8.44 870 5 
1:25 0.337 52.1 8.44 870 5 
1:15 0.563 86.8 8.44 870 5 
1:7 1.207 186.1 8.44 870 5 
1:2 4.225 651.3 8.44 870 14* 
 
* More water had to be added to dissolve the materials. 
????
?
Table A.3. ODN synthetic cycles using polymerizable phosphoramidite as capping 
agent 
Cycle 1 — 0.2 μmol synthesis, the general ODN synthesis procedure?
ODN synthetic cycle using polymerizable phosphoramidite as the capping agent 
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument 
Polymerizable capping agent: 0.15 M solution of capping phosphoramidite in 
acetonitrile, placed at the bottle 5 position 
The bottles for normal Ac2O capping agents are empty 
Activator for the capping phosphoramidite: from the same bottle for the coupling 
steps 
Synthesis scale: 0.2 μmol 
Column used: column 2; functions for other columns are not shown 
 
Step number Function number Function name Step time 
1.  106 Begin  
2.  64 18 To waste 3.0 
3.  42 18 To column 10.0 
4.  2 Reverse flush 8.0 
5.  1 Block flush 4.0 
6.  101 Phos Prep 3.0 
7.  142 Column 2 on  
8.  111 Block vent 2.0 
9.  58 Tet to waste 1.7 
10.  33 B+Tet to column 2.0 
11.  34 Tet to column 1.0 
12.  33 B+Tet to column 1.5 
13.  43 Push to column  
14.  143 Column 2 off  
15.  103 wait 25.0 
16.  64 18 To waste 3.0 
17.  42 18 To column 10.0 
18.  2 Reverse flush 8.0 
????
?
19.  1 Block flush 4.0 
20.  101 Phos Prep 3.0 
21.  142 Column 2 on  
22.  111 Block vent 2.0 
23.  58 Tet to waste 1.7 
24.  35 5+Tet to column 2.0 
25.  34 Tet to column 1.0 
26.  103 Wait 90.0 
27.  35 5+Tet to column 1.5 
28.  103 Wait 90.0 
29.  35 5+Tet to column 1.5 
30.  103 Wait 90.0 
31.  35 5+Tet to column 1.5 
32.  103 Wait 90.0 
33.  43 Push to column  
34.  103 Wait 30.0 
35.  64 18 To waste 4.0 
36.  42 18 To column 8.0 
37.  4 Flush to waste 4.0 
38.  42 18 To column 8.0 
39.  2 Reverse flush 5.0 
40.  42 18 To column 8.0 
41.  2 Reverse flush 5.0 
42.  1 Block flush 3.0 
43.  41 15 To column 8.0 
44.  64 18 To waste 4.0 
45.  1 Block flush 3.0 
46.  103 Wait 10.0 
47.  41 15 To column 8.0 
48.  64 18 To waste 4.0 
49.  1 Block flush 3.0 
50.  103 Wait 10.0 
51.  42 18 To column 15.0 
52.  4 Flush to waste 4.0 
????
?
53.  42 18 To column 10.0 
54.  2 Reverse flush 5.0 
55.  42 18 To column 10.0 
56.  2 Reverse flush 5.0 
57.  1 Block flush 3.0 
58.  105 Start detrityl  
59.  64 18 To waste 4.0 
60.  42 18 To column 10.0 
61.  2 Reverse flush 5.0 
62.  1 Block flush 3.0 
63.  167 If monitoring  
64.  44 19 To column 25.0 
65.  40 14 To column 3.0 
66.  135 Monitor triyls  
67.  40 14 To column 25.0 
68.  136 Monitor noise  
69.  40 14 To column 10.0 
70.  137 Stop monitor  
71.  42 18 To column 10.0 
72.  2 Reverse flush 8.0 
73.  168 If not monitoring  
74.  40 14 To column 6.0 
75.  3 Trityl flush 5.0 
76.  40 14 To column 6.0 
77.  103 Wait 5.0 
78.  3 Trityl flush 5.0 
79.  40 14 To column 6.0 
80.  103 Wait 5.0 
81.  3 Trityl flush 5.0 
82.  40 14 To column 6.0 
83.  103 Wait 5.0 
84.  3 Trityl flush 5.0 
85.  42 18 To column 10.0 
86.  3 Trityl flush 8.0 
????
?
87.  169 End monitoring  
88.  42 18 To column 8.0 
89.  2 Reverse flush 5.0 
90.  1 Block flush 4.0 
91.  107 End  
 
Note: Bottle 5—polymerizable capping phosphoramidite; bottle 14—detritylation 
solution; bottle 15—oxidation solution; bottle 18—acetonitrile; bottle 19—
dichloromethane; B—base or phosphoramidite; Tet—tetrazole or activator. 
 
Table A.4. Cycle 2 — 0.2 μmol synthesis, the general ODN synthesis procedure with 
shortened capping time?
ODN synthetic cycle using polymerizable phosphoramidite as the capping agent 
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument 
Polymerizable capping agent: 0.15 or 0.1 M solution of polymerizable 
phosphoramidite in acetonitrile, placed at the bottle 5 position 
The bottles for normal Ac2O capping agents are empty 
Activator for the capping phosphoramidite: from the same bottle for the coupling step 
Synthesis scale: 0.2 μmol 
Column used: column 2; functions for other columns are not shown 
 
Step number Function number Function name Step time 
1.  106 Begin  
2.  64 18 To waste 3.0 
3.  42 18 To column 10.0 
4.  2 Reverse flush 8.0 
5.  1 Block flush 4.0 
6.  101 Phos Prep 3.0 
7.  142 Column 2 on  
????
?
8.  111 Block vent 2.0 
9.  58 Tet to waste 1.7 
10.  33 B+Tet to column 2.0 
11.  34 Tet to column 1.0 
12.  33 B+Tet to column 1.5 
13.  43 Push to column  
14.  143 Column 2 off  
15.  103 wait 25.0 
16.  64 18 To waste 3.0 
17.  42 18 To column 10.0 
18.  2 Reverse flush 8.0 
19.  1 Block flush 4.0 
20.  101 Phos Prep 3.0 
21.  142 Column 2 on  
22.  111 Block vent 2.0 
23.  58 Tet to waste 1.7 
24.  35 5+Tet to column 2.0 
25.  34 Tet to column 1.0 
26.  103 Wait 30.0 
27.  35 5+Tet to column 1.5 
28.  103 Wait 30.0 
29.  35 5+Tet to column 1.5 
30.  103 Wait 30.0 
31.  43 Push to column  
32.  103 Wait 30.0 
33.  64 18 To waste 4.0 
34.  42 18 To column 8.0 
35.  4 Flush to waste 4.0 
36.  42 18 To column 8.0 
37.  2 Reverse flush 5.0 
38.  42 18 To column 8.0 
39.  2 Reverse flush 5.0 
40.  1 Block flush 3.0 
41.  41 15 To column 8.0 
????
?
42.  64 18 To waste 4.0 
43.  1 Block flush 3.0 
44.  103 Wait 10.0 
45.  41 15 To column 8.0 
46.  64 18 To waste 4.0 
47.  1 Block flush 3.0 
48.  103 Wait 10.0 
49.  42 18 To column 15.0 
50.  4 Flush to waste 4.0 
51.  42 18 To column 10.0 
52.  2 Reverse flush 5.0 
53.  42 18 To column 10.0 
54.  2 Reverse flush 5.0 
55.  1 Block flush 3.0 
56.  105 Start detrityl  
57.  64 18 To waste 4.0 
58.  42 18 To column 10.0 
59.  2 Reverse flush 5.0 
60.  1 Block flush 3.0 
61.  167 If monitoring  
62.  44 19 To column 25.0 
63.  40 14 To column 3.0 
64.  135 Monitor triyls  
65.  40 14 To column 25.0 
66.  136 Monitor noise  
67.  40 14 To column 10.0 
68.  137 Stop monitor  
69.  42 18 To column 10.0 
70.  2 Reverse flush 8.0 
71.  168 If not monitoring  
72.  40 14 To column 6.0 
73.  3 Trityl flush 5.0 
74.  40 14 To column 6.0 
75.  103 Wait 5.0 
????
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76.  3 Trityl flush 5.0 
77.  40 14 To column 6.0 
78.  103 Wait 5.0 
79.  3 Trityl flush 5.0 
80.  40 14 To column 6.0 
81.  103 Wait 5.0 
82.  3 Trityl flush 5.0 
83.  42 18 To column 10.0 
84.  3 Trityl flush 8.0 
85.  169 End monitoring  
86.  42 18 To column 8.0 
87.  2 Reverse flush 5.0 
88.  1 Block flush 4.0 
89.  107 End  
 
Note: Bottle 5—polymerizable capping phosphoramidite; bottle 14—detritylation 
solution; bottle 15—oxidation solution; bottle 18—acetonitrile; bottle 19—
dichloromethane; B—base or phosphoramidite; Tet—tetrazole or activator. 
Table A.5. Cycle 3 — 1.0 μmol synthesis?
ODN synthetic cycle using polymerizable phosphoramidite as the capping agent 
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument 
Polymerizable capping agent: 0.15 M solution of polymerizable phosphoramidite in 
acetonitrile unless otherwise noted in the article, placed at the bottle 5 position 
The bottles for normal Ac2O capping agents are empty 
Activator for the capping phosphoramidite: from the same bottle for the coupling step 
Synthesis scale: 1.0 μmol 
Column used: column 2; functions for other columns are not shown 
 
Step number Function number Function name Step time 
1.  106 Begin  
2.  64 18 To waste 3.0 
3.  42 18 To column 10.0 
4.  2 Reverse flush 10.0 
5.  1 Block flush 4.0 
6.  101 Phos Prep 3.0 
????
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7.  142 Column 2 on  
8.  111 Block vent 2.0 
9.  58 Tet to waste 1.7 
10.  33 B+Tet to column 2.5 
11.  34 Tet to column 1.0 
12.  33 B+Tet to column 2.5 
13.  43 Push to column  
14.  143 Column 2 off  
15.  103 wait 50.0 
16.  64 18 To waste 3.0 
17.  42 18 To column 10.0 
18.  4 Flush to waste 5.0 
19.  42 18 To column 10.0 
20.  2 Reverse flush 10.0 
21.  1 Block flush 4.0 
22.  101 Phos Prep 3.0 
23.  142 Column 2 on  
24.  111 Block vent 2.0 
25.  58 Tet to waste 1.7 
26.  35 5+Tet to column 2.5 
27.  34 Tet to column 1.0 
28.  103 Wait 30.0 
29.  35 5+Tet to column 2.5 
30.  103 Wait 30.0 
31.  35 5+Tet to column 2.5 
32.  103 Wait 30.0 
33.  43 Push to column  
34.  103 Wait 30.0 
35.  64 18 To waste 4.0 
36.  42 18 To column 10.0 
37.  4 Flush to waste 6.0 
38.  42 18 To column 10.0 
39.  4 Flush to waste 6.0 
40.  42 18 To column 10.0 
????
?
41.  2 Reverse flush 7.0 
42.  1 Block flush 3.0 
43.  41 15 To column 8.0 
44.  64 18 To waste 4.0 
45.  1 Block flush 3.0 
46.  103 Wait 15.0 
47.  41 15 To column 8.0 
48.  64 18 To waste 4.0 
49.  1 Block flush 3.0 
50.  103 Wait 15.0 
51.  42 18 To column 15.0 
52.  4 Flush to waste 6.0 
53.  42 18 To column 10.0 
54.  4 Flush to waste 6.0 
55.  42 18 To column 10.0 
56.  2 Reverse flush 7.0 
57.  1 Block flush 3.0 
58.  105 Start detrityl  
59.  64 18 To waste 4.0 
60.  42 18 To column 10.0 
61.  2 Reverse flush 5.0 
62.  1 Block flush 3.0 
63.  167 If monitoring  
64.  44 19 To column 25.0 
65.  40 14 To column 3.0 
66.  135 Monitor triyls  
67.  40 14 To column 25.0 
68.  136 Monitor noise  
69.  40 14 To column 10.0 
70.  137 Stop monitor  
71.  42 18 To column 10.0 
72.  2 Reverse flush 8.0 
73.  168 If not monitoring  
74.  40 14 To column 6.0 
????
?
75.  3 Trityl flush 5.0 
76.  40 14 To column 6.0 
77.  103 Wait 5.0 
78.  3 Trityl flush 5.0 
79.  40 14 To column 6.0 
80.  103 Wait 5.0 
81.  3 Trityl flush 5.0 
82.  40 14 To column 6.0 
83.  103 Wait 5.0 
84.  3 Trityl flush 5.0 
85.  42 18 To column 10.0 
86.  3 Trityl flush 8.0 
87.  169 End monitoring  
88.  42 18 To column 8.0 
89.  2 Reverse flush 5.0 
90.  1 Block flush 4.0 
91.  107 End  
 
Note: Bottle 5—polymerizable capping phosphoramidite; bottle 14—detritylation 
solution; bottle 15—oxidation solution; bottle 18—acetonitrile; bottle 19—
dichloromethane; B—base or phosphoramidite; Tet—tetrazole or other activator. 
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A Highly Convenient Procedure for Oligodeoxynucleotide Purification 
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Recipes for Preparation of Polymerization Solutions 
3.7 M of N,N-Dimethylacrylamide and 0.37 M N,N?-methylenebis(acrylamide) 
solution (cross-linking ratio 10:1): To 103 μL N,N-dimethylacrylamide (MW 99.13 
mg/mmol, density 962 μg/μL, 100 mg, 1 mmol) and 15.5 mg N,N?-
methylenebis(acrylamide) (MW 154.17 mg/mmol, 0.1 mmol), add 103 μL water. Mix 
to dissolve. The final volume of the solutions is 272 μL. 
 
5% (NH4)2S2O8 Solution: To 5 mg (NH4)2S2O8 (MW 228.18 mg/mmol), add 95 μL 
water. Mix well (5 μL solution contains 1.1 μmol (NH4)2S2O8). 
 
0.66 M TMEDA solution: To 49 μL TMEDA (MW 116.24 mg/mmol, density 0.777 
mg/μL, 38.1 mg, 0.33 mmol), add water until the total volume reaches 500 μL. Mix 
well (5 μL solution contains 3.3 μmol TMEDA). 
HPLC conditions 
Column: C-18, 5 μm, 100 Å, 250 × 3.20 mm; solvent A: 0.1 M triethylammonium 
acetate, 5% acetonitrile; solvent B: 90% acetonitrile; flow rate: 0.5 mL/min; 
detection: 260 nm; faster gradient: solvent B (0%-45%) in solvent A over 60 min; 
slower gradient: solvent B (0%-15%) in solvent A over 60 min. 
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?
Figure B.1. HPLC of crude ODN 3.2, faster gradient. The enlarged version of the 
profile shown in trace a in Figure 3.2. Failure sequences were capped with 
polymerizable phosphoramidite during synthesis, and thus have longer retention times 
than the full-length sequence. ODN 3.2 is 5?-TCA TTG CTG CTT AGA CCG CT-3?. 
Figure B.2. HPLC of pure ODN 3.2, faster gradient. The enlarged version of the 
profile shown in trace b in Figure 3.2. The ODN was purified by catching failure 
sequences by polymerization. 
????
?
 
 
 
Figure B.3. HPLC of crude 19-mer ODN 3.3, faster gradient. The 19-mer ODN 3 (5?-
CAT TGC TGC TTA GAC CGC T-3?), which is the same as 3.2 except that there is 
one less base at the 5?-end, was synthesized using the same procedure for 3.2. 
 
 
 
 
 
 
 
Figure B.4. HPLC of pure 19-mer ODN 3.3, faster gradient. The 19-mer ODN 3.3
(5?-CAT TGC TGC TTA GAC CGC T-3?) was purified using the same procedure for 
3.2. 
????
?
 
 
Figure B.5. HPLC of ODNs 3.2 and 3.3, faster gradient. ODN 3.2 and 3.3 were co-
injected into HPLC. A broadened peak was observed indicating that HPLC can 
resolve the 19-mer failure sequence from 20-mer full-length sequence. 
 
 
 
 
 
  Figure B.6. HPLC of pure ODN 3.2, slower gradient
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Figure B.7. HPLC of pure 19-mer ODN 3.3, slower gradient 
 
 
 
 
 
 
 
Figure B.8. HPLC of ODNs 3.2 and 3.3, slower gradient ODNs 3.2 and 3.3 (~1:1 
ratio) were co-injected into HPLC. With slower gradient, the two were better 
resolved. Under the same conditions, pure ODN 3.2 does not show a shoulder at the 
left side of the peak. 
????
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Figure B.9. HPLC of 20-mer ODN 3.4 containing 8-oxo-dG treated with ammonia. 
The 20-mer ODN (3.4) that contains an 8-oxo-dG [5?-TCA TTG CT(8-oxo-dG) CTT 
AGA CCG CT-3?] was synthesized and purified with reversed-phase HPLC (RSC 
Adv. 2014, 4, 8746). The product was heated in concentrated NH4OH at 80 °C for 15 
min. After cooling to room temperature, nBuOH was added. The precipitate was 
analyzed with HPLC. The fast gradient was used. The multiple peaks in the profile 
indicate that the ODN is not stable under such conditions. Because ODN 3.2 was also 
processed under the same conditions during purification and only showed a single 
peak, we infer that 3.2 does not contain damaged dG. This experiment gives 
additional proof that ODN is stable under radical acrylamide polymerization 
conditions. 
 
????
?
 
Figure B.10. HPLC of residue from 4th extraction of gel. During purification of ODN 
3.2 using the catching by polymerization approach, after extraction of full-length 
sequence with water for three times, the gel was extracted for an another time. The 4th 
extract was processed using the same nBuOH precipitation procedure and analyzed 
with HPLC. No UV active material is detectable indicating that three extractions are 
sufficient. 
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Figure B.11. HPLC of blank control experiment. The catching failure sequences by 
polymerization ODN purification procedure was followed except that crude ODN 
was not added. After nBuOH precipitation and removal of supernatant, no solid 
residue was observable in the tube. The tube was washed with 30 μL water, and 20 
μL was injected into HPLC to generate the profile, which showed no UV active 
material. 
 
?
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Methacrylation Phosphoramidite with Acid-Cleavable Linker for Eco-
Friendly Synthetic Oligodeoxynucleotide Purification 
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Figure C.1. Crude RP HPLC profile of the 31-mer ODN 4.9
 
 
 
 
 
     
 
Figure C.2. Pure RP HPLC profile of the 31-mer ODN 4.9 purified on a 0.2 ?mol 
scale 
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Figure C.3. Crude RP HPLC profile of 37-mer ODN 4.10
Figure C.4. Pure RP HPLC profile of 37-mer ODN 4.10 purified on a 1 ?mol scale
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Figure C.5. Crude RP HPLC profile of the 61-mer ODN 4.11
Figure C.6. Pure RP HPLC profile of the 61-mer ODN 4.11 purified on a 0.2 ?mol 
scale
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Figure C.7. The 37-mer ODN 4.10 purified with the catching by polymerization 
technology 
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Figure C.8. 1H NMR  of compound 4.3 
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Figure C.9. 13C NMR  of compound 4.3 
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Figure C.10. 1H NMR of compound 4.4 
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Figure C.11. 13C NMR of compound 4.4 
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Figure C.12. 1H NMR of compound 4.5 
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Figure C.13. 13C NMR of compound 4.5 
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Figure C.14. 1H NMR of compound 4.6 
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Figure C.15. 13C NMR of compound 4.6 
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Figure C.16. 1H NMR of compound 4.7 
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Figure C.17. 13C NMR of compound 4.7 
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Figure C.18. 1H NMR of compound 4.1 
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Figure C.19. 13C NMR of compound 4.1 
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Figure C.20. 31P NMR of compound 4.1 
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Figure C.21. 1H NMR of ODN 4.10 
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Figure C.22. 31P NMR of ODN 4.10 
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Figure C.23. ESI MS of compound 4.4 
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Figure C.24. ESI MS of compound 4.5 
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Figure C.25. ESI MS of compound 4.6 
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Figure C.26. ESI MS of compound 4.7 
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Figure C.27. ESI MS of compound 4.1 
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Purification of Synthetic Peptides Using a Catching Full-Length 
Sequence by Polymerization Approach 
 
????
?
      
 
Figure D.1. RP HPLC profile of crude peptide 6.11 (16-amino acid) with side chain 
protecting groups and methacrylamide tag on 
       
 
Figure D.2. RP HPLC profile of crude peptide 6.11 (16-amino acid) with side chain 
protecting groups and methacrylamide tag off 
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Figure D.3. RP HPLC profile of peptide 6.11 (16-amino acid) purified by catching 
full-length sequences by polymerization 
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Figure D.4. ESI MS of compound 6.3 
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Figure D.5. ESI MS of compound 6.4 
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Figure D.6. ESI MS of compound 6.1  
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Figure D.7. ESI MS of the 6-amino acid peptide 6.5 
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Figure D.8. ESI MS of the 16-amino acid peptide 6.11 
M-P4045-1-1_2 19.9-21.1 page4054-2 #8-23 RT: 0.19-0.59 AV: 16 NL: 2.71E6
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Figure D.9. 1H NMR of compound 6.3  
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Figure D.10. 13C NMR of compound 6.3 
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Figure D.11. 1H NMR of compound 6.4 
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Figure D.12. 13C NMR of compound 6.4 
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Figure D.13. 1H NMR of compound 6.1 
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Figure D.14. 13C NMR of compound 6.1 
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Figure D.15. 1H NMR of 6-aa peptide 6.5 
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Figure D.16. 1H NMR of 6-aa peptide 6.11 
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